The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin by Pasierb, Lisa
Duquesne University
Duquesne Scholarship Collection
Electronic Theses and Dissertations
Fall 2005
The Role of Histidine-Rich Proteins in the
Biomineralization of Hemozoin
Lisa Pasierb
Follow this and additional works at: https://dsc.duq.edu/etd
This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic
Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact
phillipsg@duq.edu.
Recommended Citation
Pasierb, L. (2005). The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin (Doctoral dissertation, Duquesne
University). Retrieved from https://dsc.duq.edu/etd/1021
 
 
The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin 
 
 
 
 
 
 
 
A Dissertation presented to the Bayer School of Natural and Environmental Sciences 
 of Duquesne University 
 
 
 
 
 
 
 
 
 
 
 
As partial fulfillment of the requirements  
for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
 
 
By 
Lisa Pasierb 
 August 26, 2005 
 
 
Dr. David Seybert, thesis director 
Dr. David W. Wright, advisor 
 
 
 
 
 
 
 
 
 
 
 
In memory of Anna Pasierb 
 
April 24, 1924 – May 31, 2005 
 ii 
 iii
Acknowledgements 
 
 First and foremost, I would like to express my sincerest gratitude to my 
advisor, Dr. David W. Wright.  His exuberating energy and conviction attracted me to 
his research group, while his unwavering faith in me taught me more than he could 
ever know.  Secondly, of course, I would like to extend my appreciation to Glenn 
Spreitzer and James Ziegler, the other two original members of the Wright group, 
whom initially tried to exert male dominance, but eventually became very faithful 
friends and colleagues.  Finally, to all the other members of the Wright group over the 
years, thanks for all of your help, suggestions, and camaraderie. 
 Next, I would like to thank the members of my committee, Dr. Mitchell 
Johnson, Dr. Partha Basu, and Dean David Seybert, for their advice and counsel.  
Particularly, I would like to thank Dean Seybert, for his role as my graduate advisor 
while I completed my research abroad.  Finally, I would like to add the Duquesne 
University Department of Chemistry and Biochemistry and Vanderbilt University 
Department of Chemistry to my list of acknowledgements, since both faculties and 
staffs made my transitions between schools an eased and enjoyable experience. 
 I would like to thank my parents, for their committed love and support; my 
sister and brother, for all of their phone calls while I was away; and my uncles, for 
their staunch belief in the abilities of their niece.  A special thanks goes out to my 
boyfriend, who traveled this journey by my side with lots of love and support. 
 In closing I would like to dedicate this work to my grandmother Anna, who 
has taught me countless lessons in life, family, and love.  I miss her dearly. 
 iv
Abstract 
 
Hemozoin formation, the consequential end product of the proteolysis of 
hemoglobin by Plasmodium falciparum, is essentially a biomineralization process 
whereby toxic free heme is aggregated into an inert crystalline solid, also known as 
malaria pigment or ß-hematin.  The histidine-rich protein II (HPR II), isolated from 
the digestive vacuole of the parasite, has been implicated in the mediation of this 
biomineral through the protein’s ability to bind heme, aggregate the biomineral, and 
be effectively inhibited by known antimalarials, including chloroquine.  The HRP II 
sequence, which is comprised of 76% of histidine and alanine residues, has a specific 
amino acid repeat motif which is reminiscent of nucleating scaffold proteins utilized 
by other biological systems in biomineralization processes. Using a peptide 
dendrimer previously developed in our laboratory as a functional HRP II mimic, we 
examined two domain repeats, Ala-His-His-Ala-His-His-Ala-Ala-Asp and Ala-His-
His-Ala-Ala-Asp-Ala-His-His, as putative hemozoin nucleating sequences.   Results 
indicated the Ala-His-His-Ala-His-His-Ala-Ala-Asp repeat of peptide dendrimer 
BNT II was the most probable nucleating domain within the HRP II sequence.  Site-
directed mutagenesis studies were then utilized to elucidate the role of the nucleating 
domain per active site amino acids.  
 
 
 
 v
Table of Contents 
 
Chapter 1 An Historical Perspective of Hemozoin Formation 
      1.1  Introduction          2 
      1.2  Historical Perspective of the Malaria Pigment (Hemozoin)    9 
      1.3  Structural Characterization of Hemozoin    12 
      1.4  Hypotheses Surrounding Hemozoin Formation   18 
      1.5  Chemical Synthesis of Hemozoin     31 
      1.6  Hemozoin Quantification      40 
      1.7  Hemozoin Formation – A Promising Route Towards Discovering  
New Antimalarials       43 
  References        47 
Chapter 2 Design and Synthesis of the Bionucleating Templates (BNTs) 
     2.1  Background and Significance      57 
     2.2  The Histidine-Rich Proteins Evidenced as Templates in the  
  Biomineralization of Hemozoin     63 
     2.3  Design and Development of a Model HRP System   67 
     2.4  The Ala-His-His-Ala-His-His-Ala-Ala-Asp Putative Domain – 
  Initial Studies of a Model HRP System    72 
     2.5  Site-Directed Mutagenesis Studies of the HRP II Mimic  87 
     2.6  BNT II and Mutant Modeling               102 
  References                  111 
Chapter 3 Putative Domain Template Studies 
     3.1  Introduction                 121 
     3.2  Functional Screening of the BNTs              126 
     3.3  Preliminary Studies                131 
     3.4  Putative Domain Studies               132 
  BNT II                  132 
  BNT IIA                 141 
     3.5  Discussion                 148 
     3.6  Conclusions                 163 
  References                  166 
Chapter 4 Site-directed Mutagenesis Studies of BNT II 
     4.1  The Mutants of BNT II – An Introduction             174 
     4.2  General Information                176 
  Mutant BNT IID                177 
  Mutant BNT IIX                184 
  Mutant BNT IIY                189 
  Mutant BNT IIZ                195 
     4.3  Conclusions                 200 
  References                  213 
 
 
 vi
Chapter 5  Application of the BNT II Model System 
  Inhibition of Hemozoin Aggregation by N4O2 Schiff Base  
  Complexes  
     5.1  Introduction                215 
     5.2  Synthesis and Characterization of N4O2 Complexes           218 
     5.3  Experimental Methods              221 
     5.4  Results and Discussion              223 
     5.5  Conclusions                232 
  References                234 
Chapter 6 Concluding Remarks   
     6.1  Hemoglobin Proteolysis as an Antimalarial Strategy           238 
     6.2  Biochemical Involvement of HRP II             239 
     6.3  Role of BNT II Model System             241 
     6.4  Summary                243 
  References                245 
Appendix I Automated Peptide Synthesis Program                                    A-1 
Appendix II Titration Binding Curves                                               A-4 
Appendix III Circular Dichroism Titration Experiments          A-28 
 vii
Table of Figures 
 
1.1  Map of malaria endemic regions         2 
1.2 Electron micrograph of hemozoin within an erythrocyte      4 
1.3 Life cycle of Plasmodium falciparum        5 
1.4 Schematic of hemoglobin proteolysis         6 
1.5 Structure of hemozoin          7 
1.6 UV-Vis spectrum of hemozoin and ferriprotoporphyrin IX      13 
1.7 IR spectra of native hemozoin, synthetic ß-hematin and hematin    14 
1.8 EXAFS of hemin and hemozoin        14 
1.9  Powder diffraction of hemozoin and synthetic ß-hematin     15 
1.10 EPR spectra of hemozoin and synthetic ß-hematin      16 
1.11   Mössbauer spectra of hemozoin and synthetic ß-hematin     17 
1.12  The sequence of histidine-rich protein II (HRP II) from P. falciparum   25 
2.1 Plasmodium falciparum trophozoite residing in an erythrocyte    57 
2.2 Abiological synthesis of hemozoin        59 
2.3 Field emission inlens scanning electron microscopy of hemozoin produced  
 by Plasmodia and non-Plasmodium species       65 
2.4 Illustration of Fmoc-4-branch MAPS resin       69 
2.5 Substrate binding curves for BNT I        75 
2.6 Substrate binding curves for BNT II        76 
2.7 Template and other protein mediated hemozoin production      77 
2.8 Time evolution for the BNT mediated formation of hemozoin    78 
2.9 pH dependence of the BNT mediated formation of hemozoin    79 
2.10 Effect of acetate buffer concentration on the BNT mediated formation of 
hemozoin           79 
2.11 FT-IR spectra of hemozoin from P. falciparum and that mediated by the 
 BNTs            80 
2.12 Synchrotron x-ray diffraction patterns of hemozoin from P. falciparum and 
 that mediated by BNT II         80 
2.13  Inhibition of the BNT II mediated production of hemozoin     81 
2.14 Circular dichroism spectra of HRP II, linear multimers of HRP II  
 sequence, BNT I, and BNT II          84 
2.15 Scale-up equations for HPLC peptide purification      94 
2.16 Semi-preparative HPLC chromatogram of BNT II      95 
2.17     Semi-preparative HPLC chromatogram of BNT IIA      96 
2.18 Semi-preparative HPLC chromatogram of BNT IID      97 
2.19 Semi-preparative HPLC chromatogram of BNT IIX      98 
2.20 Preparative HPLC chromatogram of BNT IIY      99 
2.21 Preparative HPLC chromatogram of BNT IIZ    100 
2.22 MALDI-TOF mass spectrometry for BNT II     103 
2.23 ESI+ mass spectrometry for BNT IIA      103 
 
 viii
 
2.24 9-mer sequence of BNT II modeled as a right-handed 3-10 helix and a  
left-handed polyproline type II conformation    106 
2.25  9-mer sequence of BNT IIA modeled as a right-handed 3-10 helix and a   
left-handed polyproline type II conformation    107 
2.26 9-mer sequence of BNT IID modeled as a right-handed 3-10 helix and a   
left-handed polyproline type II conformation    107 
2.27 9-mer sequence of BNT IIX modeled as a right-handed 3-10 helix and a   
left-handed polyproline type II conformation    108 
2.28 9-mer sequence of BNT IIY modeled as a right-handed 3-10 helix and a   
left-handed polyproline type II conformation    108 
2.29 9-mer sequence of BNT IIZ modeled as a right-handed 3-10 helix and a   
left-handed polyproline type II conformation    109 
3.1 Binding equilibration study for BNT IIA     131 
3.2 UV-Vis spectra of the interaction of hemin chloride with BNT II  133 
3.2 (inset) UV-Vis spectra of BNT II      133 
3.3 Hemin chloride titration binding curve for BNT II    134 
3.4 Zn(II)PPIX titration binding curve for BNT II    136 
3.5 Fluorescence quenching studies of Zn(II)PPIX with BNT II   137 
3.5 (inset) Fluorescence quenching studies of Zn(II)PPIX with BNT I  137 
3.6 Circular dichroism spectra of BNT II at various pH values   138 
3.7 Circular dichroism spectra of BNT II and spectral changes associated  
 with binding Fe(III)PPIX and Zn(II)PPIX     139 
3.8 UV-Vis spectra of the interaction of hemin chloride with BNT IIA  142 
3.9 Hemin chloride titration binding curve for BNT IIA    143 
3.10 Zn(II)PPIX titration binding curve for BNT IIA    144 
3.11 Fluorescence quenching studies of Zn(II)PPIX with BNT IIA  145 
3.12 Circular dichroism spectra of BNT IIA and spectral changes associated  
 with binding Fe(III)PPIX       147 
3.13 Substrate binding of the hypothesized putative nucleation domains  151 
3.14 Fluorescence quenching of BNT II vs. BNT IIA    153 
3.15 Hemozoin production mediated by the putative nucleation domains  154 
3.16 Thermal denaturation of BNT II      158 
3.17   Circular dichroism spectra of collagen vs. polyproline II   159 
3.18 Circular dichroism spectra of BNT II vs. BNT IIA    159 
3.19 Thermal denaturation of linear multimer of BNT II    160 
3.20 Representation of BNT II and BNT IIA sequences    165 
4.1 UV-Vis spectra of the interaction of hemin chloride with BNT IID  178 
4.2 Hemin chloride titration binding curve for BNT IID    179 
4.3 Zn(II)PPIX titration binding curve for BNT IID    180 
4.4 Fluorescence quenching studies of Zn(II)PPIX with BNT IID  181 
4.5 Circular dichroism spectra of BNT IID and spectral changes associated  
 with binding Fe(III)PPIX       183 
 ix
4.6 UV-Vis spectra of the interaction of hemin chloride with BNT IIX  184 
4.7 Hemin chloride titration binding curve for BNT IIX    185 
4.8 Zn(II)PPIX titration binding curve for BNT IIX    186 
4.9 Fluorescence quenching studies of Zn(II)PPIX with BNT IIX  187 
4.10 Circular dichroism spectra of BNT IIX and spectral changes associated  
 with binding Fe(III)PPIX       188 
4.11 UV-Vis spectra of the interaction of hemin chloride with BNT IIY  190 
4.12 Hemin chloride titration binding curve for BNT IIY    191 
4.13 Zn(II)PPIX titration binding curve for BNT IIY    191 
4.14 Fluorescence quenching studies of Zn(II)PPIX with BNT IIY  192 
4.15 Circular dichroism spectra of BNT IIY and spectral changes associated  
 with binding Fe(III)PPIX       193 
4.16 UV-Vis spectra of the interaction of hemin chloride with BNT IIZ  195 
4.17 Hemin chloride titration binding curve for BNT IIZ    196 
4.18 Zn(II)PPIX titration binding curve for BNT IIZ    197 
4.19 Fluorescence quenching studies of Zn(II)PPIX with BNT IIZ  198 
4.20 Circular dichroism spectra of BNT IIZ and spectral changes associated  
 with binding Fe(III)PPIX       199 
4.21 Comparison of the UV-Vis spectra BNT II and its mutants   201 
4.22 Substrate binding of BNT II and its mutants     202 
4.23 Fluorescence quenching of Zn(II)PPIX by BNT II and its mutants   204 
4.24 Hemozoin production mediated by BNT II and its mutants   205 
4.25 Comparison of CD spectra of 2 nmoles of BNT II and its mutants in  
 10 mM acetate buffer, pH 4.8       207 
5.1 Representation of the N4O2 Schiff base compound    224 
5.2 Effect of salt concentration on hemozoin aggregation and drug inhibition 226 
5.3 Fluorescence quenching studies of ENBPI complexes by Fe(III)PPIX 228 
5.4 Fluorescence aggregation studies of ENBPI complexes   229 
5.5 Fluorescence emission time studies for MgIIENBPI and FeIIIENBPI 230 
5.6 NMR spectrum of MgIIENBPI in 25 mM acetate buffer, pH 4.8  231 
5.7 NMR stability study of MgIIENBPI      232 
5.8 Integration of spectra for NMR stability study of MgIIENBPI  233 
6.1  Scanning electron microscopy of β-hematin synthesized by the  
dehydrohalogenation of 2,6-lutidine according to methods published by  
Bohle          242 
6.2 Scanning electron microscopy of β-hematin synthesized in aqueous  
 solution according to methods published by Blauer    242 
 
 
    
 
 
       
 x
Table of Tables 
 
2.1 Sequence homology of the histidine-rich proteins of P. falciparum    62 
2.2 Substrate binding stoichiometries of BNT I and BNT II     73 
2.3 Site-directed mutagenesis of the 9-mer sequence of BNT II     89 
F2.16 Gradient table for semi-preparative HPLC of BNT II     95 
F2.17 Gradient table for semi-preparative HPLC of BNT IIA     96 
F2.18 Gradient table for semi-preparative HPLC of BNT IID     97 
F2.19 Gradient table for semi-preparative HPLC of BNT IIX     98 
F2.20 Gradient table for preparative HPLC of BNT IIY      99 
F2.21 Gradient table for preparative HPLC of BNT IIZ    100 
2.4 Amino acid analysis of BNT II and BNT mutants    101 
3.1 CD spectral markers for Fe(III)PPIX titration with BNT II   141 
3.2 CD spectral markers for Zn(II)PPIX titration with BNT II   141 
3.3 CD spectral markers for Fe(III)PPIX titration with BNT IIA  147 
3.4 Absorbance maxima values for BNT II and BNT IIA binding to  
 Fe(III)PPIX and Zn(II)PPIX       150 
4.1 Site-directed mutagenesis of the 9-mer sequence of BNT II   175 
4.2 CD spectral markers for Fe(III)PPIX titration with BNT IID  183 
4.3 CD spectral markers for Fe(III)PPIX titration with BNT IIX  189 
4.4 CD spectral markers for Fe(III)PPIX titration with BNT IIY  194 
4.5 CD spectral markers for Fe(III)PPIX titration with BNT IIZ  200 
4.6  Summary of the functional analyses of BNT II and its mutants   210 
5.1 Acetate buffer dependence of the IC50 of the N4O2 Schiff base complexes 226 
 
 
 
 
 
*F denotes a Figure that contains a corresponding table. 
 xi
Table of Equations and Schemes 
 
1.1 Acid catalyzed hemozoin formation      39 
1.2 Anhydrous non-coordinating base hemozoin formation   39 
2.1 Standard Fmoc-peptide synthesis protocol     91 
F2.15 Scale-up equations for HPLC peptide purification    94 
 
 
 
 
*F denotes a Figure that contains equations. 
 xii
Table of Abbreviations 
 
 
1H NMR - proton nuclear magnetic resonance spectroscopy 
AA - amino acid 
ACN - acetonitrile 
BHIA - β-hematin inhibitory activity 
BNT I - bionucleating template I, a first generation peptide dendrimer with the 
sequence (Ala-His-His-Ala-His-His-Ala-Ala-Asp) 
BNT II - bionucleating template II, a second generation peptide dendrimer with the 
sequence (Ala-His-His-Ala-His-His-Ala-Ala-Asp)2 
BNT IIA - bionucleating template II alternate, a second generation peptide dendrimer  
with the sequence (Ala-His-His-Ala-Ala-Asp-Ala-His-His)2 
BNT IIC - mutant of BNT II with the sequence of (Ala-Ala-Ala-Ala-Ala-Ala-Ala- 
Ala-Asp)2 
BNT IID - mutant of BNT II with the sequence of (Ala-His-His-Ala-His-His-Ala- 
Ala-Ala)2 
BNT IIX - mutant of BNT II with the sequence of (Ala-His-Ala-Ala-His-Ala-Ala- 
Ala-Asp)2 
BNT IIY - mutant of BNT II with the sequence of (Ala-Ala-His-Ala-Ala-His-Ala- 
Ala-Asp)2 
BNT IIZ - mutant of BNT II with the sequence of (Ala-His-His-Ala-His-His-Ala- 
Ala-Lys)2 
BSA - bovine serum albumin 
CD - circular dichroism spectroscopy 
CD2Cl2 - deuterated methylene chloride-d2 
CD3CO2Na - deuterated sodium acetate-d3 
CD3COOD - deuterated glacial acetic acid-d4  
CD3OH - deuterated methanol-d3   
CDCl3 - deuterated chloroform-d 
CDNA - complementary deoxyribonucleic acid  
CH3COOH - acetic acid 
COUP - coupling mixture 
cpm - counts per minute 
CQ - chloroquine 
D2O - deuterated water 
DAB - diaminobenzidine 
DCM - dichloromethane 
DIEA - N,N’-diisopropylethylamine 
DMF - dimethylformamide 
DMSO - dimethyl sulfoxide 
DNA - deoxyribonucleic Acid  
ENBPI - ethylenediamine-N,N’-bis[propyl(2-hydroxy-R-benzylimino)] ligand 
 xiii
EPR - electron paramagnetic resonance  
ESI - electrospray ionization mass spectrometry 
EXAFS -extended x-ray absorption fine structure 
Fe(acac)3 - iron (III) acetylacetonate 
Fe(III)PPPIX - iron (III) protoporphyrin IX 
FEISEM - field emission inlens scanning electron microscopy 
Fmoc – 9-fluorenylmethyloxycarbonyl 
Fmoc-Ala-OH - N-α-Fmoc-L-alanine 
Fmoc-Asp-OtBu - N-α-Fmoc-L-aspartic acid α-t-butyl ester 
Fmoc-His(Trt)-OH - N-α-Fmoc-N-im-trityl-L-histidine 
Fmoc-Lys(Mtt)-OH - N-α-Fmoc-N-ε-4-methyltrityl-L-lysine 
FT-IR - Fourier transform infrared spectroscopy 
Ga(acac)3 - gallium (III) acetylacetonate 
H3Mabi - 2-(2’-hydroxy-3’-methoxyphenyl)-1,3-bis[4-aza-5-(2’’-hydroxy-3’’-
 methoxyphenyl)but-4'-4n-1'-yl]1,3'-imidazolidine  
HAP - histoaspartic protease 
HBTU - 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HCl - hydrochloric acid 
HOBt - N-hydroxybenzotriazole 
HPIA - heme polymerization inhibitory activity 
HPLC - high performance liquid chromatography 
HRG - histidine-rich glycoprotein 
HRP I - histidine-rich protein I 
HRP II - histidine-rich protein II 
HRP III - histidine-rich protein III 
HRP IV- histidine-rich protein IV 
HRPs- histidine-rich proteins, collectively speaking 
IC50 - effective concentration at 50% inhibition 
ICT - immunochromatographic test method for malaria detection 
IR - infrared spectroscopy 
IR - infrared, referring to this specific region of the spectrum of light  
KAHRP – knob-associated histidine-rich protein 
KBr - potassium bromide 
LPS - lipopolysaccharide 
MALDI-TOF - matrix-assisted laser desorption/ionization time-of-flight (mass  
 spectroscopy) 
MAPS - multiple antigen peptide system 
Mech - mechanical shaker 
MeOH - methanol 
MOE - molecular operating environment 
NaOH - sodium hydroxide 
Ni(II)PcS - nickel (II) tetrasulfanatophthalocyanine 
P. berghei - Plasmodium berghei 
 xiv
P. falciparum - Plasmodium falciparum 
PAGE -polyacrylamide gel electrophoresis  
PcS - tetrasulfanatophthalocyanine 
PfEMP1 - Plasmodium falciparum erythrocyte membrane protein 1 
PIP - piperidine 
PM I - plasmepsin I, an aspartic protease 
PM II - plasmepsin II, an aspartic protease 
PM IV - plasmepsin IV, an aspartic protease 
PPII - polyproline type II secondary structure 
PPIX - protoporphyrin IX 
PVDF – polyvinylidene difluoride membrane 
RBC - red blood cell 
RHRP II - recombinant histidine-rich protein II 
rpm - revolutions per minute 
RV-1 - reaction vessel 1 
SDS- sodium dodecyl sulfate 
SDS-PAGE - sodium dodecyl sulfate  
SEM - scanning electron microscopy 
TFA - trifluoroacetic acid 
TFE - trifluoroethanol 
TIS - triisopropyl silane 
TLC - thin layer chromatography 
UV-Vis - ultraviolet-visible, referring to this specific region of the spectrum of light 
XRD- x-ray diffraction  
YAC - yeast artificial chromosome 
Zn(II)PPIX - zinc (II) protoporphyrin IX 
  
 
 
 
 
 
 
 
 
Chapter 1 
Historical Perspective of Hemozoin Formation 
 
 
 
 
 
 
 
 
 
 
1.1.  Introduction 
Malaria is endemic in one hundred and seven countries1 infecting 350-500 
million people annually (Figure 1.1).2 Reported clinical cases confirm 1.5-2.7 million 
deaths per year, with the majority of the claimed lives belonging to children.    In 
Africa, the continent which tallies 90% of all malaria related deaths,3 the disease kills 
one child in twenty before the age of five years old, correlating to a death rate of 
2,800 children per day, or approximately 1 million children per year.4 Recent data 
suggests that although childhood mortality in Africa is decreasing, the percentage of 
deaths attributed to malaria is actually increasing.  The direct economic burden is 
substantial for both poverty-stricken and industrialized countries.5 Economic growth 
reductions of at least one percent per year constrain some regions in Africa.6,7 The 
United States alone concedes over 2 billion dollars annually to offset costs incurred in 
malaria plagued regions.8 
 
Figure 1.1.  Malaria endemic regions, adapted from the World Health Organization. 
 2 
From the early 1970’s through the late 1990’s, research in malaria was 
minimal, contributable to the fact the United States and most of Europe had 
eradicated the disease during the first half of the twentieth century.8 This lapse in 
research paralleled the development of only three antimalarials during the past 
twenty-five years, the same time frame in which over one thousand other drugs had 
been synthesized.9 The resurgence of malaria is due to drug and insecticide 
resistance,10-13 as well as social and environmental changes.  Plasmodium, the 
parasitic carrier of malaria, is resistant to most antimalarial drugs including 
chloroquine.  Vector resistance to pyrethroid insecticides now threatens the 
effectiveness of insecticide-treated bednet programs.  Additionally civil wars, travel,14 
and population increases contribute to heightened transmission of this deadly disease.  
Malaria-endemic countries alone have doubled in population and the disease is once 
again reaching across the oceans into both North America and Europe.15 
Many antimalarials are developed on the premise that resulting drug efficacies 
are correlated to the ability of a compound or combination of compounds to interfere 
with aspects of parasitic metabolism, which differs significantly from the human host.  
Plasmodia catabolism involves a detoxification mechanism in which liberated free 
heme is sequestered into a metabolically inert crystalline material known as hemozoin 
(Figure 1.2).16 Of the four species of parasites that infect humans (Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovalae, and Plasmodium malariae), P. 
falciparum is the deadliest, accounting for 90% of all malaria cases in Africa and 
50% in Asia and Latin America, being responsible for 95% of all malaria deaths. 
 3 
Figure 1.2.  Electron micrograph of hemozoin localized inside an erythrocyte.
Reproduced from reference 16. 
The life cycle of Plasmodia is complex, (Figure 1.3) with developmental 
stages and corresponding symptoms differing according to the species involved.  
Typically, malaria infection is initiated when an infected female Anopheles mosquito 
injects sporozoites subcutaneously into the circulatory system of a human host.  The 
sporozoite-stage parasites rapidly invade hepatocytes in the liver, undergoing asexual 
multiplication (exoerythrocytic schizogony) for 5-8 days before rupturing and 
releasing merozoites into the blood stream.  The merozoites invade host erythrocytes 
and begin a maturation period of 48 hours, assuming several distinctive growth 
phases (blood-stage schizogony).  The early trophozoite “ring” stage includes the 
ingestion of host cytoplasm and hemogloblin proteolysis.  This trophic period ceases 
after several nuclear divisions result in the formation of schizonts.  New merozoites 
 4 
 
Figure 1.3.  Life cycle of Plasmodium falciparum adapted from The Wellcome Trust. 
bud from mature schizonts and are released from red blood cells, spawning a new 
invasion of host erythrocytes.  
 Some parasitic merozoites sexually differentiate into gametocytes, the 
developmental form which is transmittable back to the vector once a mosquito bites 
an infected host (gametogenesis).  Inside the mosquito midgut, the gametocytes 
transform into male and female gametes, which then unite to form zygotes.  The 
zygotes mature into motile ookinetes, which migrate through the midgut wall and 
develop into oocysts.  The oocysts undergo several cycles of asexual replication, 
producing sporozoites.  Upon maturation, the oocyst ruptures releasing the 
sporozoites, which then migrate through the mosquito hemocoel to the salivary 
glands, where these stage-specific parasites now await injection into another host, 
thereby completing the life cycle. 
 5 
 During the intraerythrocytic phase of its life cycle, the malaria parasite can 
degrade up to 80% of an infected erythrocyte’s hemoglobin in order to obtain 
requisite amino acids.17 Hemoglobin catabolism occurs in the digestive vacuole of 
Plasmodium falciparum (pH 4.8-5.4) as a semi-ordered process18,19 involving the 
sequential action of several different proteases (Figure 1.4).  Two aspartic proteases, 
plasmepsin-I and plasmepsin-II (PM I and PM II) initially cleave hemoglobin 
between phenylalanine and leucine at positions 33 and 34 along the peptide chain.20-22 
These residues, located in a conserved domain known as the hinge region, are crucial 
to the overall stabilization of hemoglobin.  Cleavage at this site partially unfolds the 
polypeptide, exposing additional sites along the peptide chain for other proteases to 
cleave.  Falcipain, a cysteine protease,23 along with the plasmepsins (I, II, and IV24) 
and HAP,25 a histoaspartic protease,26 further degrade the globin fragments into 
peptides.  Plasmepsin I prefers to cleave phenylalanine in the P1 position, while 
plasmepsin II targets 
hydrophobic residues, 
especially leucine in the P1′ 
position.19 Falcilysin, a 
metalloprotease, then trims 
fragmented peptides to a 
metabolically useful size of 
about 6-8 amino acid residues 
 
Figure 1.4.  Schematic of hemoglobin proteolysis. 
6 
in length.27 These small peptides are further reduced to simple amino acid residues 
once such fragments are transported from the digestive vacuole to the cytoplasm.28 
Hemoglobin proteolysis consequently releases free heme 
(iron(III)protoporphyrin IX, Fe(III)PPIX), which is toxic to the parasite.  
Accumulated free heme concentrations estimated as high as 0.4 M can disrupt 
metabolic function via the peroxidation of membranes, the inhibition of enzymes, and 
the generation of oxidative free radical species, all of which can damage the cell wall 
ultimately resulting in cell lysis.  To balance the metabolic requirements for amino 
acids against the toxic release of free heme, malaria parasites, which lack a heme 
oxygenase for the subsequent breakdown of the iron porphyrin, have evolved a 
unique detoxification mechanism which involves the formation of the brown 
crystalline heme aggregate known as hemozoin (malaria pigment, β-hematin).    
Recent spectroscopic evidence (x-ray powder diffraction and Raman 
spectroscopies) confirms the structure 
of hemozoin as a coordination 
aggregate of Fe(III)PPIX  monomers 
in which the oxygen from a 
propionate of one group serves as the 
axial ligand to the ferric ion of another 
(Figure 1.5).29 Hydrogen bonding 
between the propionic acid side chains 
Figure 1.5.  Structure of hemozoin. 
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of the porphyrin rings reveals an aggregate of Fe(III)PPIX dimers.30 
Hemozoin is released along with the merozoites during oxidative burst and is 
engulfed by macrophages, where it appears to impair macrophage function31 and 
suppress cytokine production.32 Such immunological impairment of the host alone 
prompts further investigation of the biochemical nature of hemozoin.  However, 
before a comprehensive understanding of the pathogenesis of Plasmodium falciparum 
is understood, the biochemical basis for the formation of this biomineral must be 
unraveled.  
Despite the recent completion of the sequencing of the genomes of 
Plasmodium falciparum, the Anopheles mosquito, and the human host, which will 
yield thousands of new target proteins,33 the complexity of the life cycle of Plasmodia 
makes it difficult to determine which life cycle stages drug therapies should target for 
vaccines.  Vaccine delivery systems and adjuvant technology must be improved 
before stage-specific immunotherapies will be effective.34 While vaccine 
development may seem like a promising new route to combating malaria, blood stage 
antigens may not be completely effective in eliciting immunity.35 Socio-economical 
and topological factors may also dictate the type of vaccine conjured based on the 
polymorphisms sustained by the parasite in a specific region. 
An alternative drug therapy would include the inhibition of hemozoin 
production, since this metabolic process is unique to the parasite.  If the malaria 
parasite’s metabolic processing were halted at this stage, accumulation of free heme 
would ultimately result in parasite lysis.  In fact, many of the most effective 
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antimalarials are thought to mechanistically proceed by disrupting the parasite’s 
ability to synthesize hemozoin.  Though the exact mechanisms remain elusive, some 
members of the quinoline family of antimalarials are hypothesized to sterically cap 
the formation of hemozoin through π-π interactions.  While chemoprophylaxis 
continues to be the most effective means by which to combat malaria, multi-drug 
resistant parasites are emerging at an alarming rate.  Intensifying efforts to develop 
new antimalarials may only have limited successes; therefore probing the mechanism 
of hemozoin formation may provide the best insight towards the development of new 
antimalarial strategies.    
1.2.  Historical Perspective of the Malaria Pigment (Hemozoin)36 
Hemozoin, known more commonly as the malaria pigment in its infancy, was 
first documented in the early 1700’s by Giovanni Maria Lancisi, a physician who 
noted dark discolorations in the internal organs of malarial victims. He coined the 
name malaria, literally meaning “bad air,” believing the deaths were linked to a 
poisonous vapor originating from swamps.  In 1849, Rudolph Virchow first linked the 
brown-black tincture to the disease, sketching “pigmented bodies” that he discovered 
in the blood of a patient inflicted with chronic malaria.  Thirty years later Charles 
Louis Alphonse Laveran linked the dark granules to a parasitic infection, observing 
“oscillating bodies” in the blood of an infected Algerian soldier and documenting an 
additional twenty-six cases where the motility of such “dark cresent spheres” 
indicated the presence of a living organism.  
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Five years later (1884) at the Bayview Hospital in Baltimore, Councilman and 
Abbot performed autopsies on two malaria fatalities, recording the brains as being 
“dull chocolate in color,” while the livers, spleens, and lungs were enlarged with 
distinctive black discolorations.  Microscopic examination of the organs revealed that 
an irregularly shaped pigment was located not only on the outside of the organs, but 
also confined within the “red corpuscles.”  This distinctive brown staining developed 
into such an archetypical marker of malaria and progression of the parasitic life cycle 
that in 1889 Johns Hopkins Hospital instituted blood smear analyses in the diagnosis 
of the disease.  Through this effort, Camillo Golgi photographed the malaria parasite 
and correlated the amount of pigment to the severity of the infection.  Several years 
later, William George MacCallum observed the sexual formation of male and female 
gametocytes merging into a zygote. 
In 1897 Sir Ronald Ross examined a female Anopheles stephensi mosquito 
and noted comments about cells outside the mosquito midgut … “these bodies 
contained a few granules of black pigment” being identical in appearance to the 
“large quartans and cresent-derived spheres” characteristic of the substance found in 
malaria victims.  This finding first linked the mosquito as the vector in the 
transmission of malaria. 
In 1911 W.H. Brown identified the chromogenic species in the malaria 
pigment as heme, confirming its origination from hemoglobin and establishing the 
theory these dark granules were a hemoprotein.37 Moreover, Brown physically 
differentiated the malaria pigment from melanin (skin pigment), noting differences in 
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solubility and bleaching effects, given that potassium permanganate and hydrogen 
peroxide solutions failed to bleach malaria crystals, disintegrating the compound 
instead.  In 1934, Louis Sambon replaced the outdated terminology of “plasmodin” 
and “haemo-melanin” for the malaria pigment with its present terminology, 
hemozoin.38 That same year, B. N. Gosh and J. A. Sinton demonstrated the spectrum 
of hemozoin in alkaline solution was identical to that of hematin,39 and its elemental 
composition by C, N, O, and Fe was also matched,40 reinforcing the characterization 
of hemozoin as a hemoprotein.  
In 1936 a similarly insoluble synthetic compound was reported by Antonin 
Hamsik, who first identified that when the porphyrin hematin was modified in the ß-
position in acidic medium the resulting compound could no longer convert back to 
the original soluble hematin species.41 This new compound, ß-hematin, was insoluble 
in most solvents, and considered an “inactive” form of hematin.     
 In 1956 Deegan and Maegraith first reported the differential solubilities of 
crude hemozoin and hematin.  Hemozoin remained insoluble in sodium bicarbonate 
buffer (pH 9.5), whereas hematin was solubilized.  This finding provided additional 
support for the theory of a structural scaffold (protein) enveloping the heme unit in 
hemozoin, protecting the compound from solvation.  Since heme was also known to 
bind specifically to the hydrophobic sites of other proteins, the involvement of a 
novel proteinacious material in hemozoin formation remained a sound hypothesis. 
More importantly, this notable difference in solubility became the basis for the 
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modern differential solubility assay, which permits the quantitation of hemozoin free 
of other types of hematin aggregates.  
Until the early 1990’s, chemical analyses obtained from the isolation and 
purification of native hemozoin supported the premise of the malaria pigment as a 
hemoprotein; however results were often conflicting.42,16 Most researchers agreed the 
protein component was of relatively low mass (<16 kDa), but some argued the 
proteinacious material originated from the degradation of hemoglobin during parasitic 
feeding, while others maintained the protein was a novel parasite specific 
polypeptide. 
The early history of malaria spawned three Nobel laureates in the twentieth 
century.  In 1902 Sir Ronald Ross was awarded the Nobel Prize in medicine, not 
solely for his establishment of the mosquito as the vector in the disease, but also for 
his development of the mathematical models used to study the epidemiology of 
malaria.   In 1906 the Nobel honor was jointly presented to Camillo Golgi and 
Santiago Ramon ỳ Cajal in recognition for their contributions to the physiology of the 
nervous system of the Anopheles mosquito.  One year later Laveran was the recipient 
of this same award for his contributions in establishing the role of protozoa as a 
causative agent in this disease.   
1.3.  Structural Characterization of Hemozoin 
Despite its early identification, the structural and chemical nature of hemozoin 
has only been elucidated in the past fifteen years.  In 1987, Fitch and 
Kanjananggulpan first reported that hemozoin could be purified from proteins, 
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reporting the malaria pigment was 82-99% Fe(III)PPIX by weight.43 Native hemozoin 
was purified in sequential steps, first removing any hemozoin- associated proteins by 
incubation with a nonspecific protease from Streptomyces griseus, followed by a 
phospholipid extraction with a chloroform/methanol mixture according to procedures 
described by Bligh and Dyer.44 Most importantly the protein/peptide free product was 
microscopically45 and spectroscopically similar to synthetic ß-hematin, dissolving the 
notion that hemozoin was a hemoprotein.  Both crude hemozoin and synthetically 
aggregated ß-hematin recorded UV-Vis spectrums with absorbances at 655 nm and a 
broad Soret band at 400 nm in 2.5% SDS solution (Figure 1.6).  Both native and 
synthetic pigments were insoluble in 
ethanol, sodium bicarbonate, and 
chloroform, notably different from the 
solubility properties of hematin. The 
relative solubility was then quantitated 
from the height of the Soret band (400 
nm) of the remaining solid sample 
dissolved in 0.02 N NaOH after a two-
hour incubation in each solvent.   
(a) Crude      (b) Purified    (c) Aggregated 
      Pigment        Pigment       
 
Figure 1.6.  UV-Vis spectra of hemozoin
isolated from Plasmodium berghei (a,b)
and  (c) aggregated ferriprotoporphyrin in
NaOH.  Reproduced from reference 43. 
Four years later Slater and coworkers published a seminal paper in which 
hemozoin and synthetic β-hematin were determined by infrared and x-ray 
spectroscopies to be the same compound.46 The infrared spectra exhibited sharp peaks 
at 1664 and 1211 cm-1, indicative of a carboxylate coordinated to an iron center from 
 
the stretching frequencies of a C=O and C-O vibration respectively (Figure 1.7).  
EXAFS of both compounds confirmed an oxygen atom in the coordination sphere of 
the iron atom (1.886 Å)29 and a carbon atom further away (3.4 Å) (Figure 1.8).  
Elemental analysis and mass spectrometry (m/z 616.3, hemozoin dissolved in basic 
solution) revealed the pigments only consisted of Fe(III)PPIX, which led to the 
conclusion that hemozoin was an aggregate of dimers in which the Fe of one heme 
unit is coordinated to the propionate side chain of another. 
 
b
a
Figure 1.7.  Fourier-transform IR spectra of (a) Hemozoin (___) and hematin (---)
and (b) native hemozoin (___) and β-hematin (---).  Reproduced from reference 46. 
 
k in Ǻ-1 
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)k
3  
Figure 1.8.  EXAFS of hemin (___) and hemozoin (---). Reproduced from reference
46. 
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 Bohle and coworkers provided additional evidence that native hemozoin and 
its synthetic analog were chemically and spectroscopically similar via high resolution 
powder diffraction patterns (Figure 1.9).  The group discovered the diffraction 
patterns in malarial trophozoites had a unique Bragg diffraction spike that was 
different from the powder diffraction pattern determined in uninfected erythrocytes.47 
When the two spectra were subtracted from each other, not only were the broadened 
bands from the lipid bilayer in the 
spectra removed, but also the resultant 
spectrum matched the diffraction pattern 
of synthetic ß-hematin. 
 
Figure 1.9.  Powder diffraction patterns
(λ = 1.1495 Å). (a) lyophilized uninfected
erythrocytes (b) lyophilized trophozoites
from Plasmodium falciparum (c)
difference of (a) and (b) (d) synthetic ß-
hematin.  Reproduced from reference 47. 
Other physical characterizations 
of hemozoin were not so unambiguous.  
Slater reported an EPR spectrum at 10K 
to have peaks at g = 3.80 and 1.95, 
indicative of a low spin iron center.46 
Four years later Cammack and 
coworkers assigned both high spin and 
low spin EPR signals for hemozoin 
isolated from Plasmodium berghei.48 
These conflicting results were not 
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Figure 1.10.  EPR spectra for ß-
hematin at (a) 21 K (b) 15.5 K (c)
9.0 K and (d) 5.6 K.  The spectra
of hemozoin is overlayed for
comparison.  Reproduced from
reference 49. 
resolved until 1998 when Bohle et al. 
performed carefully controlled temperature 
dependent EPR studies which found 
hemozoin to have signals at g = 5.79, 3.80, 
and 2.04 at 21 K and below (Figure 1.10).49 
Spectra recorded above this temperature 
exhibited a loss in absorption intensity and 
accounted for the discrepancies in the spectra 
amongst the previous groups.  Monomeric 
Fe(III)PPIX had similar signals at g = 5.80 
and 2.04, ascribing both species as high spin 
iron compounds.  These findings supported the structural information that hemozoin 
was a dimer of reciprocating heme units. 
Mössbauer studies provided similarly litigious results.  Initially isomer shifts 
reported by Yayon were at 0.46 and 0.47 mm s-1 with quadrupole splittings of 0.80 
and 0.92 mm s-1 and line widths of 0.50 and 0.44 mm s-1, respectively for both native 
(P. berghei) and synthetic hemozoin.50 Egan and coworkers then reported isomer 
shifts of 0.24 mm s-1 for hemozoin (P. falciparum) and 0.20 mm s-1 for synthetic 
hemozoin at 78 K.51,52 Bohle characterized synthetic hemozoin at 4.2 K to have an 
isomer shift at 0.275 mm s-1 with a quadrupole splitting of 0.588 mm s-1 and a line 
width of 0.35 mm s-1.49 Such discrepancies were not resolved until the Egan lab 
(2002) reported identical spectra for both synthetic β-hematin and trophozoite isolated 
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hemozoin which had been lyophilized to avoid the strong attenuation of the signal by 
water (Figure 1.11).53 Such results highlight the importance of temperature on 
electronic relaxation effects of iron containing species and the meticulous workup of 
biological samples in order to avoid background scatter. 
Such discrepancies highlight the difficulties in the isolation and purification of 
native hemozoin, as well as the synthetic analog.  Plasmodium berghei derived 
hemozoin used by the Yayon group is not known to produce significant quantities of 
hemozoin, so questions lie in the actual composition of the product analyzed.   
Nonetheless, tedious extractions and copious washes are necessitated to obtain 
 
Figure 1.11.  Mössbauer spectra of lyophilized trophozoites (a, c and e) and ß-
hematin (b, d and f). (δ), isomer shift, (∆), quadrupole splitting, (Γ), linewidth, all
in mm s-1.  Reproduced from reference 53. 
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reproducible results.  The complete removal of protein components and free heme 
from hemozoin are invaluable in both qualitative and quantitative analyses. 
Characterizations should be carried out routinely to ensure that hemozoin is void of 
all contaminants. 
 Though hemozoin has long been both a marker for the diagnosis of malaria 
and an indicator of the parasitic life cycle, little is known about its chemical 
mechanism of formation.  In vivo attempts to investigate hemozoin formation have 
not been successful and thus, most studies have been confined to synthetic ß-hematin 
formation in either aqueous or non-aqueous reaction conditions.   
1.4.  Hypotheses Surrounding Hemozoin Formation 
The formation of hemozoin in vivo has numerous proposed mechanisms 
reporting the process is either enzyme catalyzed,54,55 lipid catalyzed,56-60 histidine- 
rich protein initiated,61-63 spontaneous,64 or autocatalytic65 (For the most recent 
reviews see Egan66 and Sullivan.67). 
In 1992 Slater and Cerami first reported the formation of hemozoin as an 
enzyme catalyzed process,54 which occurred upon overnight trophozoite incubation at 
370C with hematin in 500 mM sodium acetate buffer, pH 4.8.  14C labeled heme was 
used to detect de novo synthesized hemozoin from the quantity of hemozoin already 
present in the trophozoites extracted from the acetonitrile layer of cells.  Uninfected 
red blood cells and macrophages failed to incorporate the radiolabeled heme in 
hemozoin formation, as did synthetic and native ß-hematin.46 Denatured hemoglobin 
and albumin, serving as controls, also tested negative for hemozoin formation.  
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Chloroquine and amodiaquin, two known antimalarials, inhibited the formation of 
hemozoin, with reported IC50 values (the effective concentration at 50% inhibition) of 
120 µM and 250 µM respectively.  Moreover, the authors uncovered the pH optimum 
for the formation of hemozoin was between the pH of 5.0 and 6.0, the approximate 
pH of the parasite’s digestive vacuole.  Pigment formation was greatly diminished 
above pH > 6.0, leading the authors to speculate that hemozoin would not assemble 
outside of the digestive vacuole because the carboxylate side chains of the heme 
moiety would then be protonated, not allowing the formation of the axial Fe-O 
propionate bond.  Hemozoin formation also increased linearly over time and with 
increasing protein concentration, leading the authors to conclude a novel “heme 
polymerase” was responsible for the formation of the malaria pigment.      
A short time thereafter Egan, mimicking the acidic conditions inside the 
digestive vacuole (pH = 5), demonstrated a spontaneous formation of hemozoin64 
from basic hematin acidified with glacial acetic acid (4.5 M acetate concentration) at 
nonphysiological temperatures.  The synthetic product exhibited temperature and 
acetate concentration dependence, reporting complete hemozoin formation within 30 
minutes at 60oC, within 2 hours at 37oC, and within 8 days at 6oC. UV-Vis 
spectroscopy studies showed that increasing the concentration of acetate buffer       
(0-6.0 M), solubilized increasing concentrations of hemin chloride, which supported 
their finding of increased reaction rates when the volume of acetate buffer was 
increased and the amount of hemin remained constant.  Besides refuting an enzymatic 
mechanism of formation, the authors hypothesized that ionic strength (flux into and 
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out of a cell) could possibly play a role in the organization of malarial hemozoin, 
rationalizing that carboxylate groups from free amino acids and/or peptides resulting 
from hemoglobin proteolysis16 or an unidentified protein were able to provide an 
environment analogous to that supplied by the acetate buffer, aiding the nucleation of 
heme in the formation of hemozoin.   
Controversies revolving around the exact mechanism of hemozoin formation 
were heightened during the next few years.  Three years after the hypothesis of a 
“heme polymerase” was introduced, Dorn et al. assessed that hemozoin formation 
was an autocatalytic process,65 uncovering that both denatured parasite lysates and 
synthetic β-hematin promoted the aggregation of hemozoin.  Knowing Slater’s results 
were quantitated against quantities of hemozoin already existing in the trophozoites 
and that the insoluble extract promoted de novo pigment, Dorn proposed that the 
existing hemozoin could theoretically provide an interface capable of nucleating 
additional hemozoin.  Additionally, Dorn reported active hemozoin formation under 
the same experimental conditions (140 µM 14C labeled heme, overnight incubation at 
37oC, 500 mM sodium acetate buffer, pH 4.8) when parasite lysates were boiled for 
10 minutes at 100oC, denaturing any enzymes.  When the parasite lysates were 
subjected to Percoll density-gradient fractionation, the vacuole fraction and hemozoin 
fraction supported the formation of 14C labeled hemozoin, while the fractionated 
trophozoite lysate and membrane layers failed to do so.  Isolated hemozoin from the 
gradient fractionation was then treated with proteinase K, a chloroform-methanol 
mixture, and purified by SDS-PAGE analysis.  This hemozoin, devoid of all proteins, 
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still produced radiolabeled pigment, leading the author to conclude that hemozoin 
formation could proceed by an autocatalytic process.  Additionally, both chloroquine 
and mefloquine inhibited the formation of hemozoin from the cultured extract, as well 
as the synthetic analog.  Although refuting the theory of enzymatic formation of 
hemozoin in favor of an autocatalytic mechanism, the authors did not refute the 
possibility of a protein providing the structural framework for the active site of 
hemozoin nucleation. 
  A few months later in a Nature correspondence, Cerami released new data 
involving the HPLC elution profiles of trophozoite extracted hemozoin.68 The 
acetonitrile extract, which had no absorbance at 400 nm, the characteristic 
wavelength of the porphyrin ring structure, still supported hemozoin formation.  Mass 
spectrometry of this fraction revealed methyl esters of oleic, palmitic, and stearic 
acids. The insoluble pigment formed in this extract displayed an HPLC elution profile 
similar to that of synthetic β-hematin. This fraction also contained significant 
amounts of organically bound phosphorous and was cleavable with phospholipase B, 
suggestive of a phospholipid-catalyzed mechanism of hemozoin formation.  The 
author maintained that a novel “heme polymerase” could still exist, although one had 
not yet been isolated.  Notably, Cerami acknowledged the crucial importance of 
determining the parasite’s biological mode of heme sequestration in vivo in order to 
resolve the underlying scientific discrepancies arising amongst the in vitro 
investigations. 
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Included in this same issue of Nature was a reply from the Dorn lab, which 
independently reported the possibility of a phospholipid mechanism of hemozoin 
formation.56 Dorn now reported acetonitrile extracts from the trophozoite lysate could 
also provide the framework for hemozoin nucleation in the absence of any existing 
preformed pigment.  More surprising was the fact that the acetonitrile extract from 
uninfected erythrocytes could also initiate hemozoin nucleation.  Furthermore, 
besides extraction techniques, the lab noted the relative importance that pH could 
possibly play in the formation of hemozoin since that under aqueous conditions of 
sodium acetate buffer, pH 4.8, 50% of the propionic acid side chains of the heme 
moiety are deprotonated, the necessary chemical constraint needed for the structural 
formation of hemozoin via the Fe-O propionate linkage.   
One year later Amit V. Pandey and Babu L. Tekwani discredited the Egan 
hypothesis that the formation of hemozoin was a spontaneous process,64 citing the 
authors failed to purify the collected hematin product.69 Egan clearly cited problems 
with centrifugations and the adsorption of heme onto the cellulose acetate filters, 
nonetheless, he only washed the samples with H2O, which failed to remove any free 
heme based upon the differential solubilities of the species.  A necessitated wash with 
sodium bicarbonate (pH=9.1) was required but omitted.  While the IR analyses of the 
samples exhibited the characteristic stretching frequencies associated with hemozoin, 
the product in all likelihood was a mixture of both hemozoin and hematin.  
Replication of the experiment by Pandey’s group demonstrated the product described 
by Egan et al. was readily soluble in bicarbonate buffer, as well as sodium dodecyl 
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sulfate (SDS).  Further analyses by TLC showed a product migration similar to that of 
soluble hematin. Longer incubations at higher temperatures formed a product that was 
insoluble in sodium bicarbonate, but the authors argued the experimental conditions 
were no longer physiological (high acetate concentration, 80oC, 12 hours).  They also 
uncovered that under the employed experimental conditions (37oC, 6 hours), 
hemozoin only formed at acetate buffer concentrations of 1.0 M or higher.  In order to 
further probe the heme-acetate interactions first suggested by Egan, the group used 
14C-labeled acetate to examine the possibility of a carboxylate-iron linkage between 
hematin and acetate.  Their studies illustrated distinct binding between heme and the 
radiolabeled acetate, suggesting a heme-acetate adduct (complex) as a plausible 
intermediate in the production of hemozoin under these conditions. 
Shortly thereafter, the heme-acetate theory of complexation in the formation 
of hemozoin was scrutinized.  Foremost, Pandey and Tekwani themselves 
demonstrated that hemozoin (based on the characteristic IR frequencies) could form 
in 1 M phosphoric acid.69 Additionally, Riscoe’s group demonstrated hemozoin 
formation in 0.2 M phosphate buffer, pH 5.2, when examining xanthones as possible 
antimalarials.70 Comparisons were made again amongst the various methods 
employed to synthesize the malaria pigment.  Elemental analyses showed that 
hematin, malaria hemozoin, and synthetic ß-hematin formed in various buffers, pH 
5.2 (0.02 M phosphate buffer, 0.02 M acetate buffer, and 4 M acetate buffer) agreed 
reasonably well in composition, however the differential solubilities of the products 
in methanol, ethanol, 2.5 % SDS, DMSO, and an acetic acid:water:methanol mixture 
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(1.5:0.5:8) varied.  Reactions in 4 M acetate yielded a precipitate that was soluble in 
all solvents, displaying solvation properties similar to hematin.  Hemozoin derived 
from the 0.02 M phosphate buffer was insoluble in all of the examined solvents, 
exhibiting solubility properties like the native malaria pigment.  Reactions incubated 
in the lower ionic strength acetate buffer synthesized a solid product that was partially 
soluble in the alcoholic and acetic acid solvents, but insoluble in 2.5% SDS and 
DMSO.  A pH profile for hemozoin formation in phosphate buffer demonstrated the 
rate of hemozoin formation above pH 6 was drastically reduced, comparing well to 
the pH profile compiled for reactions run in acetate buffer. 
A more substantial argument was made by Egan when he further criticized the 
hypothesis of a heme-acetate complex in the formation of hemozoin suggested by 
Pandey and Tekwani with a few simple solubility tests.71 Hematin, which has 
heightened solubility in increased acetate concentrations, did not form hemozoin in 
11.4 M acetate under the prescribed reaction conditions, but did precipitate a material 
when the buffer was diluted to 4.5 M.  The IR of this material failed to show any 
similarities with that of ß-hematin.  If the heme-acetate postulate were valid, then 
increasing the ionic strength of the buffer should have facilitated the reaction to 
proceed more quickly.  Additionally, since the solubility of hematin increased as the 
concentration of acetate buffer increased, the reaction yield should have also been 
amplified. 
By this time native and synthetic hemozoin were considered to be structurally 
identical, being synthesized in vitro either under non-physiological conditions or in 
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seeded reactions, but no enzyme to date had been isolated nor delineated the 
structural focus for the formation of hemozoin.  In 1996, Goldberg and coworkers 
added yet another theory to the mechanics of the formation of hemozoin.  Using 
monoclonal antibodies to investigate the proteins of the digestive vacuole of             
P. falciparum, they identified a class of histidine-rich proteins (HRP’s) that mediated 
the formation of hemozoin.61   
The sequence of HRP II is comprised of 76% alanine and histidine              
(Mr 27 kD), possessing 51 repeats of an Ala-His-His repeat motif (Figure 1.12),72 a 
sequence closely resembling the Gly-His-His-Pro-His-Gly heme binding domain in 
the human histidine-rich glycoprotein (HRG).73 Specifically, each molecule of HRP 
bound approximately 17 equivalents of heme in 100 mM acetate buffer, pH 4.8.  
Moreover, the recombinant protein mediated the formation of hemozoin while 
concurrently other proteins and homo- and polypeptides such as bovine serum 
albumin (BSA), lyzozyme, polylysine, and polyasparagine failed to generate the 
Figure 1.12.  The sequence of histidine-rich protein II (HRP II) isolated from 
Plasmodium falciparum. 
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insoluble malarial pigment.  Human HRG also failed to promote the in vivo 
aggregation of hemozoin, suggesting the binding domains of the two sequentially 
related proteins have diverse functions. 
HRP II mediated hemozoin also increased in amount with increasing reaction 
time, protein concentration and hemin concentration, forming at optimal rates within 
the pH range of 4.0-6.0.  The nature of the buffer failed to affect the rate of reaction, 
though again the authors noted a increased production of the biomineral with 
increasing ionic strength.  HRP III, of which 56% of the protein is comprised of 
alanine and histidine residues, (28 Ala-His-His repeats, Mr 27 kD) also mediated the 
formation of hemozoin. HRP IV,74 a 10 kD genetic clone lacking HRP II and HRP III 
(31% histidine), reacted positively with the HRP II monoclonal antibody, but heme 
polymerization assays were not completed. These findings, along with the fact that 
preformed hemozoin promoted additional malaria pigment in in vitro assays, 
weakened the theory of an enzyme catalyzed mechanism of formation.  
When 3H labeled chloroquine and quinidine antimalarials were incubated with 
HRP II in the presence of heme (100 mM sodium acetate buffer, pH 4.8), the 
hemozoin formed exhibited considerable radioactivity.62 Incubation of HRP alone 
with labeled drugs failed to record any counts per minute (cpm).  Conversely, purified 
hemozoin without heme substrate did not accumulate the radiolabel, implicating a 
drug-heme complex in the mode of hemozoin inhibition rather than the direct binding 
of the antimalarial to hemozoin.  Moreover, this suggested the degradation of 
hemoglobin and sequestration of heme into hemozoin as independent processes, both 
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as viable targets for antimalarial strategies.  As a caveat, the binding of the drug to 
proteolyzed heme may not be indicative of the associative inhibition of the hemozoin 
formation,63 since drugs with strong heme binding affinities do not have a direct 
correlation with the potency of the antimalarial.  Blockade of either process would 
ultimately result in parasite death.  In retrospect, if the HRP’s served as a three 
dimensional template for the nucleation of hemozoin, the disruption of protein 
interactions could produce novel antimalarials.  Others began acknowledging the 
possibility of a recognizable nucleation site for the formation of hemozoin, dismissing 
the classical hypothesis of enzymatic processing.75-77 
From the structural information elucidated from the sequence of HRP II, 
Pandey and Chauhan postulated a pH mechanism of hemozoin formation.78 Though 
numerous experimental conditions effected the formation of hemozoin in vitro, the 
pH of the digestive vacuole was critical for in vivo formation; for at this critical pH 
one-half of the propionate groups of the heme moiety are deprotonated, facilitating 
the binding of the propionate group of one side chain to the central iron core of 
another.  Heme binding to the HRPs spatially orients two heme molecules into a 
preferred conformation for this iron-carboxylate bond formation.  The repetitive 
binding sequence of Ala-His-His-Ala-Ala-Asp, prepared as a linear hexapeptide, did 
not promote the nucleation of hemozoin.  
The hypothesis involving a lipid mediated formation of hemozoin resurrected 
in 1999 in two separate articles from Fitch and Tekwani.  Fitch, previously knowing 
the acetonitrile extract from infected red blood cells promoted the formation of 
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hemozoin68,65 and this extract also yielded the methyl esters of unsaturated fatty 
acids,68 found that lipids from both infected and uninfected erythrocytes promoted the 
formation of hemozoin.  After the lipids in the extract were hydrolyzed, his group 
also detected the presence of fatty acids via gas chromatography/mass spectrometry.  
Based on this observation, he then found arachidonic, linoleic, oleic, and palmitic 
acids, and the mono and di-oleoylglycerol, as standards, also promoted the formation 
of hemozoin.  This production of ß-hematin exhibited the same dependency on pH, 
temperature and acetate concentration that previous studies on the formation of 
hemozoin recorded, but in addition, the concentration of the lipids and the nature of 
detergents also displayed a profound effect on hemozoin nucleation.     
In 2001, though Pandey et al. did not study the mechanism of hemozoin 
formation, support for the histidine-rich protein mediated formation of hemozoin was 
supplanted in an attempt to elucidate the mechanism of chloroquine inhibition.79 
Besides confirming that native HRP II bound approximately 18 equivalents of heme, 
PAGE analysis stained with Coomassie Brilliant Blue revealed a heme:peptide 
complex discernable from the native protein.  Incubation with chloroquine coincided 
with the disappearance of the diaminobenzidine (DAB, a heme peroxidase) staining, 
demonstrating at least, the disruption of the heme:protein complex.   
In 2002 Tekwani et al. appended the lipid postulated formation of hemozoin 
to proceed by a free radical mechanism of formation.60 Since malaria patients were 
known to have reduced levels of antioxidants in the blood, he predicted that since 
antioxidant levels were at a diminished capacity no longer available to prevent the 
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oxidation of lipids, once oxidized, the unsaturated lipids promoted hemozoin 
formation via a free radical chain reaction.  This hypothesis was initially supported by 
the fact Orjih had concluded that both uninfected and infected cells upon treatment 
with NaOH, HCl, or CH3COOH formed hemozoin.80 Antioxidants and reducing 
agents tested positive for ß-hematin inhibition, including glutathione, sodium 
dithionite, ß-mercaptoethanol, ascorbic acid, superoxide dismutase, and dithiothreitol, 
as well as ρ-aminophenol, a compound known to terminate free radical reactions.  
This however, suggests the parasite must first ascertain control over host metabolism 
in order to manage its metabolic catabolism of hemoglobin and the subsequent 
formation of hemozoin.  
Though both the lipid mediated formation of hemozoin and HRP nucleation 
remain valid hypotheses for the assembly of this biomineral, a direct comparison of 
the two proposals has yet to be studied.  Which mechanism most efficiently processes 
hemozoin?  Here the rate of formation remains a critical, yet still unanswered 
question.  Which process would involve the least expenditure of energy on part of the 
parasite in order for it to obtain its requisite amino acids in the relatively short amount 
of time its spends in the trophic stage? Moreover, why doesn’t the parasite choose a 
physiochemical mechanism that is unique to the organism?  If lipids from uninfected 
cells and chemically processed standards still promote the formation of hemozoin, 
why is ß-hematin compartmentalized in only a few organisms? 
All in all, these scientific discrepancies in the underlying chemical 
mechanisms of hemozoin formation are exacerbated by the arguments as to the 
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structural characterization of the compound itself.  Despite the dismissal of hemozoin 
as a hemoprotein, until quite recently, garnering advances in spectroscopic 
characterizations, hemozoin was referred to as a “heme polymer” and the formation 
process was coined a polymerization mechanism.  Subsequently, at one point in time 
the malaria pigment and its synthetic analog were coined the different names of 
hemozoin and ß-hematin, respectively.  
In 1998, Dorn et al. compiled a review of the methods of hemozoin formation 
at physiological temperature (37oC), not so as to assess the methods of isolation and 
purification, but to clarify differing inhibition values.57 Chloroquine was a consistent 
inhibitor in the ability to disrupt the formation of hemozoin, but the IC50 values varied 
significantly as based upon the research group’s methodologies of native hemozoin 
isolation. Assessing the inhibitory effects of various antimalarials in 500 mM sodium 
acetate buffer, pH 4.8, the results demonstrated the hemozoin isolated from 
trophozoite lysates tended to have much higher IC50 values than those obtained from 
an acetonitrile trophozoite lysate or digestive vacuole extract.  More relevant 
however, was the finding that chemically synthesized hemozoin had inhibitory effects 
similar to the hemozoin obtained from the digestive vacuole.  This first supported the 
idea that chemically synthesized hemozoin may be the optimum method for 
synthesizing large amounts of the pigment for evaluation in in vitro assays. 
Later Bohle et al. unequivocally characterized native hemozoin and synthetic 
ß-hematin as being of the same chemical composition through synchrotron x-ray 
diffraction studies.29 This same group then provided evidence of reciprocating heme 
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dimers for the structure of hemozoin,30 coining the more appropriate terminology of 
“heme aggregate” or biomineral.  Later these authors suggested that although ß-
hematin is chemically and structurally similar to the malaria pigment, consideration 
must also be given to its morphological form when assessing the mechanism of 
formation of hemozoin and its reactivity in vivo.81 Different synthetic preparations of 
the malaria pigment produced an assortment of crystal sizes, each with dissimilar 
reactive faces. Others supported the novel term of “biocrystallite,”82 only adding to 
the complexity of the history of this unique heme compound.  
Classically nucleation and crystal growth involves a supersaturated solution.  
No direct evidence exists that once hemoglobin is catabolized by the parasite, that 
free heme accumulates in any appreciable concentration.  Furthermore, the oxidative 
damage that can result from one molecule of heme could have a cascade of 
detrimental effects on the very sustenance of the parasite. The parasite needs to 
prevent any toxic and deleterious effects of heme as efficiently as possible.  With the 
above arguments and the fact that biocrystallization rarely involves a detoxification 
pathway or excretory mechanism, we chose to classify hemozoin as a biomineral. 
1.5.  Chemical Synthesis of Hemozoin 
Due to the tedious extraction and isolation of hemozoin from trophozoites, 
many research groups sought chemical means by which to synthesize larger quantities 
of the pigment.  Beyond the first synthesis by Hamsik, hemozoin can be formulated 
either in aqueous solution with hematin and acetic acid,46,64,83,65,84-86 or via an organic 
synthesis involving the dehydrohalogenation of hemin with  2,6-lutidine.  
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Since Slater et al. first characterized that both native and chemically prepared 
hemozoin were spectroscopically the same compound,46 their preparation of             
ß-hematin is one of the most frequently referenced preparations.  Their formulation 
involves dissolving 60 µmoles of hematin in 8 mL of 0.1 M NaOH followed by the 
subsequent precipitation of the porphyrin with 49 mmol of acetic acid (or benzoic, 
propionic, or succinic acid substitution).  The suspension is heated overnight at 70oC.  
The initial precipitate is then washed four times with water, followed by two 3 hour 
washes with 0.1 M sodium bicarbonate buffer, pH 9.1, to remove any free heme.  The 
remaining insoluble material is washed an additional four times with water, 
lyophilized, and dried over P2O5, reporting yields of 40-50%.   
Egan later modified this method,64 demonstrating that hemozoin could be 
formed under less corrosive reaction conditions.  He dissolved 23 µmoles of hemin in 
3.0 mL of 0.1 M NaOH in a 60oC temperature controlled cell and then added dilute 
HCl (0.30 mL, 1.0 M) and acetate  (1.74 mL, 12.0 M), incubating the solution for 
thirty minutes (or at various other times), before quenching the reaction mixture on 
ice for five minutes.  The solution was then filtered over an 8 µm cellulose 
acetate/nitrate filter and washed with copious amount of water.  This method not only 
produced hemozoin, but also suggested its formation to be a time dependent process, 
as evidenced by the increase in the C=O and C-O stretching frequencies in the 
recorded IR spectra.  Consequently, the authors failed to dissolve any residual 
hematin with a sodium bicarbonate wash, so the results obtained as to the reactivity 
and inhibition of hemozoin were skewed.  Nonetheless, this synthesis formed 
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hemozoin under milder conditions than those employed by Slater (60oC vs. 70oC, 30 
min vs. 16 hours, 4.5 M sodium acetate buffer vs. concentrated acid). 
In 1995 while examining the formation of hemozoin, Blauer and Akkawi 
termed B-hematin,83,85 an insoluble form of ferriprotoporphyrin IX isolated as an 
intermediate in the production of hemozoin.  Herein, the product was formed by 
incubating hemin in 0.4 N NaOH with acetic acid under magnetic stirring.  The 
mixture was quenched on ice, centrifuged, and the precipitate transferred onto a filter.  
The solid was washed profusely with water and then with DMSO until the filtrate ran 
clear.  The material was rewashed with water and then ethanol and dried under 
vacuum until all residual water was removed.  The authors noted that at reaction 
temperatures of 70oC, the IR spectra were similar to ß-hematin prepared via the 
method of Slater et al.,46 with strong absorption bands at 1663 and 1209 cm-1.  
Samples however prepared at lower temperatures and with lower concentrations of 
acetic acid had additional broad absorption bands at 1647 and 1020 cm-1, which 
deviated from the IR frequencies of hemin chloride as well, which are centered near 
1715 and 1620 cm-1. These novel absorption bands and the products’ slight difference 
in solubility in acidic medium led the authors to speculate that “B-hematin” was an 
isolated intermediate in the chemical transformation of hemin chloride into               
ß-hematin. Though additional spectroscopic evidence was lacking, the authors 
suggested the differences in the IR spectra were a result of the differing coordination 
environments between the intermediate and final hemozoin product. 
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When investigating the rates of formation of B-hematin,85 the overall yields of 
the reactions were dependent upon the pH of the solution (maximum yields were 
obtained between pH 4-5) and the reaction times.  Yields also varied according to the 
type of acid used, but all acids promoted the formation of B-hematin, so long as the 
solution remained acidic during the course of the reaction. The relative yields also 
increased with decreasing concentrations of ferriprotoporphyrin IX.  Coincidentally, 
the antimalarial chloroquine inhibited the formation of the B-hematin intermediate as 
effectively as it suppressed the formation of hemozoin.  These kinetic investigations 
pioneered the relationship between the rate of hemozoin formation and reaction 
conditions (e.g. pH, time, concentration, ionic strength etc.). 
Egan’s preparation of hemozoin64 was later adopted by Basilico with 
modifications for ß-hematin synthesis in a 96-well plate.86 This protocol was used in 
the rapid screening for antimalarial drug inhibition based on previous work showing 
that both hematoporphyrin and protoporphyrin IX inhibited malaria pigment 
formation through cofacial π-π stacking interactions between the drug and hematin.84 
This microtiter plate assay was also used by Dorn to analyze the various methods of 
hemozoin production (trophozoite lysate, acetonitrile extract from the trophozoite 
lysate, digestive vacuole lysate, hemozoin isolated from the malaria parasite, and 
synthetic ß-hematin).57   
Basilico again used this assay when examining the consequential effects of the 
initial porphyrin on inhibition assays.  Hemozoin inhibition assays performed with 
hematin in sodium hydroxide (heme polymerization inhibitory activity, HPIA) and 
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alternatively with hemin chloride in DMSO (ß-hematin inhibitory activity, BHIA) 
both demonstrated a pH dependence of drug effectiveness on hemozoin inhibition.87 
The antimalarials probed demonstrated optimal effectiveness in acetate buffer around 
pH 5.1, the approximate pH of the digestive vacuole.  Interestingly, the effect was 
less pronounced when hemin chloride was the chosen initial porphyrin rather than 
hematin. Along with this, the inhibitory effects of the salts were nearly reversed for 
hematin and hemin chloride.  This highlighted the importance in experimental design 
in assay protocols, since differences in the homogeneity of the two compounds in 
solution may account for such discrepancies.  Hematin, when in sodium hydroxide 
exists mainly as µ-oxo dimers and displays a decreased solubility with decreasing pH 
levels so inhibitory effects may be weakened merely because less monomeric 
porphyrin is in solution.   When the iron porphyrin is dissolved in DMSO, the solvent 
disrupts the formation of the µ-oxo dimers, thus no interference in drug:heme 
interactions occurs because of reduced solubility.  The BHIA mainly adjusts the 
microenvironment of the porphyrin facilitating π-π stacking interactions between the 
antimalarial and hemozoin.  If a drug interacts via a different mechanism, the results 
may be biased based upon the interactions between the drug and heme, the drug and 
hemozoin, or the possibility of a drug:heme complex interacting with hemozoin. 
In 1999 Egan revalidated his acetate buffered preparation of hemozoin,64 
providing additional supporting spectroscopic evidence.71 In addition to elemental 
analysis and IR spectroscopy, x-ray powder diffraction and scanning electron 
microscopy identified the hemozoin samples.  The XRD patterns for both the author’s 
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preparation of hemozoin and Slater’s preparation from trophozoites matched well 
with Bohle’s chemical dehydrohalogenation of hemin (see below) analyzed using 
high resolution synchrotron radiation.  Microscopy samples revealed the synthetic 
hemozoin to be slightly smaller than the scans obtained from two different P. 
falciparum strains, but the overall morphological features were comparable. The 
authors suggested that hemozoin solubility could be affected by particle size and the 
water content of the sample. 
In 2000 Blauer and Akkawi published another article suggesting the formation 
of synthetic ß-hematin only formed upon prolonged drying of the reaction products.88  
Following the hemozoin preparation by Egan,71 the authors recorded the IR spectrum 
of the insoluble pigment washed only with water, but it failed to display the iron 
carboxylate peaks characteristic of hemozoin.  When however, this product was 
washed with DMSO, the insoluble product, now in a significantly lower yield, 
resembled the IR spectra of the earlier B-hematin, again isolating the “intermediate” 
involved in the formation of hemozoin.  A spectrum matching that of the malaria 
pigment was only obtained after the precipitate collected from Egan’s protocol was 
kept wet for an additional 2 hours at 70oC and then washed with DMSO until the 
filtrate was faintly colored.  A control where the sample was not heated for the 
additional amount of time produced “B-hematin.”  The authors suggested that under 
these reaction conditions that pure crystalline ß-hematin only formed upon a 
structural reorganization of the substance, which occurred during the drying process. 
A revised the protocol for synthesizing hemozoin to ensure product formation 
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included dissolving hemin in aqueous sodium hydroxide, followed by the addition of 
diluted acetic acid (final concentration 5.9 M) at 37oC with constant stirring for 2 
hours.  The reaction is then cooled in water, centrifuged, and the precipitate collected 
onto a filter.  The insoluble substance is then washed with copious amounts of water 
and DMSO, followed by additional washes of water and ethanol, before drying the 
product in vacuo at room temperature. 
The debates on the mechanics of hemozoin formation continued beyond the 
year 2000.  Little research was completed on the kinetics of formation or the 
conditions affecting its formation.  Egan first compiled such information for 
hemozoin prepared from acetate in a 2001 Biochemistry article,89 examining the 
effects of reaction conditions including temperature, pH, acetate concentration, 
stirring and seeding on the rate of hemozoin formation.  By monitoring the increase in 
IR frequency at 1210 cm-1 at various reaction times, while maintaining a constant 
acetate concentration (4.5 M), pH (pH = 4.5), and temperature (60oC), the rate of 
hemozoin formation under the prescribed conditions followed a sigmoidal kinetic 
profile with an approximate induction period of 15 minutes.  Magnetic stirring 
increased the reaction rate significantly. The authors found that decreasing the 
reaction temperature decreased the rate of formation and resulted in a longer 
induction phase, as did lowering the concentration of the acetate buffer (pH 4.5, 
60oC). The pH dependency exhibited maximal formation at pH 3.5, with the rate 
diminishing significantly above the pH of 5.0.  Seeding the reactions with either 10% 
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or 50% of preformed hemozoin at both 4.5 and 8.5 M acetate buffer had no effect on 
the rate of formation. 
Similar effects were observed when monitoring the reaction via XRD. The 
peak for hematin disappeared over time giving rise to the hemozoin peak, which has 
2θ peaks that are different from the starting material.  In parallel, the recorded XRD 
of a wet sample of hemozoin displayed the same diffraction pattern as the dried 
product; dispelling the hypothesis that hemozoin chemically synthesized from acetate 
was reorganized into its crystalline form during the drying process (IR data sampled 
in Nujol mulls compared comparably as well.).  SEM data collected at differing 
reaction times failed to be quantitative, but provided supportive insight into the 
mechanism of hemozoin formation.  Spectroscopic evidence previously supplied by 
Bohle et al. demonstrated that hemozoin is a dimer of reciprocal iron-propionate 
linkages with strong evidence of hydrogen bonding between the other unionized 
heme propionates.29,30 The SEM data collected by Egan illustrated a surface growth 
phenomenon whereby a nearly amorphous starting material transformed into small 
crystallites, indicative of possibly a nucleation and growth phase.  This invalidates the 
old notion that hemozoin is comprised of polymeric units and is formed under the 
mechanics of a polymerization mechanism. 
Egan’s review of hemozoin formation in acetate solution and the effects of the 
reaction conditions thereto, collectively summarize the enormous amount of scientific 
discrepancies seen throughout the literature. Subtle changes in the reaction conditions 
have a profound effect on the rate of synthesis and on the formation of the hemozoin 
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itself.  A alcohol-water medium presented by Blauer and Akkawi was also shown to 
increase the rate of formation of hemozoin, with a maximal yield of ß-hematin 
achieved in 40% ethanol,90 but the authors weaken a solvation theory by not focusing 
on the solubility issues surrounding hemin, but instead insist that B-hematin can be 
isolated as an intermediate in the formation of hemozoin.  
In contrast to the acetate preparation of hemozoin, Bohle et al. pioneered the 
preparation of hemozoin via the dehydrohalogenation of hemin.91 This reaction 
requires relatively mild conditions (room temperature) and produces high yields 
(>90%) compared to the approximately 50-80% yields recorded from the acetate 
preparations (Equations 1.1 and 1.2).  The chemical synthesis, which is carried out 
in an inert atmosphere, involves suspending hemin (0.489 g., 0.75 mMol) in 70 mL of 
dry methanol and then treating the suspension with excess dry 2,6-lutidine (0.5 mL, 
4.3 mMol).  The solution is then stirred in the dark for 18 hours before centrifuging 
the product at 300 rpm for 10 minutes.  After decanting the supernatant, the black 
solid is resuspended, centrifuged, and washed 5 times with 50 mL of methanol and 
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1. NaOH 
2. EtCO2H 
n[Fe(PPIX)H2Cl]   [Fe(PPIX)H]n 
(hemin chloride) 18 hours, 70oC (ß-hematin) 
 
Equation 1.1 Aqueous acid-catalyzed method of hemozoin formation. 
 
   Base 
   MeOH, DMSO 
n[Fe(PPIX)H2Cl]      [Fe(PPIX)H]n 
(hemin chloride) - n HCl  (ß-hematin) 
 
Equation 1.2 Anhydrous non-coordinating base method. 
then 4 times with 50 mL of deionized water or until the filtrate is colorless.  The solid 
is then subjected to a three hour wash in 0.1 M sodium bicarbonate, before 
centrifuging and decanting again, repeating the cycle until the filtrate is colorless.  A 
final water wash is incorporated before drying the product over phosphorous 
pentoxide in vacuo.  
The anhydrous and anaerobic conditions of the reaction play a crucial role in 
the overall yield of hemozoin, for experiments completed without dry solvents or on 
the benchtop decreased the overall yield of hemozoin and noticeably increased the 
amount of material soluble in the sodium bicarbonate wash.   Additionally, the use of 
2,6-lutidine as the base in the reaction is thought to increase product formation, since 
this compound has a lower affinity for transition metals due sterics encountered from 
the ortho-substituted methyl groups.  In contrast, the hydroxide ion used in the 
aqueous preparation of hemozoin could lead to the formation of an iron oxo-bridged 
dimer, accounting for lower yields of the insoluble ß-hematin.   
1.6.  Hemozoin Quantification 
Numerous attempts have been made to quantitatively assess the conversion of 
free hematin into the insoluble crystalline biomineral hemozoin either by microscopy 
or spectrophotometry.  Such attempts have provided merely qualitative assessments 
and such results are discussed hereto.  More sensitive methods are being developed, 
but major obstacles involve the insoluble nature of the hemozoin crystal and the fact 
that once hemozoin is in solution it is spectroscopically indistinguishable from 
ferriprotoporphyrin IX.77 
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      1.6.1.  Direct spectroscopic measurement of heme 
1.6.1a.  UV-Vis Spectroscopy 
The heme moiety from hemozoin absorbs from 388-400 nm depending on the 
substance used to dissolve the pigment.  Quantitation based solely on this 
methodology requires the sample to be relatively pure and free of all unreacted heme 
before analysis since extraneous hematin also absorbs at this wavelength.  
Purification based on differential solubilities is not only tedious and time-consuming, 
but also does not guarantee that any appreciable hemozoin mass is not lost.  This 
method however, remains the primary means by which to analyze hemozoin 
formation. 
1.6.1b.  IR Spectroscopy 
Attempts to quantitate the formation of hemozoin through infrared analysis 
have been achieved with limited successes.  Monitoring the growth in intensity of the 
carboxylate stretching frequencies is only as quantitative as the reaction itself.  The 
rate of reaction in vitro is already known to be affected by pH, temperature, acetate 
concentration etc., thus why should one assume that aliquots removed from the same 
sampled reaction over time will not have an effect the formation of hemozoin 
afterwards?  Even samples prepared simultaneously for individual analysis have 
discrepancies in the absolute peak intensities.  
1.6.1c.  HPLC Analysis 
Many have attempted to quantitate hemozoin production based on the 
differential solubility of hematin and this biomineral using high-performance liquid 
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chromatographic (HPLC) methods.  One such group92 used 4.6 x 75 mm TSK phenyl-
5PW normal and reversed phase columns (Supleco, Bellefonte, PA), injecting a 
quenched assay for hemozoin formation in water directly onto the HPLC system.  An 
initial buffer of 10 mM tetramethylammonium chloride/10 mM heptane 
sulfonate/40% acetonnitrile/60% water/H3PO4 at pH 2.5 ran at 1.0 mL/min for 20 
minutes eluted the free hematin (400 nm), while retaining the hemozoin.  The 
hemozoin was then eluted by adjusting the gradient to 10 mM tetramethylammonium 
chloride/10 mM heptane sulfonate/40% acetonitrile/60% water/NaOH, pH 12.0. 
Assays with 14C hemin demonstrated relatively little mass was lost based on 
scintillation counts of the recovered fractions.  When injecting free hematin, the 
retention times were comparable to the hematin elution profile of the reaction 
mixture.  Fault within this methodology relies on the fact that all of the free heme 
may not be disassociated from the hemozoin when in the first buffer system.  Copious 
washes with sodium bicarbonate, pH 9, or 2% SDS is necessitated in order to remove 
any free heme associated with the hemozoin.  Moreover, does the environment of the 
HPLC system supply an amenable replacement for the profuse washes? If the 
separation by the pH gradient fails to remove all associated free heme, then 
quantitation of the solubilized hemozoin at higher pH is not verifiable. 
1.6.1d.  Mössbauer Spectroscopy 
Egan and coworkers employed Mössbauer spectroscopy in a somewhat novel 
application to probe the kinetics of hemozoin formation.52 Following a standard 
acetate preparation of hemozoin (4.5 M acetate buffer, pH 4.3, 60oC) the group 
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monitored the formation of hemozoin, determining the reaction to be zero-order with 
both seeded and unseeded reactions.  Zero-order kinetics were also observed in 3 M 
and 6 M acetate.  The unique concept in their analysis via Mössbauer (78 K) is that 
hemozoin purification is not necessitated since hematin and ß-hematin have differing 
isomer shifts. Six years later under carefully temperature controlled experiments, the 
group rescinded the notion that hematin and ß-hematin were discernable by 
Mössbauer spectroscopy, reporting temperature dependent electronic relaxation 
effects for both ß-hematin and hemozoin isolated from trophozoites.53  
      1.6.2.  Highlighted Difficulties  
In retrospect, the identification of hemozoin as a marker for the progression of 
malaria is not that difficult, with the simplest diagnostics being the visible marker of 
hemozoin itself.  Quantification is however, seemingly more problematic, with 
relatively few simplistic methods of analysis available, especially when assessing the 
pathogenesis of malaria in the field.  Additionally, in vitro correlations may not 
adequately mimic the environment of the digestive vacuole, while the physical 
limitations of microscopy have not been withstanding in the in vivo attempts at 
hemozoin quantification.   
1.7.  Hemozoin Formation – A Promising Route towards Discovering New 
Antimalarials 
Hemozoin formation is an aggregation process unique to the parasite, making 
its chemical route a potential target for drug therapies.75,78 Though the parasite 
proteolysis of hemoglobin and subsequent formation of hemozoin seem unlikely to be 
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controlled by enzymatic processes,75 understanding the chemical mechanism of        
ß-hematin formation is a prerequisite for understanding the process in vivo.  Most 
researchers agree the formation of hemozoin within the parasite must have some 
nucleation site or template, which serves to initiate the growth of the non-toxic 
sequestered porphyrin.  Until recently this concept was supported by the fact a 
concentration dependent precipitation of the heme seemed unlikely due to the fact not 
all of the heme is detoxified via this mechanism.93-95 Ginsburg et al. alternatively 
proposed glutathione degraded heme once it was transported into the parasite 
cytosol,93,95 while Loria argued a degradation mediated by hydrogen peroxide 
occurred inside the digestive vacuole.94 Both glutathione and hydrogen peroxide are 
known to chemically decompose hemin, and the effects of these species on hemozoin 
are under intense investigation in our lab, as well as in others.96 Egan et al. 
contradicted both authors reporting the fate of heme to be unequivocally incorporated 
into hemozoin.53 Parasitized cells contained the same amount of hemoglobin as 
unparasitized cells, with the parasitized cells digesting up to 80% of the hemoglobin 
contained in the infected red blood cell, incorporating 95% of the degraded heme into 
hemozoin.   
Given that hemozoin crystals are uniform in shape and size, Plasmodium 
falciparum must exert a great deal of control over its synthesis; hence it is termed a 
biomineralization process.  Biology thus plays an active role in this chemical process.  
In vitro, the conversion of hematin into ß-hematin can be promoted in several ways.  
The methods differ in reaction conditions, yet all methods unequivocally produce     
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ß-hematin. Which pathway is biochemically more significant remains to be seen.  
This however, does not diminish the valuable information gained from probing such 
model systems.  Drug screens however can be most effective once a more 
knowledgeable understanding of the process of hemozoin formation is achieved. 
Despite lingering discrepancies amongst the route to hemozoin formation (i.e. 
whether hemozoin formation is promoted by phospholipids or proteins), several sites 
of potential interactions along this route are targets for new antimalarials.  Iron 
chelators, such as deferoxamine, attempt to sequester iron before the parasite can 
utilize it in hemozoin formation.  Several cysteine and aspartic acid protease 
inhibitors serve as antimalarials, inhibiting the initial steps in the breakdown of 
hemoglobin.               
Though the formation of hemozoin in vitro can occur in the absence of any 
preformed hemozoin or added “initiators,” the detoxification of heme by the parasite 
must occur in a timelier manner.  Plasmodium falciparum evolves from the early ring 
stage though the trophozoite stage in a mere 24 hours therefore our conclusion is that 
within the parasitic digestive vacuole, hemozoin formation must be a mediated 
process.  Given that to date, no lipid was isolated from the digestive vacuole, while in 
fact the histidine-rich protein, HRP II, had been localized within this organelle and 
been shown to promote the formation of hemozoin, we attempted to investigate the 
mechanistic role of the histidine-rich proteins in the nucleation of hemozoin.  Though 
no discredit is given to a lipid driven mechanism of hemozoin formation, this route is 
likely improbable in the parasite.  Lipids may very well provide a structural 
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framework in which hemozoin formation can be initiated, and commercial 
unsaturated fatty acids have nucleated hemozoin.  While 80% of the lipids identified 
in the malaria parasite are unsaturated,97 their precise role inside the digestive vacuole 
has yet to be determined.  Could the lipids exact the same effect encountered in the 
acetate preparation of hemozoin and function merely as an agent increasing the 
solubility of hematin?66 Hemozoin has been formed under aphysiological conditions 
with only hemin chloride and acetate buffer.  Moreover, other compounds that merely 
bound heme (i.e. serum albumin and polyhistidine) did not nucleate the formation of 
hemozoin. So why wouldn’t the malaria parasite chose a novel means by which to 
detoxify free heme?  Why would an organism evolve a biomineralization scheme that 
wasn’t unique to itself?  How could the parasite genetically sustain its very existence 
over time if the chosen route to hemozoin synthesis shares commonalities with its 
host and vector?  Why would the parasite synthesize such an extremely insoluble 
biomineral, and not protect its mode of formation?  Genetic preservation and the 
localization of four histidine-rich proteins within digestive vacuole support the role of 
these species-specific proteins in the formation of hemozoin.    
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Chapter 2 
Design and Synthesis of the Bionucleating Templates (BNTs) 
2.1.  Background and Significance 
While the complexity of the life cycle of Plasmodium falciparum harnesses 
the development of thousands of novel stage-specific antimalarials, the recent 
genome sequencing1-4 will not only aid in our understanding of this deadly parasite, 
but also proliferate the number of potential chemotherapeutic agents.  Even with 
high-throughput screening tools, the time frame for the development of new and 
effective drug therapies (Figure 2.1)5 shortfalls the transmission rate of P. falciparum 
and its emerging drug resistance.6 Analysis of the genome sequence has failed to 
reveal any novel parasitic enzymes which are capable of synthesizing amino acids, 
Cytosol
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Figure 2.1.  A schematic of a Plasmodium falciparum trophozoite residing in a
host erythrocyte.  The major organelles are highlighted with potential
chemotherapeutic agents.  Reproduced from reference 5. 
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thus the disruption of hemoglobin degradation and subsequent formation of hemozoin 
remain viable antimalarial targets,7,8 since the parasite must rely on host hemoglobin 
as its main source of requisite amino acids.  Though few direct methods for 
examining antimalarial effectiveness in terms of hemozoin inhibition exist to date,9-11 
this route remains one of the most promising means by which to combat malaria.  
Antimalarials, which function to antagonize the nucleation and/or formation of 
hemozoin, will indubitably result in parasite death due to unavoidable toxic 
accumulation of free heme.  Additionally, disrupting heme detoxification via this 
mechanistic approach should have little consequential effect on the host, since 
humans can biologically process free heme through the heme oxygenase/biliverdin 
reductase pathway. 
The size and shape uniformity of hemozoin crystals indicates that Plasmodium 
must precisely control its biosynthetic route of β-hematin formation.  In vitro, the 
conversion of hematin into hemozoin may be promoted via several pathways.  
Lipids,12-16 histidine-rich proteins (HRPs),17-19 and preformed hemozoin20 mineralize 
the crystalline malaria pigment de novo (For the most recent reviews see Egan21 and 
Sullivan22).  The mechanics of β-hematin formation in vivo however, are largely 
controversial due to the fact the biochemical processing of hemozoin involves the 
intimate contact of the parasite with a host erythrocyte.  Such interactions are further 
complicated by the numerous asexual growth and developmental stages that the 
parasite undergoes while residing in the human host.   
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The proposal that hemozoin formation was controlled through catalytic events 
was rejected when Dorn20 demonstrated that hemozoin, isolated from the parasite, as 
well as chemically synthesized β-hematin, could seed the reaction of the malarial 
pigment.  The biochemical processing of hemozoin was then theorized as a template 
mediated nucleation event rather than an enzymatic route to formation.  Since both 
lipids and HRPs bind heme and nucleate the formation of hemozoin in vitro, the 
question is then redirected to which model template is more physiologically relevant 
in the metabolic processing of the malarial parasite?  In other words, which controls 
the task of sequestering free heme inside the digestive vacuole and ultimately 
safeguarding the proliferation of the parasitic life form? 
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Figure 2.2.  The abiological synthesis of
hemozoin.  Reproduced from reference 23. 
Hemozoin either formed by Plasmodium falciparum or chemically 
synthesized is identical in both its chemical composition and spectroscopic properties.  
Knowing that P.  falciparum evolves from the early ring stage through the trophozoite 
stage in a mere 24 hours and that 
the abiological synthesis of the 
malaria pigment requires 6 days 
and nonphysiological conditions23 
(Figure 2.2), our hypothesis is 
that within the parasitic 
digestive vacuole, hemozoin 
formation must be a mediated 
process. 
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Plasmodium must carefully regulate its susceptibility to oxidative stress, 
avoiding the toxic effects of free heme accumulation and the ensuing potential 
oxidative damage that can occur in the digestive vacuole.  Though the parasite’s 
obvious portal is the sequestration of hemozoin, other metabolic processes can be 
hypothesized to prevent or reduce oxidative damage.  A secondary line of defense can 
be envisioned upon consideration of the acidic nature of the digestive vacuole.  
Chemically, the reactivity of iron (III) protoporphyrin IX, the monomeric unit of 
hemozoin, is reduced in acidic environments.  At low pH, free heme aggregates as 
less chemically reactive µ-oxo dimers.  Though this dimer formation would link two 
molecules of hematin via an oxygen atom in the axial position and not by the required 
propionate linkage necessary for the formation of hemozoin, the acidic nature of the 
digestive vacuole could suppress oxidation reactions and represent an additional 
targeted mode of antimalarial drug action.  As a consequence, the consideration of the 
complex homeostatic equilibrium within the digestive vacuole, and particularly the 
acidic pH (4.8-5.2), is fundamental to studying the underlying mechanics of 
hemozoin formation.   
Though there is little doubt that lipids can mediate the formation of hemozoin 
in vitro, many questions surround a lipid-mediated formation of hemozoin in vivo.  
Since as early as the late 1960’s when S. B. Brown reported the hydrogen peroxide 
oxidation of iron protoporphyrin IX,24-26 free heme has been known to have 
deleterious oxidative effects on several substrates including polyunsaturated fatty 
acids.  However, once hemozoin is engulfed by macrophages, it promotes the 
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oxidation of fatty acid substrates, specifically arachidonic and linoleic acid to a 
mixture of hydroxy eicosatetraenoic and hydroxy octadecadenienoic acids 
respectively.27-29 Why then, would Plasmodium falciparum choose to nucleate 
hemozoin on a template that it could later potentially destroy?    
In addition to this, the debate continues as to whether or not Plasmodium 
falciparum can synthesize its own fatty acids.  Originally Plasmodium falciparum 
was thought to scavenge fatty acids from host erythrocytes; being truly parasitic, 
relying on its host not only for requisite amino acids, but also supplying the template 
for its heme detoxification process.  New evidence of a type II fatty acid biosynthesis 
now exists both in vivo and in vitro for the parasite,30 originating from the 
identification of several fatty acid synthase (FAS) genes.  Waller and colleagues 
recently determined that fatty acid inhibitors, such as thiolactomycin and triclosan, 
exhibited pronounced sensitivities in the early ring stage of parasite growth.  If lipids 
were structural scaffolds for the nucleation of hemozoin then why would inhibitors 
display markedly increased activities in the growth stage that has relatively little or no 
hemozoin formation occurring?  Obviously more detailed studies, including fatty acid 
quantification, are needed.   
The HRPs appear to be the parasite’s most probable template for the 
nucleation of hemozoin.  A histidine-rich protein, HRP II, isolated from the digestive 
vacuole of P. falciparum (refer to Figure 1.12 for the sequence of HRP II), not only 
promoted the formation of hemozoin, but also bound 17 equivalents of heme.17 Given 
that the parasites can multiply an estimated eight times every two days,31 the 
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efficiency of sequestering heme is of utmost importance for the viability of 
Plasmodia, especially since each proteolyzed molecule of hemoglobin releases four 
molecules of heme.  Simply in terms of binding affinities, the HRPs appear to expend 
less metabolic energy based on effective arrest of free heme.  A HRP templated 
formation of hemozoin can also be argued from the perspective of genetic 
preservation.  Why would the parasite not evolve a detoxification scheme that was 
unique to itself?  
Given that to date, no lipid was isolated from the digestive vacuole, while 
in fact the histidine-rich protein, HRP II, had been localized within this 
organelle and been shown to promote the formation of hemozoin, we 
investigated the role of the histidine-rich proteins in the nucleation of hemozoin. 
 To date, four histidine rich proteins (HRP I, HRP II, HRP III, and HRP IV) 
have been isolated from P. falciparum and share sequence homology.  HRP I is knob 
associated and thought to be involved in cytoadherence and red blood cell rosetting, 
being only synthesized in the early stages of gametocyte development.32 HRP II,  
HRP III, and HRP IV are localized in the digestive vacuole of Plasmodium 
falciparum and possess an usually high percentage of alanine and histidine        
(Table 2.1).  HRP II, a 35 kD protein, is synthesized by the parasite during all stages 
Table 2.1.  Sequence Homology of the HRPs. 
Protein % Composition (His & Ala) 
# of Ala-His-His 
Repeats 
HRP II 76% 51 
HRP III 56% 28 
HRP IV 31%  
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of intraerythrocytic growth17,33 and metabolically exported to the cytoplasm, as 
evidenced by its detection as a water soluble protein in culture supernatant.34 HRP II 
not only aggregated hemozoin, but also was effectively inhibited by chloroquine, a 
known antimalarial.  Additionally when HRP II was used antigenically in Aotus 
monkey trials, the protein elicited protective immunity against Plasmodium 
falciparum.35,36 HRP III, a 27 kD protein, was isolated in the digestive vacuole of 
mutants devoid of HRP II expression.  A genetic cross strain which did not contain 
HRP II or HRP III still cross reacted with monoclonal antibodies from both proteins 
and was characterized as HRP IV (Mr 10 kD).37 
2.2.  The Histidine-Rich Proteins Evidenced as Templates in the 
Biomineralization of Hemozoin 
Despite the fact the HRPs have definitive sequence characterizations, the 
biological roles of these proteins remain obscure.  Recent site-directed mutagenesis 
studies of non-overlapping synthetic peptides of HRP I, HRP II, and HRP III have 
demonstrated that only HRP I possessed multiple high activity red blood cell (RBC) 
binding sites found in the central lysine rich region II (residues 301-480) of the native 
protein.38 More specifically, the screening of the HRP II mutants presented only one 
RBC binding sequence, which was a non-repetitive N-terminal sequence rich in 
asparagine residues, while HRP III failed to exhibit any specific erythrocyte binding.  
Though it has long been proposed the highly repetitive nature of Plasmodium 
falciparum proteins is advantageous to the parasite,39 its exact molecular role as a 
scaffolding protein in heme detoxification has yet to be determined.  Specific 
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interactions between the HRPs and heme remain elusive, though HRP II has been 
widely used in immunochromatographic methods for the detection of malaria 
(ParaSight F® and ICT®) and was recently highlighted as an unexplored antimalarial 
strategy.40  
Research collected thus far on the plausible role of the HRPs in the formation 
of hemozoin is indicative of a nucleation process rather than a catalytic event.  The 
presence of a specific amino acid repeat motif [Ala-His-His-Ala-His-His-Ala-Ala-
Asp in HRP II, and Ala-His-His-Ala-Ala-Asn-Ala-His-His-Ala-Ala-Asn (N-
terminus) and Asp-Asp-Ala-His-His-Asp-Gly-Ala-His-His (C-terminus) in HRP III] 
is reminiscent of nucleating scaffold proteins utilized by other biological systems in 
biomineralization processes.41,42 Such systems exploit the three-dimensional structure 
succumbed by protein folding as a surface on which to organize well-defined 
inorganic solid state materials, which function as structural supports or defense 
mechanisms43 for the organisms. Much like diatoms precipitate species specific 
hydrated silica from silaffin proteins,44 and the carnivorous marine worm Glycera 
biomineralizes atacamite, a copper chloride mineral with an associated but 
uncharacterized protein rich in glycine and histidine,45 P. falciparum controls 
hemozoin nucleation and formation on the surface of the histidine-rich protein.   
Like other known biominerals (e.g. calcite, hydroxyapatite, magnetite, etc.), 
hemozoin has a rather straightforward mineral composition, but a more complex 
structural characterization in which the lattice organization somehow reduces 
solubility.41 Besides P. falciparum, all other members of the Plasmodium species, as 
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well as a few non-Plasmodium species such as Schistosoma mansoni, Rhodinius 
prolixus, and Heamoproteus columbae, synthesize the malarial pigment.  The 
pigment deposited by these organisms varies slightly amongst species in crystalline 
surface morphologies (Figure 2.3).46 Intrinsic parasite differences, physiological 
variations (i.e. hemoglobin concentration, ion and salt concentration, and pH), or host 
dissimilarities are postulated to contribute to the final morphological shape of the 
crystal.47 Such variances in three-dimensional structure are also predicted to alter not 
only hemozoin formation, but also pigment degradation and reactivity. The shape 
heterogeneity of the crystals is reminiscent of yet another property of biominerals, 
most demonstratively visualized in the variation amongst the intricate details of the 
silicon dioxide shells of diatoms of different species.    
 In all instances, understanding how biology deposits inorganic materials into 
or onto an organic matrix with precisely controlled spatial and temporal details has 
intrigued scientists such that biomimetic chemistry has evolved as an attempt to 
synthesize advanced materials with specifically tailored properties.  Belcher et al. 
have recently determined that calcium carbonate biomineralization in vivo in red 
abalone (a marine snail) is controlled morphologically by the sequential release of 
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Figure 2.3.  Field emission inlens scanning electron microscopy (FEISEM) of
hemozoin purified from (a) Plasmodium falciparum (b) Schistosoma mansoni and
(c) Haemoproteus columbae.  Reproduced from reference 46. 
differing proteins.48 Moreover, a peptide, rich in proline, tyrosine, and glycine, is 
secreted prior to inorganic calcium nucleation, highlighting the importance of a 
protein scaffold in directing biomineral formation.  
From the perspective of biomineralization, we believe the HRPs play a 
critical role in the biological initiation/nucleation of hemozoin.  We hypothesize 
the organization of the alanine-histidine-histidine repeats within the histidine-
rich proteins of P. falciparum create unique nucleation sites for the 
crystallization of hemozoin. 
Using Plasmodium falciparum derived proteins for biomineralization studies 
pose several problems.  First and foremost, rationally designing a synthetic gene that 
would encompass simultaneous changes in a putative nucleating domain is both 
problematic and laborious.  Secondly, these proteins come from a highly infectious 
organism and culturing infectious agents musters great safety concerns.  Additionally, 
the highly repetitive DNA sequences in the HRPs make sequencing and expression 
difficult since the high adenine (A) and thymine (T) content (80%) causes replication 
problems in typical E. coli cultures since these simplistic organisms can not 
effectively replicate cDNA greater than 5 kb.  Some success has been met with yeast 
artificial chromosome (YAC) systems and fusion proteins, but effective sequencing 
remains challenging.  Additionally, cell cultures must be kept synchronized in order 
to keep the parasites in the same developmental stage. 
In retrospect, the culmination of these synthetic difficulties highlights the 
necessity of a model system.  Understanding the biochemical processing of hemozoin 
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formation will not only aid in the development of novel antimalarials, but it may also 
provide insight into the very sustenance of Plasmodium, the causative agent of a 
deadly disease that has subsisted for over 1000 centuries. 
2.3.  Design and Development of a Model HRP System  
While previous experiments using polyhistidine and linear multimer peptides 
comprised of Ala-His-His-Ala-Ala-Asp49 bound heme, all failed to nucleate the 
formation of hemozoin.  With this in mind, synthetic peptides attempting to 
bionucleate the formation of hemozoin must adhere to several design criteria.  First, 
the template must contain a minimal set of recognition motifs necessary to not only 
bind heme, but also nucleate ß-hematin.  Secondly, to effectively mimic the native 
protein, the template should bind approximately the same number of heme as HRP II.  
Finally, the template should possess some secondary structure since in vivo 
observations have determined that secondary, tertiary, and quaternary structure is 
imperative in attempts to mimic biological biomineralization processes.  Inherent 
intermolecular aggregations and intra-template interactions should be minimized in 
the overall topology to avoid blocking or capping the plausible nucleating domain, 
preventing the aggregation of hemozoin at the inorganic-organic interface.  
With a limited understanding of protein folding mechanisms, difficulties arise 
when attempting to predict amino acid sequences that will yield desired three-
dimensional scaffolds.  Dendrimers, synthetic compounds that have highly 
symmetrical polymeric branches radiating from a central core, have allowed scientists 
to ascertain some structural control in materials science.  The interspatial voids 
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stemming from the regularly repetitive nature of the branches have permitted the 
inclusion and/or confinement of ions and molecules.  The exploitation of such “host-
guest” chemistry has attracted the attention of scientists as a means of constraining 
size and shape in three-dimensional space.  While short linear peptides lack 
conformation, peptide dendrimers provide an appealing framework on which to 
incorporate non-conventional vectoral growth and porosity.  Furthermore, 
dendrimeric branches can be fine-tuned to control not only the architecture, but also 
functional interactions between the template and substrate.  Molecular recognition 
sites can be directly engineered into the structural design, insomuch that inorganic 
binding sites can be spatially arranged to control both physical properties and 
spectroscopic characterizations.  
Peptide dendrimers are broadly defined as dendrimers with peptide bonds50,51 
having found applications in the development of vaccines,52-56 diagnostic 
reagents,57,58 drug delivery systems,59 catalysts,60,61 inhibitors,62 and antimicrobials,63 
while also functioning as protein models.64-66   The assembly of synthetic peptides 
onto a template or scaffolding permits the construct not only to obtain the three-
dimensional bulk characteristic of classical dendrimers, but moreover to ascribe to the 
globular nature of proteins. The most common peptide dendrimers are constructed on 
a multiple antigen peptide system (MAPS), which unlike classical dendrimers, which 
have a central core, branching segments and terminal functionality, lack a centered 
focal point, branching from only one end.  These systems were first developed by 
Tam in attempt to present multiple copies of antigens from a single core in order to 
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increase immunogenic activities.67,52  
MAPS are often preferred over tandem peptide multimers68 since the 
polymeric peptide may posses an altered secondary structure due to its peptide chain 
elongation.  Along this same line of reasoning, MAPS often exhibit enhanced 
sensitivities over multimeric peptide copies due to an increased number of 
interactions per given unit surface area (i.e. increased density of potential binding 
sites).  Lysine is the most commonly used amino acid in the core, providing sites for 
branching segments through the α and ε amino ends.69 Multiple copies of peptide 
segments are conjugated either directly or through standard solid phase peptide 
synthesis protocols.  Commercially available MAPS include 4-branch or 8-branch 
lysine cores typically conjugated to a solid polymer resin of polystyrene with 1% 
divinylbenzene through an alanine or glycine linkage (Figure 2.4). 
Figure 2.4.  Fmoc-4-branch
MAPS resin. 
MAPS offer several advantages over 
other peptide conjugates,69,70 both kinetically 
and thermodynamically.  MAPS are stable in 
solution over a pH range from pH 2-9 and 
can also be lyophilized as a powder, which is 
advantageous over the storage conditions of 
recombinant proteins.  Additionally, the relatively small size of the lysine core allows 
the peptide to comprise the majority of the conjugate mass, which contrasts other 
peptide carriers in which the peptide mass is small compared to the relative mass of 
the carrier.  This same design construct permits the N-terminus (distal end) of the 
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peptide to be more flexible, while the C-terminus is constrained against the lysine 
scaffolding.  This, plus the close packing of the peptide segments allows the branches 
to conform to some secondary structure and enhance the overall stabilization of the 
peptide.   Conversely, the restricted space against the lysine core could also become 
problematic by increasing the steric hinderance between the peptide chains.  These 
interactions generate smaller, less accessible interstitial spaces near the core 
compared to other sites further along the peptide branch. 
Standard solid phase peptide synthesis on MAPS resins is far from trivial.  
Though many have successfully constructed peptide segments on the lysine core, 
inter-chain interactions are often problematic.71 Using lower loading resins               
(< 0.4 mmole/g and < 0.8 mmole/g for 4-branch and 8-branch MAPS respectively) 
improve synthetic yields and homogeneity by minimizing chain aggregations and 
enhancing solvent permeability.  Fewer substitutions on the resin (less coverage) 
increase the interstitial distance between peptide segments and decrease the steric 
constraints near the surface.  Controlling the population of lysine residues on the 
surface of the resin allows a greater surface area for resin swelling, which also leads 
to more efficient coupling since hydrogen bonding between the peptide chains and N-
termini is diminished.  Efficient coupling is essential in MAPS syntheses since 
deletions in the amino acid sequences are more prevalent, since all branches must be 
coupled simultaneously.  Interestingly, the tetrameric MAPS have no real advantages 
over the 8-branch MAPS when greater than 15 amino acid residues are used in the 
synthesis of the peptide.69,68  
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Recalling that native HRP II bound 17 equivalents of heme per molecule17,72 
(pH 4.8), MAPS offer an excellent template on which to incorporate multiple heme 
binding sites so as to mimic a heme binding efficiency similar to that of the native 
protein.  Moreover, the constructive design of the MAPS with a certain degree of 
rigidity near the lysine core, not only allows for the incorporation of secondary 
structure along the peptide chain, but also maintains sufficient interbranching distance 
which permits the allocation of three-dimensional space necessary for the crystalline 
aggregation of hemozoin, a critical feature missing in the linear peptide and multimer 
constructs.      
Upon examining the sequence of HRP II, in which histidine and alanine 
comprise 76% of the native protein, Ala-His-His is repeated 51 times.  Knowing that 
histidine can bind a variety of metals, this tripeptide was further scrutinized as a 
possible repeat unit within a putative nucleating domain for the formation of 
hemozoin.  Knowing that native HRP II bound 17 equivalents of heme, while also 
nucleating the formation of hemozoin, this trimeric repeat was examined for a 
plausible higher-ordered organizational scheme.  From this, two possible nucleating 
domains can be identified: the 9-mer sequence Ala-His-His-Ala-His-His-Ala-Ala-
Asp (repeated 16 times within the native protein), and Ala-His-His-Ala-Ala-Asp-
Ala-His-His (repeated 23 times).  These two amino acid sequences were 
hypothesized to be putative nucleating domains within HRP II and were 
evaluated for possible roles in the formation of hemozoin through synthetic site-
directed mutagenesis studies.  
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2.4.  The Ala-His-His-Ala-His-His-Ala-Ala-Asp Putative Domain – Initial studies 
of a Model HRP System  
2.4.1.  Chemical Characterization 
In order to uncover the components of the heme moiety in Fe(III)PPIX that 
were critical for the nucleation of hemozoin on HRP II, Ziegler et al. constructed a 
first and second generation 4-branch MAPS peptide dendrimer based on the putative 
9-mer sequence Ala-His-His-Ala-His-His-Ala-Ala-Asp, where each Ala-His-His 
tripeptide repeat was postulated to serve as the binding domain for the natural 
substrate, Fe(III)PPIX.73 The first bionucleating template, BNT I (a 1st generation 
dendrimer with 1 tandem 9-mer repeat per lysine branch), contained 8 Ala-His-His 
repeats, while a second model, BNT II, (a 2nd generation dendrimer with 2 tandem   
9-mer repeats per lysine branch) possessed 16 such repeats, capitalizing on the 
branched nature of the dendrimer core to incorporate multiple binding domains.  
Initial studies indicated the N-acylated synthetic peptides synthesized according to 
standard Fmoc solid phase synthesis protocols tested positive for monoclonal 
antibodies for HRP II using the commercially available ParaSight F test from 
Becton-Dickson Pharmaceutical (Sparks, MD). 
In addition to Fe(III)PPIX, several other substrates [protoporphyrin IX 
(PPIX), Zn (II) protoporphyrin IX (Zn(II)PPIX), tetrasulfanatophthalocyanine (PcS), 
and nickel (II) tetrasulfanatophthalocyanine (Ni(II)PcS)] were recognized by the 
BNTs (Table 2.2, Figure 2.5 and 2.6). BNT I, with eight Ala-His-His trimeric 
repeats, bound 7.1 ± 0.7 equivalents of Fe(III)PPIX.  More significantly, BNT II, with 
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Table 2.2.  Substrate Binding Stoichiometries of BNT I and BNT II. 
 
Substrate BNT I 
(8 Ala-His-His repeats) 
BNT II 
(16 Ala-His-His repeats) 
Fe(III)PPIX 7.1±0.7 12.2±1.0 
PPIX 7.7±0.2 10.4±1.0 
Zn(II)PPIX 6.8±0.5 14.0±0.6 
PcS 5.7±0.2 13.2±1.0 
Ni(II)PcS 6.5±0.1 11.0±1.0 
double the number of postulated heme binding sites, bound 12.2 ± 1.0 equivalents of 
Fe(III)PPIX, approximately twice as much substrate as BNT I.  BNT II bound 
approximately twice the amount of the other substrates as well.  Assuming the 
trimeric repeat Ala-His-His is the binding domain of the template, Fe(III)PPIX (and 
the other substrates) failed to be incorporated into all of the putative binding sites of 
BNT II (16 sites), but this was not surprising given the dendrimeric nature of the 
peptide restricts accessibility near the core due to inherent steric constraints.  BNT I is 
less sterically hindered and therefore, its stoichiometric binding is more closely 
correlated to the number of incorporated synthetic binding sites.  
Since protoporphyrin IX and tetrasulfanatophthalocyanine were also capable 
of binding to the templates, the association of the substrate with the BNT templates 
was not dependent on a metal recognition site, suggesting that substrate recognition 
was not mediated by axial ligation of a histidine residue to a metal ion.  Under the 
conditions employed in the binding assay (100 mM acetate buffer, pH 4.8, mimicking 
the environment of the digestive vacuole of P. falciparum), the imidazole ring of the 
histidine is likely protonated since the pKa of the side chain is 5.8.  Since this moiety 
is likely unavailable for axial ligation, interactions must be through π-stacking and/or 
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electrostatic forces.  A recent study of recombinant HRP II of P. falciparum 
demonstrated a similar pH dependence on heme binding.74 
After each stoichiometric binding maxima, the difference titration curves for 
the substrates show a slight negative divergence from the plateau expected with 
saturable binding of the template (Figures 2.5 and 2.6).  At high substrate 
stoichiometries a number of aggregative interactions are possible that could 
eventually result in precipitation.  Such interactions are likely responsible for this 
negative trend noted after maximal binding and are particularly prominent with 
Fe(III)PPIX, the natural substrate for the HRP proteins.  This behavior may be a 
result of the self-aggregative properties of the porphyrin substrate, but biologically 
this could be indicative of the very precise management that P. falciparum must 
ascertain in its detoxification of heme.  
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Figure 2.5.  Substrate binding stoichiometries for BNT I.  (A) Fe(III)PPIX
(B) Zn(II)PPIX  (C) PPIX (D) Ni(II)PcS (E) PcS.  Briefly, aliquots of a stock
solution of substrate (~ 1 mM) dissolved in 0.1 M NaOH were added to a
100 mM acetate buffer solution, pH 4.8, containing the appropriate amount of
nucleating template, BNT I (2-2.5 µM), and a 100 mM acetate buffer blank
solution.  Samples were equilibrated for 15 minutes prior to measurements.  
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Figure 2.6.  Substrate binding stoichiometries for BNT II.  (A) Fe(III)PPIX
(B) Zn(II)PPIX (C) PPIX (D) Ni(II)PcS (E) PcS.  Briefly, aliquots of a stock
solution of substrate (~ 1mM) dissolved in 0.1 M NaOH were added to a 100 mM
acetate buffer, pH 4.8, containing the appropriate amount of nucleating template,
BNT II, (1-1.5 µM) and a 100 mM acetate buffer blank.  Samples were equilibrated
for fifteen minutes prior to measurements. 
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More significant than binding substrates, the templates also mediated the 
formation of hemozoin (Figure 2.7) according to the in vitro heme polymerization 
assay of Sullivan.17 In the presence of free heme under acidic conditions, the 
templates promoted the formation of insoluble heme aggregates.  Polyhistidine, 
lysozyme, bovine serum albumin (BSA) and an acetate buffer control failed to 
aggregate the malarial pigment.  (Both Dorn13 and Orjih75 reported background 
hemozoin formation at 1-2 nmoles under similar experimental conditions.)  The 
results demonstrated that BNT II nucleated twice the amount of hemozoin as BNT I, 
which had half as many putative nucleating domains attached to the lysine core.  
Chloroquine (CQ) also inhibited the template-mediated production of hemozoin in 
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Figure 2.7.  Hemozoin production mediated by the bionucleating templates and
other protein substrates.  The baseline amounts are consistent with previously
published reports.13,77  
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both template assays.  Additionally hemozoin was formed in a concentration   
(Figure 2.7), time (incubation period) (Figure 2.8), and pH dependent manner 
(Figure 2.9), analogous to the activity of HRP II.  Activity diminished above a pH of 
4.8, the approximate pH of the digestive vacuole of the parasite, and as it approached 
the pKa of the imidazole side chain.  The ionic strength of the acetate buffer had little 
effect on the aggregation of hemozoin (Figure 2.10). 
The BNT mediated insoluble heme aggregates were characterized by Fourier 
transform infrared (FT-IR) spectroscopy and exhibited the characteristic vibrational 
frequencies of hemozoin76,46,22 at 1660 cm-1 and 1210 cm-1 (Figure 2.11).  The BNT 
mediated hemozoin also shared similar synchrotron x-ray powder diffraction (XRD) 
patterns with those of hemozoin isolated from P. falciparum77 (Figure 2.12). 
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 Figure 2.8.  Time evolution for the BNT mediated 
formation of insoluble heme aggregates.  Hemin (50 µM) 
dissolved in 0.1 M NaOH was incubated at 37 0C with 
2 nmoles of template in 2 mL of acetate buffer (500 mM, 
pH 4.8) for the time intervals indicated. 
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Figure 2.10.  Effect of acetate buffer concentration on the BNT mediated formation 
of insoluble heme aggregates.  Hemin (50 µM) dissolved in 0.1 M NaOH was 
incubated at 37 0C with 2 nmoles of BNT II in 2 mL of acetate buffer (pH 4.8) at 
the various indicated ionic concentrations. 
Figure 2.9.  pH dependence of the BNT mediated formation of insoluble heme 
aggregates.  Hemin (50 µM) dissolved in 0.1 M NaOH was incubated at 37 0C with 
2 nmoles of template in 2 mL of acetate buffer (500 mM) at the indicated pH for 
48 hrs. 
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Figure 2.11.  Comparison of FT-IR spectra of native hemozoin from Plasmodium 
falciparum and that mediated by the bionucleating templates, BNT I and BNT II. 
10 15 20 25 30
B
A
In
te
ns
ity
2θ
 
Figure 2.12.  Comparison of the synchrotron x-ray diffraction patterns of (A)
hemozoin mediated by BNT II and (B) hemozoin from Plasmodium falciparum. 
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 Common antimalarials, chloroquine and Zn(II)PPIX, inhibited the BNT 
mediated formation of hemozoin in a dose dependent manner (Figure 2.13), with 
IC50’s on the same order of magnitude as those previously determined for HRP II.17 
Martiney et al. had previously shown that Zn(II)PPIX and similar analogues inhibited 
the formation of hemozoin in Plasmodium falciparum trophozoite extracts,78 by 
binding to nucleation sites preventing the templating of Fe(III)PPIX.  With the BNTs 
responding similarly in a concentration dependent manner, substrate recognition was 
not based solely on ferric protoporphyrin IX metal specificity, but through π-π 
stacking or electrostatic interactions.  Though this suggested ß-hematin inhibition 
occurred by the substrate blocking the nucleation sites on the template, other 
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Figure 2.13.  Inhibition of BNT II mediated production of hemozoin.  (A) Effect of
increasing concentrations of known antimalarial chloroquine.  Results of the assay
consisting of 50 µM hemin and 1 µM BNT II in 2 mL acetate buffer (500 mM,
pH 4.8, 37 0C) and increasing concentrations of chloroquine revealed an
IC50 ≈ 30 µM.  (B) Effect of increasing concentrations of Zn(II)PPIX.  Results of the
assay consisting of 50 µM hemin and 1 µM BNT II in 2 mL acetate buffer (500 mM,
pH 4.8, 37 0C) and increasing amounts of Zn(II)PPIX revealed an IC50 ≈ 125 µM.
Each point represents the average of three individual assays with a standard deviation
of  < 5%.  The line through the data represents a multi-order exponential fit. 
81 
mechanisms of ß-hematin inhibition could possibly exist.  Besides association with 
the template, the antimalarial could interact with heme, physically preventing the iron 
porphyrin moiety from associating with the nucleating scaffold.  Additionally, the 
drug could interact with a possible heme:template complex blockading the faces of 
the biomineral impeding further hemozoin aggregation.  
2.4.2.  Conformational Analysis  
Despite its repetitive sequence similarity to the histidine-rich glycoprotein 
(HRG) (Gly-His-His-Pro-His-Gly repeat units), the nucleating domain of HRP II 
must be in association with heme via a mechanism that is vastly different from the 
bis-axial coordination that occurs with HRG.79,80 If heme binding to the putative 
binding site of HRP II were to occur via bis-axial coordination, the formation of 
hemozoin could not proceed because the protein would cap the heme substrate, 
sterically blocking the propionic side chain of the heme moiety from dimerizing with 
another heme molecule.  Moreover, under the acidic conditions that exist in the 
digestive vacuole as well as those mimicked in vitro (pH 4.8-5.2), a histidine-heme 
axial ligation is improbable since the imidazole of histidine is likely protonated, given 
the pKa of the histidine side chain has a value of 5.8.  Such results are consistent with 
the pH dependent formation of hemozoin, as well as with the abiological growth 
pattern of this biomineral. 
Given that the current structural model of hemozoin is a hydrogen bonded 
network of heme dimers, the propagation of ß-hematin must permit translational 
growth only after heme molecules occupy two proximal sites on HRP II.  A linear 
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peptide of the same 9-mer sequence, Ala-His-His-Ala-His-His-Ala-Ala-Asp, bound 
heme, but failed to mediate the formation of hemozoin.  This result, along with a 
previous study in which a hexapeptide, Ala-His-His-Ala-Ala-Asp, and its multimers 
failed to promote the formation of hemozoin,49 demonstrates the necessity of 
geometric and steric constraints in the formation of the malaria pigment.  The BNTs, 
because of the designed scaffold, possess not only the correct spatial orientation for 
heme binding, but also a surface for which to align the heme units in a temporal 
fashion so as to accommodate the formation of an iron-carboxylate bond in which the 
iron of one heme moiety is linked to a propionate group of another, propagating 
hemozoin formation by providing the necessary translational symmetry.  
In fact, circular dichroism (CD) studies supported this assessment         
(Figure 2.14).  The CD spectra of the linear peptide models (AHHAHHAAD and 
(AHHAHHAAD)2), which failed to support the formation of hemozoin, were 
identified as unordered or random-coiled structures (inset of Figure 2.14).  The 
AHHAHHAAD peptide possessed a negative band at 201 nm, maintaining a negative 
CD signal throughout the remainder of the spectrum.  The 18-mer model peptide, 
(AHHAHHAAD)2, had a negative band red-shifted to 198 nm, but the CD signal 
crossed over into the positive region of the spectrum at 217 nm.  The BNT models, 
which supported the aggregation of β-hematin, exhibited more definitive secondary 
structure above the 210 nm portion of the CD spectra.  BNT I shared spectral markers 
with the linear 18-mer peptide, (AHHAHHAAD)2, by also possessing a negative 
band at 198 nm and a positive crossover at 217 nm, but this dendrimer also had a 
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Figure 2.14.  Circular dichroism spectra of the nucleating domain peptides, native 
HRP II from Plasmodium falciparum and a 310 helix.  (…..) peptide AHHAHHAAD, 
(___) peptide (AHHAHHAAD)2, (---) BNT I, (     ) BNT II, (…..)310 helix, and (    ) 
HRP II.  Peptides lacking a definitive secondary structure are highlighted in the inset. 
The spectra of a 310 helix and HRP II are reproduced from references 80 and 73 
respectively. 
positive shoulder at 222 nm with an additional crossover at 230 nm into a deeper 
negative minimum at 240 nm, suggestive of a higher ordered structure.  Such minor 
secondary structure of the BNT I template could further explain that while the model 
did support the template mediated formation of hemozoin, ß-hematin aggregation 
according to the assay conditions was not above the baseline levels of 1-2 nmoles 
unless the concentration of the template was increased.  The CD spectrum of BNT II 
differed, with a predominant negative blue-shifted band at 202 nm, a crossover band 
at 219 nm, a slightly positive shoulder at 222 nm, and a negative minimum at 234 nm. 
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  Early conformational studies of HRP II from both Plasmodium falciparum81 
and Plasmodium lophurae82 described similar CD spectral markers.  Both of these 
histidine-rich proteins had relatively little absorbance above 250 nm due to its low 
occurrence of aromatic amino acids, and the majority of the spectrum maintained a 
near negative CD signal except for the predominant sharp negative band at ~200 nm, 
which is attributable to the high occurrence of histidine residues.  Specifically, the 
spectrum of the HRP protein from Plasmodium lophurae had a deep negative band at 
207 nm, a crossover band at 215 nm and a positive band at 222 nm; while the CD 
spectrum of the species Plasmodium falciparum was less well-resolved, possessing a 
deep negative band at 200 nm, with a possible shoulder at 225 nm that was less 
discernable.   
The CD spectrum of Plasmodium falciparum HRP II was further detailed by 
Lynn et al. who examined the effects of pH on the conformation of the recombinant 
form of the protein (rHRP II).74 Despite lacking a good representative CD spectrum 
of a 3-10 helix, the authors concluded the signature deep negative band at 200 nm, 
normally ascribed to random-coil/unordered structures, was anything but unordered, 
due to the unique stability of this protein over a broad range of pHs, ionic strengths, 
and temperatures, as well as its anomalous movement on SDS gel.  Instead the 
authors compared the CD spectrum of the protein to that of polyproline in 
trifluoroethanol (TFE), which forms a left-handed helix with three residues per turn 
forming a polyproline type II secondary structure (PPII), possessing a strong negative 
band at 206 nm and a weak positive band at 226 nm. 
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Without the crystal structure of HRP II, the unambiguous characterization of 
the conformation of the protein cannot be determined by CD data alone.  Despite this, 
and the fact the high histidine content of HRP proteins masks the behavior of the 
peptide backbone in the low ultraviolet region of the spectra, the exact conformation 
of the protein and our model peptides (which have also not been successfully 
crystallized) is not imperative for the interpretation of our experimental data.  Our 
explanation will instead focus on the fact that in either conformation (a 3-10 
helix is right-handed, while a polyproline II type secondary structure forms a 
left-handed helical turn), the helix has three residues per turn, which establishes 
a hydrophobic face of alanine residues based on the sequence of the amino acids 
examined.   
By comparison, the CD spectrum of our BNT II model suggests the peptide is 
conformationally similar to the rHRP II reported by Lynn et al, having a similar deep 
negative band at 202 nm and a shoulder at ~ 220 nm.  Despite the inherent differences 
in secondary structure that can occur in a globular protein like HRP II which has a 
molecular weight of 35 kD, the local conformation of our ~8,000 g/mole dendrimeric 
peptide is strikingly similar.  Since our linear peptide models lack any appreciable CD 
signal, the MAPS core must contribute to the overall secondary structure of the 
peptide.  The construct rigidity has not been examined in detail in the literature and 
the few examples of circular dichroism spectroscopy of MAPS dendrimers fail to 
address this very issue, insinuating that local conformation is a result of the precise 
arrangement of amino acid residues.  Upon consideration, the contribution of the 
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MAPS core to the overall CD spectrum may not be its structural orientation, when 
considering all of the plausible interactions that could occur along the peptide braches 
of the dendrimer itself.  Discussion focused on the dendrimeric core contributions to 
inherent stabilization will be introduced later. 
In all, Ziegler et al. established the bionucleating peptide dendrimers, BNT I 
and BNT II, as the first synthetic model histidine-rich protein analogs based on 
similar chemical activities.  His work is highlighted in Table 2.2 and               
Figures 2.5-2.13, added solely for the purposes of establishing the background 
information pertinent to our biomineralization studies.     In particular, BNT II bound 
heme with similar efficiency to HRP II (12 eq. vs 17 eq.) and was capable of 
mediating the formation of hemozoin. Known antimalarials were also capable of 
inhibiting the template mediated formation hemozoin with IC50’s within the same 
order of magnitude as those tested against the native protein.  Now, with the 
establishment of a conformational similarity between the BNTs and HRP II, the 
nucleating domain AHHAHHAAD may be scrutinized as a template for the 
biomineralization of hemozoin, where inherent changes in the amino acid sequence of 
the nucleating domain may elicit changes in activity based on imposed changes in 
conformation. 
2.5.  Site-Directed Mutagenesis Studies of the HRP II Mimic  
2.5.1.  Mutants of BNT II 
With the establishment of BNT II as a functional peptide mimic for HRP II, 
we elucidated the role of the nucleating domain per active site amino acid through 
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synthetic site-directed mutagenesis studies.  Our first effort included synthesizing the 
alternate hypothetical nucleating domain Ala-His-His-Ala-Ala-Asp-Ala-His-His, to 
permit a direct comparison of the two postulated hemozoin templating sequences.  In 
comparison to BNT II, swapping the trimer Ala-His-His to the end of the nucleating 
domain will reveal information as to both the binding and nucleating capabilities of 
the template when the trimeric Ala-His-His repeat is interrupted.   
To decrease the exhaustive number of mutants that could possibly be 
synthesized, our efforts focused on targeting amino acids that were physiologically 
relevant to native HRP II.  Preliminary results by Ziegler et al. in our laboratory 
already confirmed that metal recognition sites were not essential for substrate 
binding.  Additionally, since polyhistidine failed to nucleate the formation of 
hemozoin, alanine may be a critical spacer in the 9-mer templating domain, serving to 
precisely orient substrate recognition motifs.  The binding data also suggested that 
template/substrate recognition is most likely through π-π stacking and/or electrostatic 
interactions, thus histidine and aspartic acid could be critical residues. 
Initial syntheses were confined to the six mutants below (Table 2.3).  The 
mutants were named arbitrarily, with BNT IIA being the first alternate peptide mimic 
of HRP II.  Once initial studies, which included substrate binding activities and the in 
vitro heme aggregation assay, indicated that the amino acid sequence of BNT II was 
the most probable nucleating domain within the sequence of HRP II (see Chapter 3 
for experimental results), all other peptide mutations were envisioned with regards 
to the Ala-His-His-Ala-His-His-Ala-Ala-Asp sequence.  Mutant BNT IIC assessed if 
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heme binding was dominated solely by histidine residues, by mutating the His-His 
repeat with alanine residues.  BNT IID evaluated the necessity of a conserved 
aspartic acid residue, by replacing it with a nonpolar alanine.  Mutants BNT IIX and 
BNT IIY probed the histidine binding sites in terms of the relative positioning of the 
amino acid on the putative nucleating face.  BNT IIX examined conservation of the 
lead histidine in the Ala-His-His repeat unit, mutating the histidine at positions three 
and six with alanine, while BNT IIY explored the reverse order, mutating the 
histidine at positions two and five with alanine, now conserving the third and sixth 
residues in the Ala-His-His-Ala-His-His-Ala-Ala-Asp nucleating domain.  Mutant 
BNT IIZ again surveyed the role of the highly conserved aspartic acid by mutating 
the ninth position with lysine, this time not exploring the effect of polarity, but the 
effect of charge, since lysine will be deprotonated under the experimental conditions. 
Table 2.3.  Site-directed mutagenesis of the 9-mer sequence of BNT II.  *denotes a 
mutated amino acid residue.  The shaded template was insoluble under the 
experimental conditions employed (100 mM acetate buffer, pH 4.8). 
BNT  II  Ala His His Ala His His Ala Ala Asp 
BNT IIA      Ala* Asp*  His* His* 
BNT IIC   Ala* Ala*  Ala* Ala*    
BNT IID          Ala* 
BNT IIX    Ala*   Ala*    
BNT IIY   Ala*   Ala*     
BNT IIZ          Lys* 
89 
2.5.2.  Synthesis of Bionucleating Templates (BNTs) 
2.5.2a.  Reagents 
All Fmoc-4-branch MAPS resins and Fmoc-amino acids [N-α-Fmoc-L-
alanine (Fmoc-Ala-OH), N-α-Fmoc-L-aspartic acid α-t-butyl ester (Fmoc-Asp-OtBu), 
N-α-Fmoc-N-im-trityl-L-histidine (Fmoc-His(Trt)-OH), N-α-Fmoc-N-ε-4-
methyltrityl-L-lysine (Fmoc-Lys(Mtt)-OH)] were purchased from AnaSpec, Inc. (San  
Jose, CA) and kept at the recommended storage conditions until used.                 
N,N’-diisopropylethylamine (DIEA) and 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) were obtained from Advanced 
ChemTech (Louisville, KY).  BioReagent grade methanol (MeOH), 
dimethlyformamide (DMF), dichloromethane (DCM), piperidine, and                       
N-hydroxybenzotriazole (HOBt), sequencing grade pyridine, HPLC grade acetonitrile 
(ACN), and acetic anhydride were purchased from Fisher Scientific (Pittsburgh, PA).  
Trifluoroacetic acid (99.9%) (TFA) and triisopropyl silane (TIS) were acquired from 
Sigma-Aldrich Chemicals (Milwaukee, WI). 
2.5.2b.  Automated Synthesis of Templates 
The dendrimeric templates were synthesized on an Advanced ChemTech 
Model 90 Peptide Synthesizer according to standard continuous flow Fmoc-solid 
phase synthesis protocols with minor modifications (Scheme 2.1).  Detailed 
automated programming was generously supplied by AnaSpec, Inc. (Appendix I, 
pages A-1 thru A-4).  Approximately 250 mg. of Fmoc-4-branch MAPS resin was 
swelled in DCM for fifteen minutes followed by an initial Fmoc-deprotection by 
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 treatment with 20% piperidine in DMF.  Coupling cycles were accomplished with    
4-fold excess (vs. overall loading capacity of the resin) of activated amino acid for 1 
hour, using Fmoc-amino acid/HBTU/HOBt/DIEA in a 1:1:1:2 mole ratio.  The 
peptidyl resin was then washed 3X with 12.5 mL of DMF, 3X with 12.5 mL MeOH, 
and again 3X with 12.5 mL of DMF.  Subsequent deprotections were carried out by 
two successive treatments of 20% piperidine in DMF (10 min. and 40 min. cycles), 
followed by the same washing protocol listed above: DMF, MeOH, DMF.  Acylation 
of the N-terminal amines was accomplished by exposing the peptidyl resin to 20 mL 
Scheme 2.1.  Standard Fmoc-peptide synthesis protocol.   
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of 1:1:5 acetic anhydride/pyridine/DMF for 30 min.  Upon acylation the peptidyl 
resin was washed 3X with 12.5 mL DMF and then 5X with 12.5 mL of MeOH.  The 
resin was collected on a finely sintered glass frit, washed with additional MeOH, 
dried by vacuum filtration and then stored at -4 0C until cleavage occurred. 
2.5.2c.  Cleavage and Purification of BNTs 
All branched peptides were cleaved at room temperature by mixing 1.5 mL of 
cleavage cocktail consisting of 95% TFA / 5% TIS per 100 mg. of peptidyl resin.  
The capped reaction mixture was swirled by hand every ½ hour until 4 hours had 
elapsed, after which the resin was filtered onto a finely sintered glass frit.  The 
cleaved resin was washed with 5X the volume of TFA, based on the initial volume of 
cleavage cocktail used.  The peptide was then precipitated from the filtrate by the 
dropwise addition of 8X the volume of cold diethyl ether, based on the volume of 
TFA wash.  The precipitated peptide was then centrifuged on a Sorval GLC-1 or 
Beckman Coulter Allegra 21R swinging bucket rotor for fifteen minutes. The ether 
layer was decanted and the peptide pellet washed an additional three times with       
30 mL of ether.  The peptide pellet was then resuspended in water (v/v with 0.1% 
TFA) and minimal acetonitrile (v/v with 0.1% TFA, <20% total volume) and 
lyophilized on a LabConco FreeZone 4.5L Benchtop Freeze Dry System           
(Model 77500, Kansas City, MO). 
 Each branched peptide was purified by reversed phase high-performance 
liquid chromatography (HPLC) on a Waters 600 HPLC equipped with a Waters 996 
Photodiode Array Detector using a Waters Nova-Pak C18 300 Å 15 µm                   
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(3.9 X 150 mm) column before scaling for semi-preparative or preparative HPLC 
purifications.  Briefly approximately 1 mg. of peptide was dissolved in 1 mL of water 
(v/v with 0.1% TFA) and filtered through a Millex-GV 0.22 µm low protein binding 
Durapore PVDF membrane.  A 20 µl sample was injected onto the column 
equilibrated with water (v/v with 0.1% TFA) at 0.5 mL/min.  A linear gradient of 
100% water (v/v with 0.1% TFA) to 50% CH3CN (v/v with 0.1% TFA) was 
performed over thirty minutes for initial purification.  The gradient was then 
optimized for each BNT.  
 Analytical HPLC gradients conditions were then scaled for semi-preparative 
or preparative purification according to the equations listed in Figure 2.15.  Semi-
preparative peptide purification was completed on a Waters 600 HPLC equipped with 
a Waters 996 Photodiode Array Detector using a PrepLC™ 25 mm Radial 
Compression Module compressed with isopropanol.   The module in series with a 
PrepLC™ 25 mm extension tube held two Delta-Pak™ C18 300 Å 15 µm (25 x 100 
mm) columns.  The initial column was fitted with Delta-Pak™ C18 300 Å 15 µm 
Guard-Pak™ (25 x 10 mm).  All other semi-preparative and preparative HPLC was 
performed on a Waters Prep LC 4000 equipped with a Waters 2487 Dual Wavelength 
UV/Vis Detector using a Delta-Pak™ C18 300 Å 15 µm (30 x 300 mm) column.  All 
MAPS peptides were detected at a wavelength of 210 nm. 
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Flow rate at constant linear velocity and equal column length 
Fprep = Fanal X (Dprep)2 
                       (Danal)2 
 
Flow rate at different column length 
 
Fprep = Fanal X Lprep X (Dprep)2 
                       Lanal       (Danal)2 
 
Sample Load 
 
Mprep = Manal X Lprep X (Dprep)2 
                          Lanal        (Danal)2 
 
Flow Rate 
 
tprep = tanal X Lprep X (Dprep)2 X Fanal 
                     Lanal       (Danal)2     Fprep 
 
Gradient Delay Volume 
 
Td = Vd X   Vprep 
        Fprep      Vanal 
 
 
- 1 
Fanal = analytical flow rate 
Fprep = preparative flow rate 
Danal = diameter of analytical column 
Dprep = diameter of preparative column 
Lanal = length of analytical column 
Lprep = length of preparative column 
Manal = analytical sample load 
Mprep = preparative sample load 
tanal = gradient run time for analytical column 
tprep = gradient run time for preparative column 
Vd = delay volume of instrument 
Vanal = volume of analytical column 
Vprep = volume of preparative column 
Figure 2.15.  Scale-up equations for HPLC peptide purification. 
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 Specific flow rates and gradient conditions for each BNT are listed below with 
a representative sample chromotogram (Figures 2.16 - 2.21).  BNT IIC was 
insoluble in aqueous media, eluting with 100% CH3CN (v/v with 0.1% TFA) and 
therefore not a viable mutant for analysis according to our experimental conditions 
(pH 4.8). 
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Time        
(min.) 
Flow Rate 
(mL/min.) 
%A %B 
0.00 13.70 100 0 
11.50 13.70 100 0 
21.50 13.70 70 30 
46.50 13.70 50 50 
Figure 2.16.  Semi-preparative HPLC chromatogram of BNT II and
corresponding gradient table. %A = H2O with 0.1% TFA. %B = ACN with
0.1% TFA.  BNT II was purified using a Waters 600 HPLC equipped with a
PrepLC™ 25 mm Radial Compression Module with two Delta-Pak™ C18
300 Å 15 µm (25 x 100 mm) columns run in series.  BNT II was the major
peak eluting from ~21.5 – 24.0 min. as determined by amino acid analysis. 
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Time 
(min.) 
Flow Rate 
(mL/min.) 
%A %B 
0.00 13.70 90 10 
11.50 13.70 90 10 
51.50 13.70 80 20 
Figure 2.17.  Semi-preparative HPLC chromatogram of BNT IIA and
corresponding gradient table.  %A = H2O with 0.1% TFA.  %B = ACN with
0.1% TFA.  BNT IIA was purified using a Waters 600 HPLC equipped with a
PrepLC™ 25 mm Radial Compression Module with two Delta-Pak™ C18
300 Å 15 µm (25 x 100 mm) columns run in series.  BNT IIA was the major
peak eluting from ~24.8 – 29.5 min. as determined by amino acid analysis. 
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Figure 2.18.  Semi-preparative HPLC chromatogram of BNT IID and 
corresponding gradient table.  %A = H2O with 0.1% TFA.  %B = ACN with 
0.1% TFA.  BNT IID was purified using a Waters 600 HPLC equipped with a 
PrepLC™ 25 mm Radial Compression Module with two Delta-Pak™ C18 
300 Å 15 µm (25 x 100 mm) columns run in series.  BNT IID was the major 
peak eluting from ~22.6 – 24.5 min. as determined by amino acid analysis. 
Time 
(min.) 
Flow Rate 
(mL/min.) 
%A %B 
0.00 17.50 100 0 
15.75 17.50 100 0 
20.75 17.50 70 30 
30.75 17.50 65 35 
50.00 17.50 60 40 
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Figure 2.19.  Semi-preparative HPLC chromatogram of BNT IIX and
corresponding gradient table.  %A = H2O with 0.1% TFA.  %B = ACN with
0.1% TFA.  BNT IIX was purified using a Waters 600 HPLC equipped with a
PrepLC™ 25 mm Radial Compression Module with two Delta-Pak™ C18
300 Å 15 µm (25 x 100 mm) columns run in series.  BNT IIX was the major
peak eluting from ~20.8 – 24.1 min. as determined by amino acid analysis. 
Time 
(min.) 
Flow Rate 
(mL/min.) 
%A %B 
0.00 19.50 100 0 
11.50 19.50 100 0 
21.50 19.50 70 30 
36.50 19.50 50 50 
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Figure 2.20.  Preparative HPLC chromatogram of BNT IIY and 
corresponding gradient table.  %A = H2O with 0.1% TFA.  %B = ACN with 
0.1% TFA.  BNT IIY was purified using a Waters Prep LC 4000 with a Delta-
Pak™ C18 300 Å 15 µm (30 x 300 mm) column.  BNT IIY was the major 
peak eluting from ~8.9 – 10.4 min. as determined by amino acid analysis. 
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Figure 2.21.  Preparative HPLC chromatogram of BNT IIZ and 
corresponding gradient table.  %A = H2O with 0.1% TFA.  %B = ACN with 
0.1% TFA.  BNT IIZ was purified using a Waters Prep LC 4000 with a Delta-
Pak™ C18 300 Å 15 µm (30 x 300 mm) column.  BNT IIZ was the major peak 
eluting from ~14.0 – 15.6 min. as determined by amino acid analysis. 
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After HPLC purification, all peptides were analyzed for purity based on amino 
acid analysis either performed by AnaSpec, Inc. (San Jose, CA) or the Vanderbilt 
Peptide Sequencing and Amino Acid Analysis Shared Resource (Nashville, TN) 
except for template BNT IIA, which was previously analyzed at Boston College by 
collaborator Richard T. Chang.  From the amino acid analysis results below      
(Table 2.4), all templates synthesized in house were greater than 98% pure after 
HPLC purification and lyophilization (BNT IIA synthesized and purified at Boston 
College was 94.5% pure).  For amino acid analysis, the MAPS core adds 0.75 lysine 
residues per chain (0.75 x 4 = 3 lysine residues) and 0.25 alanine residues per chain 
(0.25 x 4 = 1 alanine residue) for the 4-branch peptide.83 For the bionucleating 
templates BNT II, BNT IIC, BNT IID, and BNT IIZ, the experimental values for 
lysine are typically higher than the theoretical values due to the high signal from the 
Template BNT  II 
BNT  
IIA 
BNT 
IIC 
BNT 
IID 
BNT 
IIX 
BNT 
IIY 
BNT 
IIZ 
Amino Acid        
Ala 32.90 (33) 
 64.87 
(65) 
40.88 
(41) 
48.81 
(49) 
47.81c 
(49) 
32.92 
(33) 
His 31.90 (32) 
 ---- 31.86 
(32) 
16.05 
(16) 
15.91 
(16) 
31.60 
(32) 
Asp 8.00 (8) 
 7.80b 
(8) 
---- 8.14b 
(8) 
8.08 
(8) 
--- 
Lys 3.14
a 
(3) 
 3.33a 
(3) 
3.26a 
(3) 
3.00 
(3) 
3.03 
(3) 
11.14a 
(11) 
% purity 99.55 94.55 99.14 99.31 99.52 98.17 99.19 
Table 2.4.  Amino acid analysis of BNT II and BNT mutants. Experimental values 
are in bold text while the predicted values are indicated in parentheses. a – lysine 
values are high due to high signal from histidine.  b – aspartic acid value is high 
and low due to high signal from alanine.  c -  alanine is low. 
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histidine residues.  BNT IIX and BNT IIY with only 16 histidine residues yielded 
lysine values (3.00 and 3.03 respectively) more closely correlated to the actual value 
than those mutants that had double the number of histidine residues.  In addition to 
the interference resulting from the high number of histidine residues, the high number 
of alanine residues also masks the aspartic acid signals as seen in BNT IIC and     
BNY IIX.     
Mass spectral analyses were performed on both MALDI-TOF and 
electrospray ionization (ESI) mass spectrometers at both the University of Pittsburgh 
Biotechnology Center (Pittsburgh, PA) and at Vanderbilt University (Nashville, TN), 
but the results were inconclusive.  ESI chromatograms were typically very broad in 
both positive and negative ionization modes, while the MADLI-TOF chromatograms 
exhibited only those peaks associated with the matrix, despite the array of matrix 
components used.  Such results are not uncharacteristic of MAPS peptides, since 
mass spectral analyses typically yield poor, unresolved results.  MALDI-TOF and 
electrospray ionization data was obtained for BNT II (Figure 2.22) and BNT IIA 
(Figure 2.23), respectively, which suggests that stabilization may be sequence 
dependent, since both BNT II and BNT IIA have the same number and type of amino 
acids.  
2.6.  BNT II and Mutant Modeling 
At the outset of any biomineralization process, an organic matrix with a 
functionalized surface must be arranged within a reaction environment.84 Next, 
interfacial recognition between the inorganic mineral and organic substrate occurs via  
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Figure 2.23.  Electrospray ionization mass spectrometry for BNT IIA in the 
positive ionization mode. 
 
Figure 2.22.  MALDI-TOF mass spectrometry for BNT II. 
 
complementarity of lattice geometry, topography, spatial symmetry, stereochemistry, 
polarity, electrostatic interactions, or a combination of the above.42 Afterward, the 
templated two-dimensional biomineral undergoes vectoral expansion in three 
dimensions, having its orientation and growth specifically directed by the template in 
such that crystalline size, shape, and morphology are often constrained to the physical 
and compositional domain of the architecture.  Finally, during the last stage of 
biomineralization, additional cellular components participate in the storage, transport 
and/or removal of the biomineral. 
Though the biosynthetic route of hemozoin formation involves the intimate 
and complex interactions of Plasmodium falciparum with a host erythrocyte,            
β-hematin formation can be paralleled to the four generically classified stages of 
biomineralization processes.  Specifically, before hemozoin formation can begin, the 
HRP II protein must be localized within the digestive vacuole of Plasmodium 
falciparum.  Next, free inorganic heme, a requisite byproduct of the parasitic 
proteolysis of hemoglobin, interacts with HRP II in such that free heme is sequestered 
from the digestive organelle.  Once in association with the lattice of the HRP II 
protein, the inorganic iron porphyrin forms a hydrogen-bonded network of dimers 
with neighboring heme units, constructing the architectural hierarchy of the malaria 
pigment.   Finally during the last stage of β-hematin biomineralization, the malaria 
parasite transfers the pigment to other sites throughout the host through oxidative 
burst.   
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As an aside from hemozoin derived specifically from Plasmodium falciparum, 
it is interesting to note that other species that produce hemozoin, form a material that 
is compositionally the same as the malaria pigment.  The morphological attributes 
however, often differ since the organic matrix has alterations in the number of repeat 
units in the protein sequence compared to that of HRP II. 
 In order to better understand the critical interactions between HRP II and 
heme in the binding and nucleation of hemozoin, the biomimetic peptide BNT II and 
its mutants were modeled as potential right-handed 3-10 helices and left-handed 
polyproline type II helices using the Chemical Computing Group’s MOE 2002.03 
program (Molecular Operating Environment, Montreal, Canada).  This modeling 
program, nor any other currently available at the time, was capable of evaluating the 
entire biomimetic template, since the contribution of the dendrimer core could not be 
accounted for thermodynamically.  However, since BNT II shared the spectral 
features of HRP II described by Panton81 as well as Lynn,74 the 18-mer peptide 
branches were modeled in both conformations.  Recall however, that neither the       
9-mer nor the 18-mer linear peptide models adhered to either conformation      
(Figure 2.14), both having only weak CD signaling throughout the wavelength of 
interest.  This modeling was thus predicated under the assumption that each of the 
four peptide branches was conformationally independent of the others, having its 
secondary structure imparted from the MAPS core as well as possible intramolecular 
interactions.   
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For the purposes of our investigations, this conformational discrepancy is of 
little relevance to our research and cannot be resolved until the crystal structure of 
HRP II is solved.  Either way, whether the helix is right or left handed, the imperative 
information occurs in the fact there are three amino acids per turn of the helix.  This 
imparts similar hydrophobic and putative nucleating faces for which to analyze the 
nucleation and formation events surrounding hemozoin formation.  Each template 
peptide chain in both the 3-10 and PPII conformations (Figures 2.24-2.29) is 
presented below and will be discussed in depth in the proceeding chapter. 
 
Figure 2.24.  The 18-mer peptide branch of BNT II modeled as a right-handed 3-10 
helix (top) and a left-handed polyproline type II conformation (bottom).  The amino 
acid sequence follows (Ala-His-His-Ala-His-His-Ala-Ala-Asp)2. 
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Figure 2.25.  The 18-mer peptide branch of BNT IIA modeled as a right-handed
3-10 helix (top) and a left-handed polyproline type II conformation (bottom).  The
amino acid sequence follows (Ala-His-His-Ala-Ala-Asp-Ala-His-His)2. 
 
Figure 2.26.  The 18-mer peptide branch of BNT IID modeled as a right-handed
3-10 helix (top) and a left-handed polyproline type II conformation (bottom).  The
amino acid sequence follows (Ala-His-His-Ala-His-His-Ala-Ala-Ala)2. 
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Figure 2.27.  The 18-mer peptide branch of BNT IIX modeled as a right-handed
3-10 helix (top) and a left-handed polyproline type II conformation (bottom).  The
amino acid sequence follows (Ala-His-Ala-Ala-His-Ala-Ala-Ala-Asp)2. 
 Figure 2.28.  The 18-mer peptide branch of BNT IIY modeled as a right-handed
3-10 helix (top) and a left-handed polyproline type II conformation (bottom).  The
amino acid sequence follows (Ala-Ala-His-Ala-Ala-His-Ala-Ala-Asp)2. 
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 Both conformations enable the visualization of the putative nucleating faces of 
the templates and the determination of the amino acid residues that are critical for 
substrate recognition.  In such that the template orients the nucleation of the mineral, 
both the spatial distribution and functionality of the involved amino acids, which 
ultimately dictate the secondary structure and conformation of the surface groups, are 
imperative for successful biomineralization.  Detailed knowledge of the events that 
underlie the structural modifications of the repetitive sequence of HRP II are 
imperative to understanding key mechanisms, not only in the formation of hemozoin, 
Figure 2.29.  The 18-mer peptide branch of BNT IIZ modeled as a right-handed
3-10 helix (top) and a left-handed polyproline type II conformation (bottom).  The
amino acid sequence follows (Ala-His-His-Ala-His-His-Ala-Ala-Lys)2. 
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but also in post invasion events such as the pathogenesis of Plasmodium falciparum 
and the corresponding host immune response.  Specific interference with β-hematin 
formation could substantially reduce parasitism and remains a relatively unexplored 
antimalarial strategy.40,11  Though various studies have substantiated the interaction of 
heme with HRP II as a valid target of antimalarial drug action, this very interaction 
complicates the mode of action for antimalarial drugs since the drug can possibly 
interact with the heme component, the protein, or the complexed heme:protein unit.  
The result is a plethora of contradictory science surrounding hemozoin formation and 
antimalarial drug action often with legitimate results but unanswered mechanisms. 
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Chapter 3 
Putative Domain Template Studies 
 
 
3.1.  Introduction 
Despite the fact that more than one hundred years have elapsed since the 
discovery of the malaria parasite, the complex biochemistry of Plasmodia still 
hampers the current scientific understanding of antimalarial drug action.  While the 
recent completion of the P. falciparum genome1 will undoubtedly provide new drug 
targets, understanding the modes of action of any malarial antagonist is unlikely to be 
resolved until a better understanding of the life cycle of the parasite is evolved. 
The malarial parasite invades host red blood cells, transforming through four 
life cycle stages, the merozoite, ring, trophozoite, and schizont stages, all within      
48 hours after invasion.  During this intraerythrocytic phase, P. falciparum can 
catabolize up to 80% of an infected erythrocyte’s hemoglobin2 in its acidified 
digestive vacuole (pH 4.8-5.5) in order to obtain requisite amino acids.  Hemoglobin 
degradation consequently results in the release of free heme, which would be toxic to 
the parasite if not sequestered by the organism into an inert crystalline substance 
known as hemozoin.   
The malaria parasite’s heme detoxification pathway is vastly different from 
human heme detoxification, which utilizes a heme oxygenase/biliverdin reductase 
pathway.  As a result, hemoglobin degradation, as well as the subsequent formation of 
hemozoin, has received significant attention due to its implications in drug 
development.3 Moreover, this essential biochemical processing of hemozoin is 
retained in drug resistant strains of the parasite, suggesting that a better fundamental 
basis of the mechanism of hemozoin formation will elicit an improved understanding 
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of antimalarial drug action, since many antimalarials, including chloroquine, are most 
active during the blood stage of infection where hemoglobin degradation occurs 
(trophozoite stage). 
While the molecular compositions of hemozoin and its synthetic analogue, 
commonly known as β-hematin, have been resolved by Bohle et al.4 as being 
identical, the chemical mechanism of formation remains largely controversial due to 
fundamental differences that exist between the in vivo and in vitro methods of 
formation (For a more thorough review refer to Chapter 1.).  Within the biological 
milieu of the parasite, hemozoin is synthesized in aqueous solutions, with numerous 
hypotheses surrounding its formation, including: mechanisms involving enzyme 
catalysis,5,6 spontaneous formation,7 autocatalysis with preformed hemozoin,8 lipid 
catalysis,9-13 and nucleation on the histidine-rich protein II (HRP II).14-16 
Synthetically, hemozoin can be formed in aqueous solution with hematin and acetic 
acid, though other acids have been used,7,8,17-21 and also in non-aqueous solution by 
the dehydrohalogenation of hemin with 2,6-lutidine in an inert atmosphere.22 Whether 
in vitro or in vivo, the precise mechanism of hemozoin formation is mired by the fact 
that the progression of hemozoin formation has not yet been able to be continuously 
monitored by spectroscopic techniques. 
Many antimalarials, including chloroquine and quinoline based drugs are 
thought to function by inhibiting hemozoin formation,5 suggesting these drugs 
function by disrupting the assembly and/or  production of the malaria pigment.  Such 
proposed mechanisms of antimalarial drug action include the direct interaction with 
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hematin via π-π stacking of its aromatic structure with that of heme,23-26 by drug 
intercalation with the growing face of the hemozoin crystal preventing further crystal 
development,4,27 or by the displacement hematin from substrates such as lipids or 
HRP II28-30 in such that free heme concentrations become toxic to P. falciparum.  
Likewise, if the formation of the malaria pigment is premised as a 
biomineralization process three possible scenarios for disrupting the biosynthesis of 
hemozoin templated on HRP II can be envisioned.  First, the potential drug can 
interact directly with hematin preventing its nucleation onto the surface of the 
template.  Alternatively, the drug can blockade the surface of the template in such that 
its face is not physically accessible for hematin binding.  Finally, the drug could 
possibly interfere by preventing the requisite bond formation between monomers of 
Fe(III)PPIX during the nucleation of hemozoin.    
With this in mind, it becomes imperative to understand which amino acid 
residues of HRP II are critical in the templating, nucleation, and formation of 
hemozoin.  Halting hemozoin formation at this growth stage heralds the histidine-rich 
protein II as an unexplored antimalarial strategy.31 Herein lays the inspiration and 
motivation for site-directed mutagenesis studies of the two putative binding domains 
of HRP II, functionally mimicked in our bionucleating templates, BNT II and the 
alternative putative binding domain, BNT IIA.  
The earliest studies of HRP II as an antimalarial strategy began shortly after 
the protein was isolated and identified, though its direct implication to hemozoin 
formation had not yet been established.  Given that the protein’s usually high content 
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of histidine is unique to Plasmodium falciparum and not the host, scientists examined 
the effects of the incorporation of histidine analogues into culture medium and the 
impact of such on the asexual growth and protein synthesis of the parasites in vitro.32 
Though few of the chemically modified histidines were inhibitory, the results were 
semi-quantitative at best, since asexual parasite growth was determined by 
microscopy and the effects of the analogues on protein synthesis had not been studied 
in detail.  Thereafter, studies involving the histidine-rich proteins of Plasmodium 
falciparum  (HRPs I-IV) received little attention until HRP II was determined to play 
a critical role in the detoxification of heme, binding 17 equivalents of heme and 
participating in the aggregation of hemozoin.15  
The binding of heme alone does not elicit hemozoin formation.  Numerous 
examples of linear multimers adapted from the sequence of HRP II have been shown 
to bind heme, however until now, such sequences other than the native protein have 
failed to promote the formation of hemozoin.  Pandey et al. had demonstrated that 
heme binding to synthetic peptides based on hexapeptide repeats of Ala-His-His-Ala-
Ala-Asp from HRP II was proportional to the number of repeat units in the peptides,33 
although hemozoin formation failed to occur. Obviously, template substrate 
interactions must be more involved, possibly invoking some conformational change 
in the template that could orient heme molecules into a proper spatial orientation 
necessary for hemozoin formation. 
The bionucleating templates, the BNTs, which are essentially MAPS peptide 
dendrimers, possess a hierarchy of structure that enables stable and ordered 
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conformations.  Such polymeric scaffolds do not occlude peptide assembly and are 
often favored over tandem repeat peptides because the majority of the peptide chain is 
available for substrate interactions, thereby increasing both activities and assay 
sensitivities.34 Through defined molecular weights, monodispersity, steroeregularity 
and sequence and compositional control at the single amino acid residue level, 
inherent chemical reactivity and conformational rigidity can be assessed.  Such point 
mutations allow for a direct comparison of the biological relevance of single amino 
acid residues in the highly unusual conservation of histidine and alanine containing 
sequences in HRP II.  In the end, such novel engineering allows for the judicious 
manipulation of both the peptide and dendrimer fragments.   
Using the dendrimeric architectures with specified peptide sequences would 
circumvent the problems often associated with protein folding of larger sequenced 
peptides.  Additionally, the peptide dendrimer could allow the molecular recognition 
phenomena to appear as a result of the constructive interactions between amino acids 
and substrate.  A drawback of the dendrimer however, is that the constructional 
constraints of the tetrameric core could possibly occlude binding near the surface due 
to inherent steric hinderance.  
The impact of a functional model of HRP II would be invaluable for not only 
in vitro antimalarial drug susceptibility data, but also for epidemiological purposes 
since antimalarial drug resistance is a widespread issue in the control of P. falciparum 
malaria.  Assays utilizing HRP II for malaria detection, such as the commercially 
available monoclonal antibody kits specific for HRP II, already have advantages over 
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the mainstream parasite quantification techniques.35 Non-protein assays such as the 
isotopic assay, which measures parasitic metabolic activity via the incorporation of 
[3H]hypoxyanthine, and a schizont maturation assay, which tallies the number of 
parasites that develop from the ring to schizont stage, assess parasitic activity at a 
partial timeframe within the parasite’s 48 hour intraerythrocytic life cycle.  With  
HRP II-based assays, since the protein is produced throughout the entire 48 hour 
intraerythrocytic life cycle, infection/treatment can be monitored throughout the 
complete blood stage of Plasmodium falciparum.  
3.2.  Functional Screening of the BNTs 
Initially BNT II (which possesses the Ala-His-His-Ala-His-His-Ala-Ala-Asp 
sequence repeated twice per dendrimeric branch) and BNT IIA (which possesses the 
alternative putative binding domain, Ala-His-His-Ala-Ala-Asp-Ala-His-His sequence 
also repeated twice per branch), were analyzed for binding capabilities with the 
natural substrate of HRP II, iron (III) protoporphyrin IX [Fe(III)PPIX], and an 
alternate porphyrin, zinc (II) protoporphyrin IX [Zn(II)PPIX].  Such studies were 
adopted from Zielger36 based on the UV-Vis difference titration methods of 
Morgan.37,38 Additional substrate binding was evaluated through fluorescence 
quenching studies of the zinc porphyrin, also adopted from Morgan.39  
Both putative nucleating domain templates were also monitored for the ability 
to aggregate hemozoin according to the in vitro heme polymerization assay developed 
by Sullivan,15 hereafter more appropriately referred to as the in vitro heme 
aggregation assay.   
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Circular dichroism studies of BNT II and BNT IIA evaluated any 
conformational changes that may have occurred upon substrate (hemin) binding.  
Results will be assimilated in regards to both protein/peptide conformational analysis 
and dendrimeric secondary structure.  
      3.2.1.  Preparation of Stock Solutions 
Stock solutions of the templates were prepared in 100 mM sodium acetate       
buffer, pH 4.8, from lyophilized peptide samples and refrigerated until used.  
Concentrations were determined based on amino acid analysis.  Prior to use, the 
peptide solutions were equilibrated to room temperature and thoroughly mixed to 
ensure full peptide dissolution.  Stock solutions of hemin chloride [Fe(III)PPIX, 
Sigma-Aldrich Chemicals, St. Louis, MO] and zinc protoporphyrin IX [Zn(II)PPIX, 
Mid-Century Chemicals, Chicago, IL] were prepared in 0.1 M NaOH.  The porphyrin 
solutions were kept refrigerated until used for a maximum of two weeks before being 
discarded. 
      3.2.2.  Porphyrin Binding Assay 
Following the UV-Vis difference titration methods of Morgan,37,38                 
2-10 nmoles of the bionucleating template dissolved in 100 mM sodium acetate 
buffer, pH 4.8, were added to a 1.0 mL semi-micro quartz cell (10 mm, Starna Cells, 
Atascadero, CA).  Blanks contained 1.0 mL of the aforementioned buffer.  Aliquots 
of hemin chloride or Zn(II)PPIX (~1 mM) dissolved in 0.1 M NaOH were then 
titrated into both the blank and reference cuvettes. Samples were equilibrated for 
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fifteen minutes prior to measurements on an Aligent 8453 UV-Vis spectrometer 
(Wilmington, DE). 
The amount of the porphyrin bound to the BNT was measured by monitoring 
the change in absorbance at the appropriate Lambda maxima, usually near 420 nm for 
the hemin chloride titrations and 380 nm for the zinc porphyrin titrations, with the 
absorption maxima varying slightly according to the template being investigated.  The 
change in absorbance was normalized to 1 absorbance unit and the x-axis recorded as 
a ratio of porphyrin to template.  Additionally, templates that did not bind a 
significant amount of porphyrin were re-examined at higher peptide concentrations, 
so that a sufficient amount of data points could be recorded before binding ceased and 
porphyrin aggregation was apparent. 
      3.2.3.  Fluorescence Quenching Studies with Zn(II)PPIX 
In addition to the UV-Vis titration methods, template binding was also 
monitored by fluorescence quenching of Zn(II)PPIX.  According to the assay, an 
appropriate amount of 100 mM sodium acetate buffer, pH 4.8, was added to a quartz 
spectrofluorometer cell (10 mm, Starna Cells, Atascadero, CA), along with varying 
amounts of the quenching template.  A stock solution of Zn(II)PPIX dissolved in    
0.1 M NaOH was then added, diluting the porphyrin to a final concentration of   
1X10-5 M in a 4.0 mL sample volume.  The total volume of the porphyrin did not 
exceed 10% of the sample volume in order to maintain buffering capacity.  The 
sample was scanned rapidly from 450-700 nm upon addition of the fluorophore on a 
Cary Eclipse Fluorescence Spectrophotometer (Varian Inc., Walnut Creek, CA) using 
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an excitation wavelength at 410 nm, 10 mm slit width, scan rate of 120 nm/min. and 
photomultiplier tube set at 800 v. The data was analyzed as a direct plot of the 
normalized fluorescence intensity at 586 nm against the ratio of the BNT and 
Zn(II)PPIX. 
      3.2.4.  In Vitro Heme Aggregation Assay 
The templates were assayed for hemozoin formation by incubating 2 nmol of 
template and 100 µM hemin chloride (dissolved in 0.1 M NaOH) in a total volume of 
2.0 mL of 100 mM sodium acetate buffer, pH 4.8, for 48 hours at 37 0C.  Controls 
contained 100 µM hemin chloride in 2.0 mL of 100 mM sodium acetate buffer.  The 
volume of hemin added was less than 10% of the total volume of the solution in order 
to maintain buffering capacity.  After 48 hours the samples were vortexed, transferred 
to 50 mL polycarbonate Oak Ridge centrifuge tubes, and centrifuged at 19,000 g for  
1 hour at 4 0C on a Sorvall RC-5B refrigerated super-speed centrifuge equipped with 
a SS-34 fixed angle rotor.  The supernatant was discarded and the pellet resuspended 
in 5 mL of 0.1 M sodium bicarbonate solution, pH 9.1, to solubilize any free heme.  
The centrifuge tubes were then vortexed every ½ hour for two hours before 
centrifuging again and decanting the supernatant.  The pellet was treated with an 
additional sodium bicarbonate wash and centrifuged.  The remaining pellet was 
washed with water, vortexed, and centrifuged until the pH of the decanted supernatant 
was neutral.  The final pellet of aggregated heme was quantitated on the basis of its 
absorbance at 400 nm (ε = 100,000).  Briefly, the pellet was dissolved in 1.0 mL of 
0.1 M NaOH and vortexed every 15 minutes for 1 hour before recording the 
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absorbance measurement on an Aligent 8453 UV-Vis spectrophotometer 
(Wilmington, DE).  Hemozoin production was expressed in nmoles.  Controls, with a 
background hemozoin production of approximately 1-2 nmoles, were routinely 
subtracted from the BNT mediated production of hemozoin.  Background hemozoin 
production corresponded well with previously published results under similar 
experimental conditions.10,40 
      3.2.5.  Circular dichroism spectroscopy 
Template stock solutions dissolved in 100 mM acetate buffer, pH 4.8, were 
diluted to 10 mM buffer concentrations (2-15 nmoles of template) in a 3.0 mL quartz 
cuvette and scanned.  Aliquots of hemin chloride dissolved in 0.1 M NaOH were 
titrated into the cuvette and allowed to equilibrate for fifteen minutes prior to 
measurements.  The signal from a 10 mM acetate buffer blank was also recorded and 
subtracted as a background signal.  Titrations continued until the buffering capacity 
was lost and hemin aggregation apparent.  All CD experiments were averaged over 
five scans from 190-269 nm at a scan rate of 0.5 nm/0.5 sec on an AVIV Model 215 
Circular Dichroism Spectrometer (Lakewood, NJ) equipped with a pH probe.  
Control experiments with hemin chloride (dissolved in 0.1 M NaOH) alone in 10 mM 
acetate buffer, pH 4.8, under identical instrumentation settings and conditions did not 
give any appreciable CD signal indicating the changes in the CD spectra arise from 
template:heme interactions.  The ellipticity was expressed as the mean residue molar 
ellipticity, [θ] (deg cm-2 dmol-1).  The spectra were smoothed by the Savitzky-Golay 
algorithm. 
 130 
3.3.  Preliminary Studies 
To ensure the binding assay protocol provided an adequate equilibration time 
for the templates, an equilibration time study was performed with BNT IIA and 
compared with the equilibration times previously established by Ziegler.36 Initial 
estimates concluded this alternate domain template bound 7-9 equivalents of hemin 
chloride, thus the time study involved monitoring the change in absorbance upon 
binding slightly fewer equivalents of hemin (6 eq.) to ensure that problems associated 
with saturable binding were not present.  From the results below in Figure 3.1, the 
majority of the binding occurred within five to ten minutes after the addition of hemin 
chloride.  Relatively small changes in the absorbance were observed thereafter, thus a 
fifteen minute equilibration time was used throughout the binding studies, similar to 
the binding time constraints employed by Ziegler for BNT II.36  
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 Figure 3.1.  Binding equilibration study of BNT IIA with 6 equivalents of hemin
chloride in 100 mM acetate buffer, pH 4.80, at 22oC.  The inset depicts the
complete time range of the experiment. 
BNT II and BNT IIA were more soluble than recombinant forms of HRP II, 
dissolving to concentrations of approximately 10 mg mL-1 in 100 mM acetate buffer, 
pH 4.8, as compared to 1 mg mL-1 for the protein.41  
3.4.  Putative Domain Studies  
(The Ala-His-His-Ala-His-His-Ala-Ala-Asp and Ala-His-His-Ala-Ala-
Asp-Ala-His-His Domains) 
      3.4.1.  BNT II (The Ala-His-His-Ala-His-His-Ala-Ala-Asp Domain) 
3.4.1a. Interaction with Heme 
The electronic absorption spectrum for the interaction of hemin chloride with 
BNT II has a single Soret peak centered around 419 nm (Figure 3.2).  BNT II alone 
has no appreciable absorbance in the 300-600 nm region (Figure 3.2 inset).  Hemin 
chloride in 100 mM sodium acetate buffer, pH 4.80, mimicking the pH of the 
digestive vacuole of P. falciparum (pH 4.5-5.5), has a characteristic Soret band at  
385 nm.  Thus upon binding, the Soret region of the spectrum red-shifted 
approximately 34 nm from its original value with Fe(III)PPIX.  Visible changes to the 
absorption spectra were observed after the addition of only 1 equivalent of heme.  
Though the data presented is normalized to enhance the red-shift in the Soret region 
upon substrate binding, the spectra sharpened and continued to increase in intensity 
until a plateau was reached or a slight decrease in absorbance was recorded.  At this 
point binding was noted to have ceased and hemin aggregation was visibly apparent.   
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 Figure 3.2.  UV-Vis spectrum of the interaction of hemin chloride with BNT II, 
represented by the (___) solid line.  Samples of approximately 1 equivalent of hemin 
chloride were added to 1-5 nmoles of template in 100 mM acetate buffer, pH 4.8. 
Hemin chloride in buffer alone is represented by the (---) dashed line.  Spectra were 
normalized to enhance the red-shift of the Soret band upon substrate binding. 
The UV-Vis spectrum of BNT II had no appreciable absorbance in the 300-600 nm 
region (inset).  
As seen in Figure 3.3, the first postulated putative binding domain, BNT II 
bound 9.83±0.21 equivalents of heme.  Purified HRP II bound 17 equivalents of 
hemin chloride under similar buffer conditions.15 Given the geometry of the MAPS 
core, it is not surprising that BNT II bound slightly fewer equivalents of hemin than 
the native protein, seeing how interior sites may be occluded near the dendrimeric 
core.   The hemin binding stoichiometries for BNT II are also slightly lower than that 
reported by Ziegler et al.,36 though with notably less error.  Incidentally, the MAPS 
core (commercially purchased from AnaSpec Inc., San Jose, CA) was slightly 
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modified from the previous work, having an alanine linkage at the base of the 
dendrimeric scaffolding rather than a glycine residue.  If the sole consideration for 
hemin binding concerned intermolecular interactions, the differences in the MAPS 
core may be insignificant, but given the dendrimeric nature of the template, 
intramolecular forces may also interplay.  
 
Figure 3.3.  Hemin chloride titration binding curve for BNT II.  The plot was 
generated from the UV-Vis difference absorption spectra based on methods 
established by Morgan.37,38  The data presented is the averaged result of three 
independent binding titration experiments.  Individual binding experiments are 
shown in Appendix II, page A-4. 
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After the stoichiometric binding maxima, the difference titration curve seems 
to reflect a significant change in the electronic structure of the species in solution.  
Most titration binding curves exhibit only a slight divergence from the plateau upon 
 134 
saturable binding, but the hemin binding curve associated with BNT II decreases 
drastically.  Typically at such high stoichiometries of hemin substrate, this decrease in 
absorbance intensity was also followed by visibly apparent hemin aggregation and/or 
precipitation.  Though a number of aggregative interactions are possible, it is 
intriguing to note such behavior is reminiscent of nucleation steps in 
biomineralization processes.  
3.4.1b. Interaction with Zinc (II) Protoporphyrin IX  
Zinc protoporphyrin IX was also recognized by BNT II, binding 13.40±0.31 
equivalents of the substrate (Figure 3.4).  This does not necessarily imply that 
Zn(II)PPIX has a different binding domain from the iron porphyrin since BNT II 
bound more equivalents of the zinc porphyrin, but suggests such interactions between 
the substrate and template may slightly vary with secondary interactions occurring 
somewhere along the peptide dendrimer.  The fact that protoporphyrin IX was also 
capable of binding to BNT II as determined by Ziegler,36 suggests that substrate 
association with BNT II is not driven by the axial ligation of a histidine residue to a 
metal.36 Furthermore, since the pKa of histidine is 5.8, the moiety is most likely 
protonated under the experimental reaction conditions, and therefore axial ligation to 
a metal is doubtful.  
 The fluorescence quenching studies of Zn(II)PPIX provided additional 
evidence for the interaction of the zinc porphyrin with BNT II.  With the final 
concentration of Zn(II)PPIX being 1X10-5 M in 4.0 mL of solution, various 
concentrations of BNT II in 100 mM acetate buffer, pH 4.8, quenched the 
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fluorescence of the fluorophore (Figure 3.5).  The fluorescence intensity at the [BNT 
II]/[Zn(II)PPIX] of 0.1 was already decreased by 45% of the original value.  The 
change in fluorescence intensity at the same 0.1:1 ratio of template to porphyrin only 
decreased by 23% when BNT I was examined (Figure 3.5 inset).  These results are 
expected and consistent with other studies involving BNT I, since the first generation 
dendrimer has half as many of the designed binding domains.  The fluorescence of 
BNT II was completely quenched at a 0.3:1 ratio of template to porphyrin. 
 
 Figure 3.4.  Zn(II)PPIX titration binding curve for BNT II.  The plot was
generated from the UV-Vis difference absorption spectra based on methods
established by Morgan.37,38  The data presented is the averaged result of five
independent binding titration experiments.  Individual binding experiments are
shown in Appendix II, page A-5. 
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 Figure 3.5.  Fluorescence quenching studies of Zn(II)PPIX with BNT II.  Samples
were excited at 410 nm and monitored at the emission maxima of the fluorophore.
The inset displays the experiment with the single nucleating domain, BNT I, for
comparison. 
3.4.1c.  Heme Aggregation Activity 
In the presence of free heme under acidic conditions, the BNT II dendrimer 
promoted 5.63±0.04 nmoles of insoluble aggregated heme product.  This value was 
the average of five separate reactions and compared well to the 5.5±0.5 nmoles of 
hemozoin produced by the same template when Zielger et al. 36 performed the assay.  
 The assay protocol called for exhaustive washing cycles of sodium 
bicarbonate and water, which could ultimately lead to inconsistent results if not 
completed meticulously.  Not only was the differential solubility of the heme 
products important in the processing of the samples in order to obtain values free of 
hematin derivatives, but also proper centrifugation was crucial in order to pellet the 
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small sample of hemozoin that remained.  Further discussion on the heme aggregation 
activity of BNT II is presented in the discussion of the putative domain studies, 
Section 3.5. 
3.4.1.d.  Circular Dichroism Studies 
Though the circular dichroism spectra of BNT II did not substantially change 
over a broad pH range (Figure 3.6), the spectra of hemin titration interacting with 
BNT II did (Figure 3.7 A).  Although the 10 mM concentration of the sodium acetate 
buffer greatly reduced the buffering capacity of the heme titration assays, the notable 
changes in the circular dichroism spectra suggest a physical interaction between   
BNT II and hemin at pH 4.8.  Such changes in the CD spectra were also noted upon 
the addition of Zn(II)PPIX (Figure 3.7 B).  Despite the fact that BNT II bound a 
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 Figure 3.6.  Circular dichroism spectra of BNT II at pH 4.86 (___) and (----) pH 6.03,
7.03, 8.13, and 9.05. Note: The change in pH was monitored by the dropwise
addition of 0.1 M NaOH and therefore spectra were recorded as a change in CD
signal rather than in units of molar ellipticity. 
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significant amount of both Fe(III)PPIX and Zn(II)PPIX, the CD titration experiments 
with both porphyrins exhibited some dissimilarities.  Hemin binding notably altered 
the spectrum of BNT II after the addition of only one equivalent of the iron 
porphyrin, while Zn(II)PPIX did not cause such perturbations until additional 
equivalents were added.  Moreover, the deep negative peak centered around 200 nm 
red-shifted approximately 1 nm upon the addition of one equivalent of Fe(III)PPIX, 
while the spectrum of the zinc porphyrin associated with BNT II remained the same.  
After binding six equivalents of hemin this same peak shifted approximately 2 nm 
from its original value, while the addition of the same number of equivalents of 
Zn(II)PPIX altered the spectrum by only 0.5 nm.  Complete CD titration experiments 
are listed in Appendix III, pages A-28 and A-29. 
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Figure 3.7.  Circular dichroism spectra of BNT II and the corresponding spectral
changes upon addition of (A) Fe(III)PPIX at (___) 0 eq., (----) 1.36 eq., and (……)
6.12 eq. and (B) Zn(II)PPIX at (___) 0 eq., (----) 1.73 eq., and (……)6.05 eq. 
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 Tables 3.1 and 3.2 compare the spectral features for the binding of the iron 
(III) and zinc (II) porphyrins respectively.  Typically a negative ellipticity centered 
around 222 nm is indicative of α-helicity in polypeptides.  As demonstrated below, 
the binding of both metal porphyrins modifies this region of the spectra to the exact 
same extent upon the addition of six equivalents of each porphyrin (383 deg 
cm2/dmole).  This suggests that for at least BNT II helicity is not only increased upon 
binding both Fe(III)PPIX and Zn(II)PPIX, but also the mechanism of this binding 
seems to be similar.  The fact that BNT II bound more equivalents of the zinc 
porphyrin when compared to Fe(III)PPIX in the binding titration assays performed 
earlier suggests a secondary zinc binding site may be present that may not be located 
at a CD active position. Further insight into this hypothesis was not explored due to 
the fact the zinc porphyrin is not the natural substrate involved in the aggregation of 
hemozoin.  In addition, the limited buffering capacity of the 10 mM sodium acetate 
solution greatly reduced the amount of porphyrin that could be examined. 
While interpretation of the CD spectra for BNT II is obviously made difficult 
by the high content of histidine which dominates the absorbance properties of the 
spectra, similarities between recombinant HRP II42 and BNT II can be made.  In 
addition to sharing the same spectral markers, both rHRP II and BNT II are stable 
over a broad range of pHs.  Both display a red-shift in the peak centered around 200 
nm and a negative divergence of the CD spectra at 222 nm upon hemin binding.  
While the secondary structure of BNT II has yet to be conclusively established, the 
 140 
Table 3.1.  CD spectral markers for Fe(III)PPIX titration with BNT II averaged over
five individual scans.  Each value in parentheses is the molar ellipticity data obtained
at the corresponding wavelength, which was included to illustrate the change in
secondary structure upon porphyrin binding. 
BNT II π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 202.0 (-10675.57) 
222.0 
(591.28) 
234.0 
(-165.86) 
1.36 eq. Hemin 202.5 (-9301.80) 
222.0 
(574.60) 
235.0 
(-128.47) 
6.12 eq. Hemin 203.5 (-6940.78) 
222.0 
(208.37) 
235.0 
(-279.36) 
BNT II π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No Zn(II)PPIX 199.75 (-24138.37) 
222.0 
(1480.49) 
235.0 
(423.96) 
1.73 eq. Zn(II)PPIX 199.75 (-23031.47) 
222.0 
(1445.47) 
235.0 
(510.88) 
6.05 eq. Zn(II)PPIX 200.0 (-19585.62) 
222.0 
(1097.26) 
233.0 
(271.80) 
Table 3.2.  CD spectral markers for Zn(II)PPIX titration with BNT II averaged over
five individual scans.  Each value in parentheses is the molar ellipticity data obtained
at the corresponding wavelength, which was included to illustrate the change in
secondary structure upon porphyrin binding. 
fact that hemin chloride interaction elicits a structural change in the peptide supports 
a prerequisite of a higher ordered structural requirement in the biomineralization of 
hemozoin. 
      3.4.2.  BNT IIA (The Ala-His-His-Ala-Ala-Asp-Ala-His-His Domain) 
3.4.2a. Interaction with Heme 
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The electronic absorption spectrum for the interaction of hemin chloride with 
BNT IIA has a single Soret peak centered near 417 nm (Figure 3.8).  Again, like 
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 Figure 3.8.  UV-Vis spectrum of the interaction of hemin chloride with BNT IIA,
represented by the (___) solid line.  Samples of approximately 1 equivalent of hemin
chloride were added to 1-5 nmoles of template in 100 mM acetate buffer, pH 4.8.
Hemin chloride in buffer alone is represented by the (---) dashed line.  Spectra were
normalized to enhance the red-shift of the Soret band upon substrate binding. 
BNT II, the peptide BNT IIA in the absence of hemin has no appreciable absorbance 
in the 300-600 nm region (data not shown).  Therefore, upon binding, the Soret 
region of the spectrum red-shifted approximately 32 nm from the original Soret 
region at 385 nm for hemin chloride alone.  Visible changes to the absorption spectra 
again were observed after the addition of only 1 equivalent of heme and normalized 
to enhance the red-shift in the Soret region upon substrate binding.  Saturable binding 
was noted when the increase in absorbance reached a plateau and afterwards began to 
decrease. 
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The alternative putative binding domain, BNT IIA, bound 8.70±0.81 
equivalents of hemin chloride (Figure 3.9), which is approximately 1 equivalent less 
than BNT II.  When considering the arrangement of the amino acids in either the 3-10 
helix or left-handed polyproline II conformations as suggested earlier, BNT II has an 
arranged face of [(HHDHHDHHDHHD)2]4 while BNT IIA shares a similar face of 
[(HDHHDHHDHHDH)2]4.  With sterics likely playing a factor in the design of the 
templates, and a lack of a crystal structure, it becomes nearly impossible to explain 
the binding values with any certainty at this point, since the arranged faces of the two 
peptides are similar in amino acid composition. 
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 Figure 3.9.  Hemin chloride titration binding curve for BNT IIA.  The plot was
generated from the UV-Vis difference absorption spectra based on methods
established by Morgan.37,38  The data presented is the averaged result of five
independent binding titration experiments.  Individual binding experiments are
shown in Appendix II, page A-6. 
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Like BNT II, the BNT IIA binding curve did not exhibit a plateau region seen 
with typical saturable substrate binding assays.  Such results are indicative of 
porphyrin aggregation.   
3.4.2b. Interaction with Zn(II) Protoporphyrin IX 
When porphyrin binding was assayed with Zn(II)PPIX, BNT IIA bound 
3.96±0.45 equivalents of Zn(II)PPIX (Figure 3.10), which is about half as many 
equivalents as noted with Fe(III)PPIX binding.   
The fluorescence quenching experiments involving BNT IIA supported the 
reduced binding capability of Zn(II)PPIX (Figure 3.11), when compared to BNT II.  
 Figure 3.10.  Zn(II)PPIX titration binding curve for BNT IIA.  The plot was
generated from the UV-Vis difference absorption spectra based on methods
established by Morgan.37,38  The data presented is the averaged result of eight
independent binding titration experiments.  Individual binding experiments are shown
in Appendix II, pages A-7 and A-8. 
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At a 0.1:1 ratio of BNT IIA to Zn(II)PPIX the fluorescence of the chromophore was 
already quenched.  In contrast with BNT II at this same ratio of template to 
porphyrin, BNT IIA was no longer interacting with the excess porphyrin in solution.  
A fifty percent quench in the fluorescence was noted at a BNT IIA to porphyrin ratio 
of 0.02:1.    
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 Figure 3.11.  Fluorescence quenching studies of Zn(II)PPIX with BNT IIA.  
Samples were excited at 410 nm and monitored at the emission maxima of the 
fluorophore.  
3.4.2c.  Heme Aggregation Activity 
The BNT IIA dendrimer promoted 2.60±0.60 nmoles of insoluble aggregated 
heme product based on an average of twelve individual experiments after background 
hemozoin formation was subtracted, which for this set of experiments was 1.60±0.10 
nmoles of aggregated heme. 
 145 
3.4.2d. Circular Studies 
After initial CD studies with BNT II, circular dichroism spectroscopy was 
only used to monitor heme binding, since Fe(III)PPIX is the natural substrate 
involved in hemozoin formation.  Additionally, since the full binding capacity could 
not be achieved due to the limited buffering capacity of the 10 mM sodium acetate 
solution, changes in the circular dichroism spectra upon hemin binding were 
evaluated after approximately 1 equivalent of hemin was added and then again at half 
of the experimentally determined full binding capacity.  For example, BNT IIA bound 
8.70 equivalents of hemin chloride under the experimental conditions employed in the 
porphyrin binding assay, so in the circular dichroism experiments, binding at half-
capacity was assessed at approximately 4 equivalents of hemin.   
As seen in Figure 3.12, BNT IIA has a deep negative peak centered around 
198 nm.  Like BNT II, BNT IIA displays a positive peak at 222 nm and also a 
negative trough near 234 nm.  The deep negative peak however, is much broader than 
that of BNT II.  The addition of approximately 1 equivalent of hemin chloride did not 
alter the spectrum significantly either, as occurred with BNT II.  The spectrum did 
red-shift upon the addition of higher equivalents of hemin chloride. Spectral shifts 
associated with binding approximately one equivalent of hemin and at half maximal 
binding are listed in Table 3.3 (See Appendix III, page A-30 for complete CD 
titration experiments for BNT IIA).  It is interesting to note the spectral marker near 
234 nm diminishes at higher equivalents of hemin, as demonstrated in Figure 3.12 by 
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the dotted line representing 4.88 eq. of hemin, and a new minimum centers around 
227 nm.  
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 Figure 3.12.  Circular dichroism spectra of BNT IIA (___) and the corresponding
spectral changes upon the addition of hemin chloride.  Spectra are shown upon the
addition of 0.81 (----) equivalents of substrate and 4.88 equivalents (…...) of substrate
(½ of the full binding capacity experimentally determined for BNT IIA).  Actual
spectral shifts and signal intensities are listed in Table 3.3 
BNT IIA π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 198.0 (-12263.11) 
222.0 
(425.38) 
234.0 
(-203.47) 
0.81 eq. Hemin 198.3 (-12135.38) 
222.0 
(279.22) 
233.0 
(-218.94) 
4.88 eq. Hemin 201.0 (-8611.48) 
222.0 
(-977.79) 
227.0 
(-1008.51) 
Table 3.3.  CD spectral markers for Fe(III)PPIX titration with BNT IIA averaged
over five individual scans.  Each value in parentheses is the molar ellipticity data
obtained at the corresponding wavelength, which was included to illustrate the
change in secondary structure upon porphyrin binding. 
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3.5.  Discussion  
Within the HRP II sequence, which is comprised of 76% of histidine and 
alanine residues, the prevalence of an Ala-His-His repeat becomes apparent.  Upon 
further examination of this trimeric repeat, a higher organizational scheme is 
revealed. An Ala-His-His-Ala-His-His-Ala-Ala-Asp domain is repeated 16 times 
while an alternative domain, Ala-His-His-Ala-Ala-Asp-Ala-His-His, is repeated      
23 times.  With the establishment of BNT II as a functional peptide mimic of HRP II 
by Zielger et al.,36 we elucidated the role of this putative nucleation domain, Ala-His-
His-Ala-His-His-Ala-Ala-Asp, against the alternative hypothetical nucleation domain, 
Ala-His-His-Ala-Ala-Asp-Ala-His-His, sequenced within another peptide dendrimer 
deemed BNT IIA (the first Alternate of BNT II).  Our bionucleating templates each 
possessed four dendrimeric branches with the respective sequences repeated twice per 
branch, resulting in each peptide dendrimer possessing 8 copies of the particular 
putative nucleation domain.  Distinctions between the two domains allowed for the 
evaluation of the significance of the Ala-His-His repeat in the two postulated 
hemozoin templating sequences.  Placement of the Ala-His-His repeat to the end of 
the nucleation domain, as in BNT IIA, will reveal information as to both the binding 
and nucleating capabilities of the template when the Ala-His-His repeat is interrupted, 
as well as revealing which domain is the most probable hemozoin nucleation domain 
within the HRP II sequence.    
When investigating antimalarial strategies targeting hemogloblin catabolism 
and the processes therein, the reaction medium cannot be disregarded since hemozoin 
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formation is confined to the parasite's digestive vacuole, which sustains an acidic 
environment (pH 4.5-5.5).  Such acidity can have a twofold effect on both reactivity 
and stability.  First, since the pKa of histidine is 5.8, positively charged His+ is 
unavailable to bind to metals.  Secondly, heme insolubility and other 
aggregation/precipitation issues occur when the pH is acidic, requiring meticulous 
and tedious workups of such studies in order to obtain results free of non-hemozoin 
Fe(III) aggregates. 
Free, unbound heme has a low, broad Soret peak centered at 385 nm as 
detected by UV-Vis spectroscopy.  In heme binding assays, observing an increase in 
the Soret absorbance and/or red-shift in the Soret peak is indicative of substrate 
binding while decreases in absorbance and/or a blue-shift in the Soret peak 
characterizes substrate binding interference or inhibition.  The natural histidine-rich 
protein II in acidic medium (pH 4.5-5.5) bound heme with a Soret peak red-shifted to 
414 nm.  Linear multimers of HRP II sequences [(Ala-His-His-Ala-His-His-Ala-Ala-
Asp)2 and (Ala-His-His-Ala-His-His-Ala-Ala-Asp)3, but at pH 7.4] were also capable 
of heme binding, with a detectable Soret peak centered at 413 nm.43 Our peptide 
dendrimers, BNT II and BNT IIA, had Soret peaks indicative of substrate binding as 
well, with peaks centered around 419 nm and 417 nm respectively.  Although the 
absorbance wavelengths varied according to the template (Table 3.4), both were 
slightly red-shifted from that of HRP II.   
The absorbance maximas involving the Zn(II)PPIX substrate also varied 
according to the template, with detectable Soret peaks at 380 nm and 392 nm for  
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BNT II and BNT IIA respectively (Table 3.4).  The absorption spectra of the zinc 
porphyrin binding assays did experience an increase in intensity in the Soret 
absorbance, but both were blue-shifted from the Soret peak of Zn(II)PPIX, which is 
centered around 400 nm. 
Template Fe(III)PPIX Absorbance Maxima (nm) 
Zn(II)PPIX 
Absorbance Maxima (nm) 
BNT II 419 380 
BNT IIA 417 392 
Table 3.4.  Absorbance maximas for templates BNT II and BNT IIA with 
Fe(III)PPIX and Zn(II)PPIX. 
 Initial porphyrin binding studies indicated that BNT II and BNT IIA had 
relatively similar Fe(III)PPIX binding affinities (9.83±0.21 and 8.70±0.81 eq. 
respectively) (Figure 3.13).  Assuming the histidine residues are involved in binding, 
both BNT II and BNT IIA have the same number of Ala-His-His repeats and 
consequently bound similar equivalents of the natural iron substrate.  BNT IIA 
however, had a drastically reduced ability to bind the zinc porphyrin, binding only 
3.96±0.45 equivalents of substrate, while BNT II was capable of binding 13.40±0.31 
equivalents.  In fact, when reviewing earlier work presented by Ziegler et al.,36 a first 
generation peptide dendrimer, BNT I, which had the Ala-His-His-Ala-His-His-Ala-
Ala-Asp sequence repeated once per branch (half as many as BNT II), bound more of 
the zinc porphyrin (6.80±0.50 eq.) than the second generation template BNT IIA 
(Figure 3.13), which disrupted the Ala-His-His repeat.  From the data presented, the 
perturbed spatial distributions of the amino acids within the nucleating domain, 
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specifically the interruption of the Ala-His-His repeat, affected binding between the 
zinc substrate and template.  The discrepancies in the binding data may be suggestive 
of nonspecific interactions between the substrate and template or possibly indicative 
of specific interactions between the polymer chains of the dendrimeric peptide.  
The fluorescence quenching studies provided an alternative means by which 
to examine the zinc porphyrin interactions since both templates shared similar iron 
porphyrin efficacies, but had vastly different values for Zn(II)PPIX.  As a precaution, 
it was crucial that the concentration of the zinc porphyrin remained constant          
(1X10-5 moles/L), while varying the concentration of the peptide templates to ensure a 
monomeric state of porphyrin.  If porphyrin concentrations become too high, the 
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 Figure 3.13.  Substrate binding of the hypothesized putative nucleation domains. 
BNT II and BNT IIA with Fe(III)PPIX and Zn(II)PPIX.  The first generation 
dendrimer, BNT I was added to expand the discussion of the templates with the 
permission of Zielger et al.36 
monomers aggregate to dimers, which fail to fluoresce.  Additionally, since the 
experiment is performed in aqueous solutions, fluorescence intensity readings do not 
increase linearly as the concentration of the porphyrin increases, as it would be if 
carried out in organic medium and therefore more reproducible results are obtained if 
the concentration of the porphyrin is unvaried.  This method also negated the salt 
effect since the concentration of buffer is kept constant throughout the 
experimentation, seeing how salts can promote porphyrin aggregation. 
The fluorescence quenching studies did support the reported disproportion in 
the zinc protoporphyrin binding data between BNT II and BNT IIA.  Typically the 
fluorescence of Zn(II)PPIX continues to decrease as there are less monomers in 
solution, resulting from the template binding to the zinc porphyrin.  The rate of 
decrease in fluorescence intensity for both templates follows a first order exponential 
decay pattern (Figure 3.14), suggesting the mode of binding with the zinc porphyrin 
may be similar between the two templates.   The fluorescence quenching of 
Zn(II)PPIX displayed a three fold increase with BNT II compared to BNT IIA (0.03:1 
vs. 0.01:1 ratios of template to porphyrin), which was the same excess noted in the 
UV-Vis binding titration experiments (13.40 and 3.96 equivalents for respectively).  
Actual stoichiometries for the fluorescence quenching studies were not determined 
since a number of porphyrin self-aggregation processes could occur at the working 
concentration of Zn(II)PPIX.  
As noted before, heme binding alone does not elicit hemozoin formation. 
Results obtained from the in vitro heme aggregation assays, indicated BNT II 
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 Figure 3.14.  Fluorescence quenching of Zn(II)PPIX with putative domain peptides 
BNT II and BNT IIA. 
aggregated twice as much hemozoin as both BNT I (again from Zielger36) and BNT 
IIA (Figure 3.15).  Even though BNT II and BNT IIA bound nearly equal amounts of 
the iron porphyrin, hemozoin production was drastically reduced in the latter mutant.  
Seemingly, again the interruption of the Ala-His-His repeat in BNT IIA impeded the 
production of hemozoin by as much as half.  Upon further sequence examination of 
BNT IIA, the full sequence of the Ala-His-His-Ala-His-His-Ala-Ala-Asp domain can 
be located once along the chain length.  Consequently, the production of hemozoin 
mediated by BNT IIA is equivalent to that mediated by BNT I, which also has this 9-
mer sequence repeated only once per dendrimeric branch.  
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Figure 3.15.  Hemozoin production mediated by the putative nucleation domains.
Molecular models of the templates as 3-10 helices are added for dimensional clarity.
BNT I was added to expand the discussion of the templates with the permission of
Zielger et al.36 
 
          The unusually high content of histidine in HRP II and our bionucleating 
templates warrants additional considerations when analyzing the data collected.  
Histidine exists in a partially protonated, partially deprotonated form at physiological 
pH, thus changes in pH are likely to influence the biological effects exerted by these 
residues.  The effect of pH on proteins rich in histidine has been well documented, 
demonstrating that such proteins are extremely pH sensitive, being modified not only 
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by the solution phase, but also by subsequent binding interactions.44 Since metal and 
heme binding are pH dependent, substrate binding diminishes when histidine residues 
become protonated.  Such tightly controlled binding capabilities are likely to 
influence other cellular interactions in addition to the parasitic homeostasis involved 
in the biomineralization of hemozoin.  Thus, it becomes imperative to characterize 
such binding sites and uncover the role of the abundant histidine residues in HRP II. 
With the peptides modeled as potential right-handed 3-10 helices and left-
handed polyproline type II conformations, every second and third residue in both     
9-mer putative nucleation domains (amino acids in positions 2,3,5,6,8 and 9) are 
packed towards the outside, being exposed to solvent, while the conserved alanine 
residues (at positions 1,4 and 7) are on the opposite face, collapsing inward as a result 
of the hydrophobic interchain interactions.  This suggests that the high histidine 
content alone may not be sufficient for procuring the heme binding sites involved in 
the formation of the biomineral, and is supported by the fact that polyhistidine, itself 
existing in a random coil configuration, failed to promote the formation of insoluble 
heme aggregates.36 
Circular dichroism spectroscopy is widely used for studying peptide and 
protein conformations.  The role of specific residues can be explored through site-
directed mutagenesis studies capitalizing on the sensitivity of this spectroscopic 
method to detect and characterize any structural alterations resulting from the 
corresponding amino acid substitution.  A recent study included such analyses on 
HRP I peptides in attempt to induce immunogenicity through amino acid mutations 
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that increased helicity.45 Our efforts incorporated the use of circular dichroism 
spectroscopy to not only detect the spectral differences associated with the specific 
template mutations, but to also identify any secondary structural changes that may be 
induced upon hemin binding.  
Conformational analysis by circular dichroism spectroscopy gives rise to two 
fundamental questions that remain unresolved despite recent advances in x-ray 
crystallography and both high resolution and multidimensional NMR.  The first 
debate regards how exactly protein or peptide native structure is encoded in the amino 
acid sequence.46 The second dispute examines the individual properties of the amino 
acid residues and the corresponding contribution to both the local environment and 
overall secondary structure of the protein or peptide, attempting to correlate 
conformation and activity.47 
The folding of a protein or peptide into a higher ordered structure is a 
fundamental requirement necessary to induce or invoke a proper biological response 
or activity.  Templates, when used in the design of protein mimics, have been 
successful at reinforcing and directing such intramolecular folding.  Template 
assembled protein mimics have been constructed to self-assemble into three α-helical 
bundles48,49 and collagen-like triple helices.50 Moreover, the use of such templates can 
stabilize the overall structure by reducing the entropy involved in protein/peptide 
folding.50 Our templates however, are more involved than traditional protein mimics, 
being that the BNTs can be characterized as both peptides and polymeric dendrimers.  
With this in mind, while protein folding principles rely mainly on a linear encoding of 
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torsion angles along the peptide backbone (φ,ψ) and side-chain interactions, polymer 
and dendrimer modeling suggests solvation and interchain interactions are also 
pertinent in determining secondary structure.46   
The tetrabranched 18-mer peptide, BNT II, possessed a more ordered 
conformation than both BNT I and the linear constructs (Chapter 2, Figure 2.14), a 
feature shared by other MAPS peptides,51,52 as well as template-assembled collagen 
mimetics.50,53 The enhanced secondary structure of BNT II over (AHHAHHAAD)2 is 
not surprising given the nucleating domain is presented four times.  This multiplicity 
is further demonstrated by the fact the linear 18-mer peptide had to be approximately 
3.8 times more concentrated than the similar MAPS construct in order to obtain any 
appreciable CD signal (unpublished results). 
The interpretation of the increase in intensity in the CD signal between BNT I 
and BNT II however, may not be conclusively explained via circular dichroism 
experiments.  Recognizing the templates are dendrimers, the increase in CD signal 
noted for BNT II may not reflect an increase in secondary structure per se, but may 
instead reflect an increase in more CD active groups since the generation of the 
dendrimer has increased also, a trait seen with other peptide dendrimers.54 Though 
this property is not uncommon for circular dichroism studies involving dendrimers, 
the secondary structure enhancement is not rooted in the multiplicity factor alone.  
Inter and intramolecular interactions, including both hydrogen bonding and 
electrostatic forces, could also augment secondary structure.  Ellipticity itself may be 
rooted in the binding strength of intermolecular hydrogen bonding between the 
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dendritic peptide segments.55,56 As seen with BNT II during thermal denaturation 
experiments (Figure 3.16), both inter and intramolecular aggregations effect the 
conformation of the peptide dendrimer.  Such aggregative forces may play a 
prominent role in the nucleation and assemblage of hemozoin, as seen in the in vitro 
hemozoin aggregation assays, in which BNT II nucleated twice as much aggregated 
heme as BNT I. 
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 Figure 3.16.  Thermal denaturation of BNT II.  As the temperature of the sample 
increased, the negative ellipticity at ~197 nm increased, while the ellipticity at 
~220 nm decreased. 
Considering the more rigid structural constraints imparted by the MAPS core, 
the circular dichroism features typically classified by particular secondary structures 
in globular proteins may inadequately characterize the BNTs.  An improved CD 
model for the BNTs may include the natural and templated collagen triple helix,57,58 
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 Figure 3.17.  Circular dichroism
spectra for (-x-x-x-) collagen and
(-o-o-o-) poly-L-proline II.
Reproduced from reference 59. 
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Figure 3.18.  Circular dichroism spectra of
putative domain peptides BNT II (___) and
BNT IIA (---). 
which has three individual helices 
intertwined with each other.  The circular 
dichroism spectrum of collagen exhibits a 
CD spectrum similar to polyproline II, 
having a large negative trough around  
197 nm and a small positive shoulder at       
220 nm (Figure 3.17).59 These spectral 
features are shared by both BNT II and 
BNT IIA (Figure 3.18), which blue-shift 
slightly from the typical polyproline II 
conformation, which has a strong negative band at 200 nm and a weak positive band 
at 226 nm.  In fact, the CD spectrum of BNT IIA closely resembles the spectrum of a 
dendrimeric lysine branched 
“minicollagen” peptide reported by 
Fields et al.53 More interesting is 
the fact the thermal denaturation 
experiments also behave like those 
performed on collagen, where the 
ellipticity at 225 nm decreases with 
increasing temperature, a signature 
of the denaturation of the collagen 
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triple helix.57 This ellipticity associated for BNT II is slightly blue-shifted at 220 nm 
(Figure 3.16), but fails to explain why a similar thermal denaturation study with the 
linear peptide (Ala-His-His-Ala-His-His-Ala-Ala-Asp)2 harbored the same results 
(Figure 3.19). 
Figure 3.19.  Thermal denaturation of the linear multimer of BNT II, (Ala-His-His-
Ala-His-His-Ala-Ala-Asp)2.  As the temperature of the sample increased, the negative 
ellipticity at ~197 nm increased, while the ellipticity at ~220 nm decreased. 
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As stated before, circular dichroism studies were also utilized as a 
spectroscopic tool with which to enhance our understanding of iron (III) 
protoporphyrin IX binding to our modeled templates, where we could monitor the 
change in secondary structure as a function of increasing heme concentration.  The 
influences of metal binding on the secondary structure of histidine-rich peptides are 
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abundant.  Though both linear and dendrimeric Ala-His-His-Ala-His-His-Ala-Ala-
Asp nucleating domains bound a significant amount of heme, only the peptide chains 
with 18 amino acids exhibited any secondary structure (again see Chapter 2, Figure 
2.14).  Increasing the chain length to an appropriate size may give rise to a favorable 
conformational feature along the peptide backbone, which could result in more 
favorable interactions between the peptide and substrate. 
 An additional point of consideration in the CD experiments involves the 
amino acid sequence and the placement of the histidine residues.  Broo et al. reported 
the environment around a histidine residue in a folded peptide could alter the pKa of 
that histidine residue.60,61 With this in mind, not only does heme binding change with 
each mutation, but also conformational changes could be attributed to both changes in 
the sequence and each subsequent heme molecule that is bound.  The heme group is 
however a symmetrical chromophore, exhibiting no inherent optical activity.  Any 
subtle changes in the CD spectrum must arise from the peptide existing in a more 
fixed orientation as a consequence of the binding, or from the heme molecule 
possessing an asymmetrical axial ligation or molecular plane distortion once bound to 
the BNT.  If the latter were of any real consequence, the templates that bound the iron 
porphyrin would only display changes in intensity in the CD spectrum upon binding 
additional equivalents of heme, rather than the wavelength shifts that are noted. 
In retrospect concerning the evaluation of the histidine residues, it must be 
noted that BNT II and BNT IIA (and every mutant included in Chapter 4) maintained 
a hydrophobic core of alanine residues at positions 1,4, and 7 along the domain 
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sequence. Though initially these core residues were not given consideration to 
mutations since the bionucleating templates design criteria was based solely on 
binding capabilities and hemozoin production, it may have been of interest to 
incorporate amino acid residues which were aimed at disrupting this core to examine 
any effects on the secondary structure,62 and if any such spectral changes could be 
correlated to the results obtained from the substrate binding curves.  However, in light 
of the designed peptides, such alterations would indeed effect hemozoin formation 
since the three dimensional scaffold necessary for templating heme onto the 
substrates would be disrupted. 
Finally, though the tetravalent lysine MAPS core shows no appreciable 
secondary structure in our own (data not shown) and  independent circular dichroism 
studies,63 the contributions from the core on the peptide segments can not be ignored.  
The rigidity imparted by the MAPS core makes it difficult to unambiguously correlate 
the conformation and activity of the BNT peptides.  The CD results however, show 
some evidence that helical conformation may be important for hemozoin formation.  
Both BNT II and BNT IIA displayed some alteration in the template secondary 
structure upon heme binding (Figure 3.7A, Table 3.1 and Figure 3.12, Table 3.3).  
BNT II, which bound more heme and aggregated more hemozoin than BNT IIA, 
displayed pronounced spectral changes in comparison to BNT IIA.  This increased 
negative ellipticity upon substrate binding is not uncommon in metal binding motifs64 
and other peptide dendrimers.65  
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3.6.  Conclusions 
Contradictory to the problems associated with the expression of HRP II in 
Escherichia coli,66 using dendrimeric MAPS templates in the de novo design of a 
HRP II mimic permits the facile assembly and functionalization of peptides at the 
single amino acid level.  Unlike linear peptide chains, the BNTs adopt a higher 
ordered structure. 
The interaction of the hemin chloride and zinc protoporphyrin IX substrates  
with the bionucleating templates, BNT II and BNT IIA, provided insight into the 
interaction of the porphyrins with HRP II.  The absorption spectra of the substrates 
with both templates were altered in the saturation binding experiments, indicative of 
substrate association with each template. Additionally, the fluorescence of the 
Zn(II)PPIX chromophore was quenched upon substrate:template interactions.  
Finally, such interactions were also noted in the circular dichroism spectra, as 
detected by changes not only in signal intensity, but also in the recorded wavelength 
maxima and minima. 
Two histidine rich amino acid sequences were proposed to be the critical 
residues involved in hemozoin formation, the Ala-His-His-Ala-His-His-Ala-Ala-Asp 
sequence in the dendrimeric template BNT II and the Ala-His-His-Ala-Ala-Asp-Ala-
His-His sequence in the alternate template, BNT IIA.  Despite both sequences having 
the same number and type of amino acid residues, the results indicate the arrangement 
of such amino acids is critical in hemozoin formation.  BNT II bound 9.83±0.21 
equivalents of heme, while BNT IIA bound a nearly similar amount of 8.70±0.81 
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equivalents of the same substrate.  This suggests that the substrate binding 
recognition site within the two sequences has not been interrupted, since both have 
similar efficacies.  The zinc porphyrin binding site along the chains of BNT II and 
BNT IIA however has been disrupted.  BNT II bound more Zn(II)PPIX (13.40±0.31 
eq.) than heme (9.83±0.21 eq.), while BNT IIA showed a reduced binding capability 
(3.96±0.45 eq. of Zn(II)PPIX vs. 8.70±0.81 eq. of Fe(III)PPIX).  Such results suggest 
different binding sites for each metal porphyrin. 
Though BNT II and BNT IIA have similar iron porphyrin efficacies, the 
sterics of the dendrimer core could alter the alignment of the peptide chains, and 
therefore contribute to the small discrepancies in the heme binding data.  Such 
perturbations may be small however, but in light of the results obtained from the in 
vitro heme aggregation assay, where BNT II nucleated twice as much insoluble heme 
aggregates as BNT IIA, are of real consequence.  Subtle changes in the arrangement 
of amino acids along the peptide chain and between dendrimeric branches could 
prevent the requisite bond formation in the nucleation of hemozoin, in which the 
propionate of one heme group serves as the axial ligand to another.  Recalling the first 
generation dendrimer from Ziegler36 nucleated half the amount of ß-hematin as the 
second generation BNT II, it is interesting to note that BNT IIA formed comparable 
amounts of the insoluble heme aggregates in comparison to BNT I.  Upon 
examination, BNT I had the Ala-His-His-Ala-His-His-Ala-Ala-Asp sequence domain 
repeated once per dendrimeric branch.  The 18 residue sequence of BNT IIA also 
repeated this same 8-mer sequence once per dendrimeric branch (Figure 3.20). 
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Figure 3.20.  Representation of the amino acid sequences of BNT II and BNT IIA. 
The Ala-His-His-Ala-His-His-Ala-Ala-Asp repeat is isolated along the peptide 
chains, indicating the frequency of this particular sequence. 
Results indicate the 9-mer amino acid sequence for BNT II (Ala-His-His-Ala-
His-His-Ala-Ala-Asp) is the most probable nucleating domain, based on the ability to 
not only bind heme, but also nucleate β-hematin.  Subsequent experiments were 
designed to elucidate the role of the nucleating domain active site amino acids in 
the formation of hemozoin based on synthetic site-directed mutagenesis studies 
using BNT II and are presented in Chapter 4. 
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Chapter 4 
Site-directed Mutagenesis Studies of BNT II 
4.1.  The Mutants of BNT II - An Introduction 
With the 9-mer sequence of BNT II, Ala-His-His-Ala-His-His-Ala-Ala-Asp, 
being the most probable nucleating domain, based on the ability not only to bind 
heme, but also to nucleate β-hematin, subsequent experiments were designed to 
elucidate the role of the nucleating domain active site amino acids in the formation of 
hemozoin based on synthetic site-directed mutagenesis studies.  Thirty-two histidine 
and alanine residues and eight aspartic acid residues comprise the parent BNT II 
template, excluding amino acid contributions from the MAPS core.  The high binding 
activity of this HRP II mimic suggests the histidine residues at positions 2,3,5, and 6 
(and therefore also positions 11,12,14,and 15) may be functionally and structurally 
important for activity based on results obtained against the alternative hypothesized 
nucleation domain of BNT IIA, Ala-His-His-Ala-Ala-Asp-Ala-His-His (See Chapter 
3 for the putative domain studies).   Furthermore, the diminished hemozoin formation 
activity of BNT IIA suggests the trimeric Ala-His-His repeat must be necessarily 
conserved, providing either the appropriate binding site or spatial requirement for     
β-hematin aggregation.  These sequence requirements spawned the development of 
BNT II mutants (Table 4.1).   
The first mutant synthesized was BNT IIC, which attempted to probe the Ala-
His-His repeat by replacing the histidine residues with alanine in an attempt to 
ascertain if heme binding was solely dominated by histidine residues.  This mutant 
was however insoluble under the experimental conditions employed (pH 4.8). 
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Before attempting to investigate the trimeric repeat again, a single point 
mutation was made, not only for the eased peptide assembly from a synthetic 
standpoint, but also to explore the necessity of the conserved aspartic acid residue 
along the 9-mer sequence.  Here the aspartic acid residues were replaced with 
nonpolar alanine residues in mutant BNT IID. 
BNT II Ala His His Ala His His Ala Ala Asp 
BNT IIC 
 
Ala Ala Ala Ala Ala Ala Ala Ala Asp 
BNT IID 
 
Ala His His Ala His His Ala Ala Ala 
BNT IIX 
 
Ala His Ala Ala His Ala Ala Ala Asp 
BNT IIY 
 
Ala Ala His Ala Ala His Ala Ala Asp 
BNT IIZ 
 
Ala His His Ala His His Ala Ala Lys 
Table 4.1.  Site-directed mutagenesis of the 9-mer sequence of BNT II.  Mutated
amino acids residues are outlined with -----. 
 With the inability to assess if the histidine residues in the original BNT II 
sequence were the single-handed determinant in heme binding and hemozoin 
biomineralization, the trimeric repeat was then evaluated in terms of the relative 
position of this amino acid on the putative nucleating face.  With the templates 
modeled as potential right-handed 3-10 helices and left-handed polyproline II 
conformations, every third or approximately 3.4 residues is involved in a helical turn. 
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Mutant BNT IIX disturbed these turns by mutating the histidine residues with alanine 
at the third and sixth positions along the 9-mer sequence.  Mutant BNT IIY explored 
the reverse arrangement of the histidine residues, conserving the deemed helical 
spatial requirements of the histidine residues at these positions, while making alanine 
mutations at positions two and five. 
 Finally, since BNT IID surveyed the conservation of the aspartic acid residue 
in terms of polarity, BNT IIZ reconsidered this amino acid in terms of charge.  By 
replacing the aspartic acid with lysine, which will be deprotonated under the 
experimental conditions, we can clarify whether electrostatic interactions are requisite 
in heme binding.   
4.2.  General Information 
All experiments performed on the BNT II mutants were the same as those 
described for the parent template BNT II, including Fe(III)PPIX and Zn(II)PPIX 
binding assays, fluorescence quenching studies with Zn(II)PPIX, the in vitro heme 
aggregation assay, and circular dichroism analysis. For complete details on 
experimental procedures see Chapter 3, Section 3.2, Functional Screening of the 
BNTs.   
Regarding mutant solubility in 100 mM acetate buffer, pH 4.8, BNT IIZ, 
which had lysine replacing aspartic acid in the ninth and eighteen positions along the 
putative binding domain, displayed an enhanced solubility compared to the parent 
peptide dendrimer BNT II, which was soluble up to concentrations of approximately 
10 mg mL-1.  BNT IID, which had the aspartic acid residue mutated to alanine, was 
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considerably less soluble (~1-2 mg mL-1) than the other mutants.  BNT IIX and BNT 
IIY exhibited a somewhat reduced solubility compared to BNT II.  BNT IIY was 
slightly more soluble than BNT IIX (~ 6 mg mL-1 of BNT IIY vs. 3-4 mg mL-1 of 
BNT IIX).  When considering the mutations for the respective templates in light of 
peptide solubility, it appears that the Ala-Ala-His trimeric repeat of BNT IIY 
enhances the solubility of the peptide versus the Ala-His-Ala trimeric repeat of BNT 
IIX.  This however, is not surprising given the arrangement of amino acids along the 
nucleating face if modeled in the right-handed 3-10 helix or the left-handed 
polyproline II conformation. With three or nearly so amino acid residues per turn, the 
residue of BNT IIX exposed to the solvent would be alanine, which is hydrophobic, 
as compared to the hydrophilic histidine residue present at that position in BNT IIY. 
      4.2.1.  Mutant BNT IID – Results and Discussion 
      (The Ala-His-His-Ala-His-His-Ala-Ala-Ala Mutant Domain) 
The electronic absorption spectra for the interaction of hemin with BNT IID 
had a single Soret peak centered at 413 nm (Figure 4.1).  Like BNT II, this peptide 
had no appreciable absorbance in the 300-600 nm region of the spectra (data not 
shown).  Though the spectra again red-shifted from that of hemin chloride alone   
(385 nm), BNT IID had a much broader spectrum than its parent BNT II (Chapter 3, 
Figure 3.2).  Visible changes to the absorption spectra were observed after                 
1 equivalent of heme was added, but heme aggregation was also apparent in the 
cuvette.  The electronic absorption spectrum was then reevaluated after 0.1 
equivalents of heme were added, as shown in Figure 4.1. 
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 Figure 4.1.  UV-Vis spectrum of the interaction of hemin chloride with BNT IID,
represented by the (___) solid line.  Samples of approximately 0.1 equivalents of
hemin chloride were added to 7-10 nmoles of template in 100 mM acetate buffer,
pH 4.8.  Hemin chloride in buffer alone is represented by the (---) dashed line.
Spectra were normalized to enhance the red-shift of the Soret band upon substrate
binding. 
Initially BNT IID was deemed a non-binding peptide with hemin chloride 
since a substrate binding curve could not be constructed due to the presence of 
aggregated heme.  However, upon re-examination with an increased amount of 
template (7-10 nmoles) and reduced number of equivalents of hemin chloride, 
saturable binding was achieved.  The absorbance maxima continued to increase from 
413 nm to 417 nm upon the addition of more hemin chloride.   
BNT IID bound 1.45±0.17 equivalents of hemin chloride (Figure 4.2).  Note 
however, the increased error in the normalized binding data due to the more rapid 
occurrence of heme aggregation.  Upon sequence examination, when compared to its 
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 Figure 4.2.  Hemin chloride titration binding curve for BNT IID.  The data
presented is the averaged result of ten independent binding titration experiments.
Individual binding titration curves are shown in Appendix II, pages A-9 and
A-10. 
parent BNT II, it appears the aspartic acid is a critical residue in the binding of 
Fe(III)PPIX.  While BNT II was capable of binding nearly 10 equivalents of the iron 
porphyrin, mutating the aspartic acid with alanine as in BNT IID, drastically reduced 
the binding capabilities with this porphyrin.  At this point it becomes indeterminate 
whether the reduced binding capabilities are due to the change in polarity at this 
position, or whether the reactivity of the side chain affected binding. 
BNT IID also bound the zinc porphyrin (Figure 4.3), binding 3.14±0.71 
equivalents of this porphyrin.  The binding capability with Zn(II)PPIX was twice as 
much as that with Fe(III)PPIX, a trend also seen with mutant BNT IIA (Chapter 3, 
Section 3.4.2b). 
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Figure 4.3.  Zn(II)PPIX binding titration curve for BNT IID.  The data presented is 
the averaged result of sixteen independent binding experiments.  Individual binding 
titration curves are shown in Appendix II, pages A-12 and A-13. 
Though the zinc protoporphyrin IX binding assays may appear immaterial 
because this porphyrin fails to be incorporated into an aggregated material such as    
ß-hematin, both alone and as an extension of preformed hemozoin crystals,1 this 
porphyrin is a known malarial antagonist.   The fact that Zn(II)PPIX can bind to   
HRP II in the absence of Fe(III)PPIX, yet still bind to the same sites of the crystal 
surface of ß-hematin as quinoline antimalarials implies a tightly controlled 
mechanism of hemozoin formation and inhibition.  Such interactions cannot be solely 
dependent on π-π interactions or the zinc porphyrin would behave similarly to that of 
the iron substrate.  Our template dendrimers, which make single amino acid mutations 
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along a putative binding domain, delve further into which sites are pertinent for 
binding and the biomineralization of hemozoin.   
Results from the binding data of BNT IID suggest that while the aspartic acid 
residue is critical for the binding of hemin chloride, it plays little role in the binding 
of zinc(II)protoporphyrin IX.  Accompanying discussion will be offered in the 
conclusions, Section 4.3, after the remaining mutants are presented. 
The fluorescence quenching experiments involving Zn(II)PPIX with BNT IID 
demonstrated a reduced binding capability (Figure 4.4).  At a BNT IID to Zn(II)PPIX 
ratio of 0.1:1, the fluorescence intensity was reduced by 33% and did not diminish to 
50% until the ratio of template to porphyrin was approximately 0.35:1.  The 
fluorescence of the fluorophore was completely quenched at a 0.8:1 ratio of BNT IID 
to zinc porphyrin. 
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 Figure 4.4.  Fluorescence quenching studies of Zn(II)PPIX with BNT IID.  Samples 
were excited at 410 nm and monitored at the emission maxima of the fluorophore. 
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BNT IID aggregated only 0.50±0.20 nmoles of heme according to the in vitro 
heme polymerization assay.  This miniscule production of insoluble aggregated heme 
again supports the role of the aspartic acid residue in the formation of ß-hematin. 
As seen in the circular dichroism spectra below (Figure 4.5), BNT IID has a 
deep, broad negative peak centered around 195 nm, a positive shoulder at 222 nm and 
a positive trough at 234 nm.  Unlike the spectra of BNT II, the spectra of BNT IID 
remained positive throughout the remainder of the spectra after 215 nm.  The addition 
of hemin chloride did not alter the spectra significantly.  Although the molar 
ellipticity increased upon hemin binding, the spectra did not red-shift throughout the 
wavelengths examined.  Spectral shifts associated with hemin binding are listed in 
Table 4.2.  Complete CD titration experiments are listed in Appendix III, page      
A-31. 
The lack of associated spectral changes upon hemin binding could provide a 
possible explanation as to why BNT IID failed to promote any significant amount of 
insoluble heme aggregate.  In addition to the aspartic acid being a critical residue in 
the binding of the heme substrate, the lack of secondary structure, not only depicted 
by the template, but also displayed upon hemin binding, suggests that the 
conformation offered by the template is not favorable for hemozoin formation. 
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BNT IID π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 195.4 (-14752.82) 
223.0 
(2158.69) 
234.0 
(1681.49) 
0.33 eq. Hemin 196.0 (-14189.81) 
222.0 
(1841.79) 
236.7 
(1203.11) 
1.00 eq. Hemin 195.7 (-13043.04) 
222.0 
(1684.50) 
236.7 
(1099.31) 
Table 4.2.  CD spectral markers for Fe(III)PPIX titration with BNT IID averaged
over five individual scans.  Each value in parentheses is the molar ellipticity data
obtained at the corresponding wavelength, which was included to illustrate the
change in secondary structure upon porphyrin binding. 
 Figure 4.5.  Circular dichroism spectra of BNT IID (___) and the corresponding
spectral changes upon the addition of hemin chloride.  Spectra are shown upon the
addition of 0.33 (----) equivalents of substrate and 1.00 (…...) equivalent of substrate.
Actual spectral shifts and signal intensities are listed in Table 4.2. 
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      4.2.2.  Mutant BNT IIX – Results and Discussion 
      (The Ala-His-Ala-Ala-His-Ala-Ala-Ala-Asp Mutant Domain) 
The interaction of hemin chloride with BNT IIX produced the electronic 
absorption spectrum in Figure 4.6.  The peptide dendrimer again had no appreciable 
absorbance in the 300-600 nm range.  Upon the addition of 0.3 equivalents of hemin 
chloride, the spectrum displayed a single Soret peak centered near 400 nm, which is   
red-shifted 5 nm from the value recorded with Fe(III)PPIX in acetate buffer, pH 4.8, 
alone.  This interaction of the template, BNT IIX, with hemin chloride is however 
blue-shifted from iron protoporphyrin IX association with both BNT II and native 
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 Figure 4.6.  UV-Vis spectrum of the interaction of hemin chloride with BNT IIX,
represented by the (___) solid line.  Samples of approximately 0.3-0.5 equivalents
of hemin chloride were added to 9-10 nmoles of template in 100 mM acetate
buffer, pH 4.8.  Hemin chloride in buffer alone is represented by the (---) dashed
line.  Spectra were normalized to enhance the red-shift of the Soret band upon
substrate binding. 
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HRP II.  The absorbance maxima shifted to 417 nm over the course of the porphyrin 
binding assay, and thus was analyzed at this wavelength. 
As seen in Figure 4.7, the binding of hemin chloride with BNT IIX is 
saturable, although the graph still deviates from a plateau region typically associated 
with saturable binding (as discussed in Chapter 3, Section 3.4.1a).  The titration 
curve shows that 3.37±0.39 equivalents of Fe(III)PPIX bound to BNT IIX at 
saturation.  In comparison to BNT II, which bound 9.83±0.21 equivalents of heme, 
mutating the third and sixth histidine residues to alanine greatly reduced the binding 
capabilities of this template.   
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 Figure 4.7.  Hemin chloride titration binding curve for BNT IIX.  The data 
presented is the averaged result of fifteen independent binding titration 
experiments.  Individual binding titration curves are shown in Appendix II, pages 
A-14 thru A-16. 
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BNT IIX also interacted with Zn(II)PPIX, coincidently binding the same 
number of equivalents of this porphyrin (3.33±1.36) as it did the iron substrate 
(Figure 4.8).   
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Figure 4.8.  Zn(II)PPIX binding titration curve for BNT IIX.  The data presented is 
the averaged result of sixteen independent binding experiments.  Individual binding 
titration curves are shown in Appendix II, pages A-17 and A-18. 
The fluorescence quenching experiments involving BNT IIX failed to exhibit 
similar saturation values as the binding titration curves.  As seen in Figure 4.9, 
according to the protocol established in the fluorescence quenching experiments, the 
fluorescence of 40 nmoles of Zn(II)PPIX (1 X 10-5 M) was not quenched until a   
BNT IIX to porphyrin ratio of 5.5:1.  This high number of required template is 
atypical in comparison to the other BNTs examined thus far.  First, fluorescence 
intensity was reduced by 50% at template to porphyrin ratios whereby other templates 
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had already completely quenched the fluorescence of the fluorophore.  This possibly 
suggests single point associations for the template BNT IIX and Zn(II)PPIX, since an 
excess of over five molecules of BNT IIX were needed to quench the fluorescence of 
a single molecule of fluorophore.  Furthermore, the fluorescence of Zn(II)PIIX was 
quenched by the other templates once the fluorescent intensity was reduced by 60% 
to a relative intensity near 0.4.  The intensity of the fluorescence of Zn(II)PPIX in the 
presence of BNT IIX was diminished 100% to near baseline fluorescence values. 
Figure 4.9.  Fluorescence quenching studies of Zn(II)PPIX with BNT IIX.
Samples were excited at 410 nm and monitored at the emission maxima of the
fluorophore. 
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    BNT IIX was also dismal at aggregating insoluble heme product, promoting 
the formation of 0.40±0.30 nmoles of product.   
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As displayed in the circular dichroism experiments (Figure 4.10), BNT IIX 
has a deep negative peak centered around 200.5 nm, a positive shoulder at 220.6 nm, 
and a positive trough at 233.6 nm.  The spectrum of BNT IIX in the absence of hemin 
chloride remained positive throughout the remainder of the spectrum after 215 nm.  
The addition of hemin chloride did not red-shift the region centered around 200 nm to 
any significant degree (0.5 nm max), much like BNT IID, which also bound very few 
equivalents of hemin chloride.  The spectra only changed in the region centered 
around 230 nm, where the ellipticity in this area became negative upon the addition of 
substrate.  Again, the lack of secondary structural change upon hemin binding may be 
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 Figure 4.10.  Circular dichroism spectra of BNT IIX (___) and the corresponding
spectral changes upon the addition of hemin chloride.  Spectra are shown upon the
addition of 1.34 (----) equivalents of substrate and 2.33 (…...) equivalents of substrate
(near ½ of the full binding capacity experimentally determined for BNT IIX).  Actual
spectral shifts and signal intensities are listed in Table 4.3. 
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implicated in the bleak formation of aggregated heme. Spectral shifts associated with 
hemin binding are listed in Table 4.3.  Complete CD titration experiments are listed 
in Appendix III, page A-32.  
BNT IIX π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 200.5 (-10497.39) 
220.6 
(300.12) 
232.6 
(18.21) 
1.34 eq. Hemin 200.7 (-9321.21) 
220.0 
(196.29) 
231.5 
(-48.33) 
2.33 eq. Hemin 201.0 (-9158.02) 
220.0 
(201.68) 
231.3 
(-95.55) 
Table 4.3.  CD spectral markers for Fe(III)PPIX titration with BNT IIX averaged 
over five individual scans.  Each value in parentheses is the molar ellipticity data 
obtained at the corresponding wavelength, which was included to illustrate the 
change in secondary structure upon porphyrin binding. 
      4.2.3.  Mutant BNT IIY – Results and Discussion 
      (The Ala-Ala-His-Ala-Ala-His-Ala-Ala-Asp Mutant Domain) 
BNT IIY in association with hemin chloride in 100mm sodium acetate buffer, 
pH 4.8, displayed the electronic absorption spectrum in Figure 4.11, having a single 
Soret peak centered at 412 nm.  BNT IIY alone had no appreciable absorbance in the 
300-600 nm range.  Thus, the association of the iron porphyrin with the template red-
shifted the Soret region of hemin chloride by 27 nm upon the addition of                 
0.5 equivalents of heme.  Additional equivalents of heme red-shifted the absorbance 
maxima to 420 nm. 
Mutant BNT IIY bound 7.82±0.45 equivalents of iron substrate (Figure 4.12).  
Replacing the second and fifth histidine residues with alanine reduced the binding 
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 Figure 4.11.  UV-Vis spectrum of the interaction of hemin chloride with BNT IIY, 
represented by the (___) solid line.  Samples of approximately 0.5-1 equivalents of 
hemin chloride were added to approximately 3 nmoles of template in 100 mM acetate 
buffer, pH 4.8.  Hemin chloride in buffer alone is represented by the (---) dashed line. 
Spectra were normalized to enhance the red-shift of the Soret band upon substrate 
binding. 
capabilities of the template in comparison to the parent, BNT II.  The binding data 
however, suggests the conserved histidine residues at positions three and six along the 
putative domain of BNT II are significant in establishing heme:template interactions, 
seeing how BNT IIY binding is dramatically increased from its sister BNT IIX, which 
mutated these same residues. 
The increased substrate recognition was also experienced with Zn(II)PPIX.  
BNT IIY bound 8.56±0.80 equivalents of zinc protoporphyrin IX, over twice as much 
as its sister BNT IIX, though a significant amount less than its parent BNT II            
(~ 13 equivalents).   
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 Figure 4.13.  Zn(II)PPIX binding titration curve for BNT IIY.  The data presented
is the averaged result of seven independent binding experiments.  Individual
binding titration curves are shown in Appendix II, pages A-21 and A-22. 
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 Figure 4.12.  Hemin chloride titration binding curve for BNT IIY.  The data 
presented is the averaged result of nine independent binding titration experiments. 
Individual binding titration curves are shown in Appendix II, pages A-19 and 
A-20. 
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 Zn(II)PIIX fluorescence quenching experiments involving BNT IIY were 
different from BNT II and the other mutants examined thus far.  Despite binding a 
fairly high number of Zn(II)PPIX molecules, much like BNT II this mutant was 
typically a poor fluorophore quencher.  Like its sister mutant BNT IIX, the ratio of 
template to porphyrin at which complete fluorescence quenching was observed was 
above 1:1.  Specifically, the fluorescence was quenched at a 1.61:1 ratio of BNT IIY 
to Zn(II)PPIX, however the fluorescence value only decreased by 20% of the 
normalized fluorescence.  At the 0.1:1 ratio of mutant to fluorophore, commonly 
examined for BNT II and all mutants, the fluorescence was only diminished by 
roughly 4%.  In light of the amino acid mutations made, alanine replacements at 
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Figure 4.14.  Fluorescence quenching studies of Zn(II)PPIX with BNT IIY.  Samples 
were excited at 410 nm and monitored at the emission maxima of the fluorophore. 
positions 2 and 5 significantly affected mutant ability to quench the fluorophore.   
BNT IIY promoted 0.27±0.15 nmoles of insoluble aggregated heme based on 
an average of twelve independent experiments.  The background hemozoin formation 
for the assay was slightly lower than 1-2 nmoles typical with other assays, with the 
blanks aggregating 0.47 nmoles of heme. 
 The CD spectrum of BNT IIY (Figure 4.15) displays a deep negative peak at 
210.5 nm and a shoulder and trough at 221 nm and 232 nm respectively, closely 
sharing the spectral properties of its parent, BNT II.  The addition of approximately 
1.5 equivalents of hemin failed to alter the shape of the circular dichroism spectrum, 
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 Figure 4.15.  Circular dichroism spectra of BNT IIY (___) and the corresponding 
spectral changes upon the addition of hemin chloride.  Spectra are shown upon the 
addition of 1.47 (---) equivalents of substrate and 4.40 (….) equivalents of substrate 
(½ of the full binding capacity experimentally determined for BNT IIY).  Actual 
spectral shifts and signal intensities are listed in Table 4.4. 
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altering only the molar ellipticity value.  The addition of further equivalents of hemin 
chloride did red-shift the CD spectrum, but only by a maximum of 1 nm.  Spectral 
shifts associated with binding approximately one equivalent of hemin chloride and 
near half maximal binding are listed in Table 4.4.  The entire CD titration experiment 
is listed in Appendix III, page A-33.   
BNT IIY π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 201.5 (-12301.80) 
221.6 
(128.66) 
232.0 
(-318.77) 
1.47 eq. Hemin 202.0 (-11531.07) 
221.3 
(-120.58) 
231.5 
(-488.17) 
4.40 eq. Hemin 202.5 (-9242.26) 
221.0 
(-360.44) 
230.0 
(-581.39) 
Table 4.4.  CD spectral markers for Fe(III)PPIX titration with BNT IIY averaged
over five individual scans.  Each value in parentheses is the molar ellipticity data
obtained at the corresponding wavelength, which was included to illustrate the
change in secondary structure upon porphyrin binding.  
When compared to BNT IIX, which mutated the histidine residues opposite of 
BNT IIY (positions 2 and 5 versus 3 and 6), the changes in the CD spectrum are more 
pronounced than with the sister mutant.  Seemingly, the histidine residues conserved 
in this mutant are more active participants in heme binding.  Preserving the amino 
acids in the third and sixth positions along the chain, support increased binding values 
and amplify the changes that occur along the peptide backbone upon porphyrin 
interaction.  This provides supporting evidence the putative binding domain has 
conformationally vital residues every three amino acids.  
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       4.2.4.  Mutant BNT IIZ – Results and Discussion 
      (The Ala-His-His-Ala-His-His-Ala-Ala-Lys Mutant Domain) 
The electronic absorption spectrum for the interaction of hemin chloride with 
BNT IIZ is shown in Figure 4.16.  Though the peptide had no appreciable absorbance 
in the 300-600 nm range, its interaction with the iron porphyrin shifted the Soret band 
31.5 nm from 385 nm to 416.5 nm upon the addition of only 1 equivalent of heme.  
The Soret region continued to red-shift approximately 1 nm, after the addition of 
subsequent equivalents of heme. 
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Figure 4.16.  UV-Vis spectrum of the interaction of hemin chloride with BNT IIZ, 
represented by the (___) solid line.  Samples of approximately 0.7 equivalents of 
hemin chloride were added to 3 nmoles of template in 100 mM acetate buffer, pH 4.8. 
Hemin chloride in buffer alone is represented by the (---) dashed line.  Spectra were 
normalized to enhance the red-shift of the Soret band upon substrate binding. 
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 As shown in Figure 4.17, the binding of heme with BNT IIZ is saturable.  The 
titration curve shows that 9.81±0.88 equivalents of heme were bound to BNT IIZ at 
saturation.  BNT II also bound over nine equivalents of substrate, suggesting that the 
aspartic acid mutation with lysine in the ninth position along the domain sequence of 
BNT IIZ, had little effect on hemin binding.  Electrostatics therefore, is not a 
prominent force in the binding of the iron substrate. 
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 Figure 4.17.  Hemin chloride titration binding curve for BNT IIZ.  The data
presented is the averaged result of eight independent binding titration experiments.
Individual binding experiments are shown in Appendix II, pages A-23 and A-24. 
BNT IIZ also interacted with Zn(II)PPIX, as shown in Figure 4.18.    The 
6.44±0.81 equivalents of zinc bound is less than half of that bound by BNT II.  
Though hemin binding between these mutants did not seem to be affected by the 
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lysine mutation, zinc binding was significantly changed suggesting that electrostatic 
interactions may be a key factor in template association with zinc protoporphyrin IX. 
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 Figure 4.18.  Zn(II)PPIX titration binding curve for BNT IIZ.  The data presented is 
the averaged result of thirteen independent binding titration experiments.  Individual 
binding experiments are shown in Appendix II, pages A-25 thru A-27. 
As expected, since BNT IIZ bound less equivalents of the zinc porphyrin in 
comparison to BNT II, the fluorescence of Zn(II)PPIX was also quenched more 
rapidly when associated with this template (Figure 4.19).  Recalling the fluorescence 
of BNT II was quenched by nearly fifty percent at a template to porphyrin ratio of 
0.1:1, the fluorescence of the chromophore at this same ratio is completely quenched 
by BNT IIZ.  A fifty percent reduction in the fluorescence intensity was displayed at a 
0.015:1 ratio of BNT IIZ to Zn(II)PPIX.  
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 Figure 4.19.  Fluorescence quenching studies of Zn(II)PPIX with BNT IIZ.  Samples 
were excited at 410 nm and monitored at the emission maxima of the fluorophore. 
BNT IIZ aggregated 2.37±0.43 nmoles of heme.  Background hemozoin 
formation was again lower at 0.5 nmoles.  Seemingly BNT IIZ was the only mutant 
capable of aggregating any appreciable amount of heme. 
The secondary structure of BNT IIZ in 10 mM acetate buffer, pH 4.8, is 
displayed in the CD spectra appearing in Figure 4.20.  BNT IIZ had a deep negative 
peak around 198 nm and a small shoulder near 220 nm, but the entire spectrum  
remained negative in molar ellipticity.  Heme binding increased the molar ellipticity 
value and red-shifted the deep negative peak approximately 1 nm (Table 4.5).  These 
features are much like those displayed by BNT II and BNT IIY, which also bound 
significant amounts of heme.  Regardless of the increased hemin chloride binding, 
BNT IIZ and the aforementioned templates more importantly shifted 1 nm upon 
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interacting with 1 equivalent of substrate.  This suggests that once bound, hemin 
chloride tightens the conformation of the templates.  If this does indeed occur,  the 
binding of subsequent equivalents of the iron porphyrin may align these molecules in 
the proper orientation for upcoming hemozoin formation.  The shoulder near 235 nm 
appears much weaker in BNT IIZ  than in the other mutants.  The complete CD 
titration experiment for BNT IIZ is listed in Appendix II, page A-34. 
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 Figure 4.20.  Circular dichroism spectra for BNT IIZ (___) and the corresponding
spectral changes upon the addition of hemin chloride.  Spectra are shown upon the
addition of 1.15 (---) equivalents of substrate and 4.60 (….) equivalents of substrate (½
of the full binding capacity experimentally determined for BNT IIZ).  Actual spectral
shifts and signal intensities are listed in Table 4.5. 
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BNT IIZ π-π* (nm) (x,y) 
n-π* (nm) 
(x,y) 
π-π* (nm) 
(x,y) 
No hemin 198.4 (-11733.92) 
220.3 
(-230.73) 
235.7 
(-1636.68) 
1.15 eq. Hemin 199.4 (-10350.31) 
220.3 
(-167.35) 
235.6 
(-1419.54) 
4.60 eq. Hemin 199.6 (-9271.85) 
219.2 
(-761.17) 
235.7 
(-1853.82) 
Table 4.5.  CD spectral markers for Fe(III)PPIX titration with BNT IIZ averaged
over five individual scans.  Each value in parentheses is the molar ellipticity data
obtained at the corresponding wavelength, which was included to illustrate the
change in secondary structure upon porphyrin binding. 
4.3.  Conclusions 
As seen in Figure 4.21, the Soret region of the UV-Vis spectra of the mutants 
in association with hemin chloride differed from that of BNT II upon the addition of 
0.3-1 equivalent of substrate.  The addition of more hemin chloride caused the Soret 
region to move even further to 417-420 nm, depending on the mutant.   The mutants 
that bound the least amount of heme (BNT IID and BNT IIX) had the Soret region 
centered near 417 nm at saturation, blue-shifted from the parent BNT II by 1 nm. 
BNT IIY and BNT IIZ, which bound a significant amount of heme, possessed Soret 
bands near 420 nm and 418 nm respectively.  BNT IIX was the mutant that displayed 
the greatest alteration in the Soret region (17 nm) upon saturable binding.  
The binding titration experiments demonstrated which amino acid mutations 
significantly affected the binding of Fe(III)PPIX and Zn(II)PPIX (Figure 4.22).   
BNT II, the Ala-His-His-Ala-His-His-Ala-Ala-Asp domain template, bound 
approximately 10 equivalents of the iron porphyrin and 13.5 equivalents of the zinc 
 200 
 Figure 4.21.  UV-Vis spectra of the interaction of hemin chloride with BNT II and its
mutants.  Samples of approximately 0.3-1 equivalents of hemin chloride were added
to 1-10 nmoles of template in 100 mM acetate buffer, pH 4.8. 
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porphyrin.  Removing the aspartic acid residue and replacing it with alanine, affected 
the binding of both porphyrins to the greatest degree, as seen with mutant BNT IID.  
Mutant BNT IIX with alanine mutations made to the third and sixth residue also 
reduced the binding capabilities of the template.  Thus far, the histidine and aspartic 
acid residues appear to be critical in the binding of both Fe(III)PPIX and Zn(II)PPIX.  
Mutant BNY IIY showed that modifying the second and fifth residues did not have 
the dramatic effect on binding that replacing the third and sixth residues did with 
mutant BNT IIX.  In fact BNT IIY binding levels approached those of BNT II.  These 
results support the notion the conformation of the BNTs mirrors that of HRP II in 
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 Figure 4.22.  Substrate binding of BNT II and its mutants with Fe(III)PPIX and 
Zn(II)PPIX. 
either a 3-10 or polyproline type II secondary structure, since every third amino acid 
residue plays a prominent role in sequestering substrates. 
Mutant BNT IIZ, which replaced aspartic acid with lysine, restored the heme 
binding capability of the template to levels near its parent BNT II, suggesting that 
electrostatics do not play a role in heme binding.  However, the same is not true for 
zinc protoporphyrin IX binding.  In the mutants discussed thus far, 1-4 equivalents 
more of zinc protoporphyrin IX bound to the templates in comparison to Fe(III)PPIX 
binding.  The same is not true for BNT IIZ which bound approximately 10 
equivalents of hemin and only slightly above six equivalents of Zn(II)PPIX.  This 
implies that although hemin binding may not be contingent on electrostatic 
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interactions, zinc binding is decreased when this affiliated residue is deprotonated.  
The positive lysine mutation did reduce the binding capabilities when Zn(II)PPIX 
was in association with the template.  This suggests a different binding site along the 
peptide dendrimer between the two porphyrins, since polarity greatly reduced the 
binding of both porphyrins (as with BNT IID), while electrostatic associations were 
only prominent in zinc binding (as with BNT IIZ). 
The fluorescence quenching studies help to pictorially represent some of the 
differences in Zn(II)PPIX binding amongst the mutant templates.    As seen in  
Figure 4.23, the rates of fluorescence quenching varied with each mutant.  BNT IIX 
and BNT IIY are of particular interest.  The fluorescence intensity of BNT IIX was 
diminished by 100% upon complete quenching of the fluorophore, while BNT IIY 
reduced its intensity by 20% upon quenching.  Moreover, when mutations to the 
histidine residues occurred, as with BNT IIX and BNT IIY, the ratio of template to 
porphyrin at complete fluorescence quenching was above 1:1, while BNT IID and 
BNT IIZ, which conserved these amino acid residues, behaved more like its parent  
BNT II.  This suggests that both histidine residues are involved in securing the points 
of interaction between Zn(II)PPIX and the templates.  Beyond this, it appears that 
while BNT IID and BNT IIZ quench the fluorophore at ratios less than 1:1, the 
interaction of BNT IIZ with the zinc porphyrin must be slightly more fixed or 
interlocked, since the rate of quenching is increased with this template in comparison 
to its parent, BNT II. 
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Figure 4.23.  Fluorescence quenching studies of Zn(II)PPIX by BNT II and its
mutants.  Note the scaling differences in the x-axes and also the y-axis change for
BNT IIX. 
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 Figure 4.24.  Hemozoin production mediated by BNT II and its mutants.  Molecular 
models of the templates as 3-10 helices are added for dimensional clarity. 
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Hemozoin production mediated by BNT II and its mutants is tallied in   
Figure 4.24.  Again, the removal of the aspartic acid is not only critical in porphyrin 
binding, but also in the aggregation of hemozoin, as seen with BNT IID.  The most 
noticeable dissimilarity between binding and hemozoin formation becomes apparent 
upon examination of BNT IIX and BNT IIY.  While BNT IIY, possessing alanine 
mutations to the second and fifth positions along the putative domain of BNT II, was 
capable of binding more porphyrin than BNT IIX, which had the same mutations but 
instead to the third and sixth amino acids, this trend did not follow suit where 
hemozoin aggregation was concerned.  In fact, replacing either of the histidine 
residues reduced the amount of hemozoin formed even more so than the aspartic acid 
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mutation in BNT IID.  Mutating the ninth residue with lysine in BNT IIZ lessened 
hemozoin production in comparison to its parent BNT II, but this was the only mutant 
with β-hematin production above 1 nmole after background subtraction. 
Though the CD experiments were performed in order to examine the effect of 
heme binding on secondary structure of the BNTs, other considerations should be 
given to such examinations since the BNTs are also dendrimers.  Secondary structural 
propensities of dendrimers are modified as a function of the hydrodynamic volume, 
which is greatly affected by solvent conditions.2-4 Decreasing the hydrodynamic 
volume typically increases the secondary structural content.  Additionally, any 
collapse of the dendrimer structure may perturb local secondary structure by possibly 
increasing the packing of amino acid side chains or by backfolding of the dendrimeric 
branches.5 Both occurrences could decrease or at least change the degree of helicity 
incurred by the BNT.   Such interactions were intentionally minimized by conserving 
the hydrophobic face of alanine residues in the 1,4, and 7 positions along the binding 
domain.  
The CD spectra of the mutants are shown in Figure 4.25.  In comparison to 
BNT II (See Figure 4.25 inset), BNT IID which had alanine replacing the aspartic 
acid along the putative domain sequence, unfolded or loosened the conformation of 
the original peptide dendrimer, as depicted by the blue-shifted and broadened deep 
negative peak.  After 210 nm the signal intensity of the remainder of the CD spectrum 
rose above negative molar ellipticity values.  BNT IIY preserved the original 
conformation of BNT II to the greatest extent, blue-shifting the deep negative peak 
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centered near 202 nm for BNT II by 0.5 nm, when the third and sixth histidine 
residues are left unchanged.  BNT IIX, which mutated these positions, altered the 
same region of the spectra by blue-shifting that region by an additional 1.5 nm.  The 
conformation of BNT IIZ shifted this deep negative peak below 200 nm.   
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 Figure 4.25.  CD spectra of 2 nmoles of the mutants of BNT II in 10 mM acetate
buffer, pH 4.8.  (---) BNT IID, ( ) BNT IIX, (….) BNT IIY, and (___) BNT IIZ.  The
inset displays the CD spectrum of BNT II. 
The rigidity imparted by the MAPS core makes it difficult to unambiguously 
correlate the conformation and activity of the BNT peptides.  The CD results 
however, show some evidence that helical conformation may be important for 
hemozoin formation.  BNT IID had the least tendency to adopt any secondary helical 
conformation alone and upon the titration of hemin chloride, and was found to be 
least active in both porphyrin binding assays and relatively inactive in the template 
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mediated formation of hemozoin.  BNT IIX had minimal changes in secondary 
structure upon hemin binding and was also not proficient at either porphyrin binding 
or hemozoin formation.  BNT IIY bound a higher number of equivalents of both 
porphyrins and possessed a secondary structure in the largest part identical to BNT II, 
but the template mediated production of hemozoin by this mutant was diminished 
with the His-His repeat interrupted.  Mutant BNT IIZ performed well with its abilities 
to mimic BNT II in binding capabilities, but the modification seen in the secondary 
structure most likely can be correlated to the reduction in the number of nmoles of 
aggregated heme in comparison to BNT II.  The CD spectrum of BNT IIZ did cause 
the most pronounced changes in secondary structure upon hemin binding as depicted 
by the increase in negative ellipticity upon porphyrin association.  Such behavior is 
not uncommon in metal binding motifs6 and other peptide dendrimers7. 
In summary, the results presented indicate the 9-mer sequence of BNT II, Ala-
His-His-Ala-His-His-Ala-Ala-Asp, is the major nucleating domain sequence 
responsible for eliciting appreciable hemozoin formation. Of the thirty-two histidine 
and alanine residues and eight aspartic acid residues in the parent template, the high 
binding activity of the His-His repeat is functionally and structurally important for 
activity.  Any mutation to this repeat diminishes binding activity and greatly reduces 
the formation of hemozoin.  The polarity of the aspartic acid residue is critical in both 
activities, since an alanine residue mutation fails to bind elevated levels of the 
porphyrins and participate in the aggregation of hemozoin.  While BNT IIZ has 
similar binding capabilities to BNT II, the replacement of the aspartic acid residue by 
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lysine at positions eight (and also sixteen) along the putative domain sequence, does 
not provide the necessary chemical environment to elicit maximal hemozoin 
formation activity.  The electrostatics surrounding this residue is not necessarily 
relevant for the binding of Fe(III)PPIX, but topological constraints likely play a role 
in hemozoin formation. 
Ultimately, the functional analyses of BNT II and its mutants are to be 
debated from the perspective of amino acid sequence, since single amino acid 
mutations permitted the inherent chemical reactivity to be assessed as point 
mutations.  With the experimental design of the porphyrin binding assays and 
hemozoin aggregation assay, the examination of such mutations should be easily 
addressed.  However, the results of the circular dichroism experiments prompted a 
refinement of our thinking since the molecular models demonstrated behavioral 
characteristics more like dendrimers and collagen rather than straightforward 
peptides.  Substrate interactions may not be solely along the peptide chain, but may 
exist between the dendrimeric peptide branches.  Intermolecular interactions may also 
affect inherent binding and hemozoin nucleation properties.   
Initially the two putative hemozoin nucleation domain sequences of BNT II 
and BNT IIA were examined in order to determine which was the most probable 
sequence within HRP II to actually participate in hemozoin formation.  Initial results 
indicated that binding of heme alone did not elicit hemozoin formation since both 
BNT II and BNT IIA bound nearly similar equivalents of heme substrate (Table 4.6).  
Moreover, the examination of the two hypothesized hemozoin nucleation domains of 
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BNT II and BNT IIA and earlier studies by Ziegler et. al8 suggested that hemozoin 
formation was sequence dependent.  Aggregated heme formed in the presence of 
BNT IIA was nearly half of that mediated by BNT II.  In fact, the production of 
hemozoin in association with BNT IIA was similar to the first generation dendrimer, 
BNT I,8 which possessed only one copy of the Ala-His-His-Ala-His-His-Ala-Ala-Asp 
repeat of BNT II per branch.  Upon further examination, this sequence can be located 
once per branch within the eighteen amino acid residues of BNT IIA.  Seemingly 
BNT II, with twice the number of Ala-His-His-Ala-His-His-Ala-Ala-Asp repeats 
mediated the formation of hemozoin to levels two times greater than BNT IIA. 
Template 9-mer Sequence Fe(III)PPIX 
Binding 
(eq.) 
Zn(II)PPIX 
Binding 
(eq.) 
Aggregated 
Hemozoin 
(nmoles) 
Secondary 
Structure of  
BNT II 
BNT II AHHAHHAAD 9.83±0.21 13.40±0.31 5.63±0.04 -------- 
BNT IIA AHHAADAHH 8.70±0.81 3.96±0.45 2.60±0.60 loose 
BNT IID AHHAHHAAA 1.45±0.17 3.14±0.71 0.50±0.20 loose 
BNT IIX AHAAHAAAD 3.37±0.39 3.33±1.36 0.40±0.30 loose 
BNT IIY AAHAAHAAD 7.82±0.45 8.56±0.80 0.27±0.15 Like BNT II 
BNT IIZ AHHAHHAAK 9.81±0.88 6.44±0.81 2.37±0.43 Like BNT II 
 
Table 4.6.  Summary of the functional analyses of BNT II and its mutants. 
The suggested sequence dependency of hemozoin formation led to the 
examination of specific point mutations with the Ala-His-His-Ala-His-His-Ala-Ala-
Asp sequence in attempt to ascertain the amino acid residues along the domain 
sequence of BNT II that were critical in hemozoin formation. As stated earlier, the 
third and sixth histidine residues are critical in the binding and aggregation of 
hemozoin, as is the aspartic acid residue as determined by the functional screening of 
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the BNT mutants (Table 4.6).  Mutant BNT IIZ however demonstrated that while the 
ninth residue is affected by polarity (BNT IID), the consequences of electrostatics are 
less effectual.  
The identification of particular binding sites for both Fe(III)PPIX and 
Zn(II)PPIX through the above mutations were unsuccessful, as well as correlating 
heme binding and hemozoin formation.  High heme binding activities did not 
necessarily impart high levels of hemozoin aggregation (particularly BNT IIY and 
BNT IIZ).  Additionally, patterns in Zn(II)PPIX binding values were of little 
consequence, with the BNTs appearing to have associative binding activities with a 
minimum of three molecules of zinc substrate.  
The CD binding experiments however, expound some connections between 
heme binding, hemozoin formation activity and secondary structure. Mutants BNT 
IID and BNT IIX, which had CD spectra blue-shifted from the spectrum of BNT II, 
exhibited both poor porphyrin binding capabilities and hemozoin aggregation 
activities.  BNT IIY and BNT IIZ, which displayed CD spectra similar to BNT II 
were more efficient at porphyrin binding.  Since BNT II and BNT IIY conserved the 
third, sixth, and ninth residues one would expect the binding values to be necessarily 
the same, however BNT IIY bound slightly fewer equivalents of the substrates.  The 
disruption of the His-His repeat with alanine partially unfolds and/or distorts the 
peptide chain, decreasing porphyrin binding.  The lysine residue in BNT IIZ does 
little to perturb the secondary structure of the peptide dendrimer and therefore binding 
capabilities are restored to levels near the parent BNT II.  However, the length of the 
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amino acid lysine, may occlude the ability of the template to aggregate hemozoin, 
especially when considering the steric constraints imparted by this residue near the 
MAPS core. 
Mark Kac, noted mathematician once stated that the purpose of models was 
“to polarize our thinking,” helping to pose questions and make testable predictions.   
In this way, the BNT peptide mimics served as true models, generating hypotheses 
that cannot be constructed without such experimentation, while also leaving new 
unanswered questions as to the extent of amino acid sequence dependency or 
secondary structural requirement in hemozoin formation. 
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Chapter 5 
Application of the BNT II Model System:  
Inhibition of Hemozoin Aggregation by N4O2 Schiff Base Complexes  
5.1.  Introduction 
The proteolysis of hemoglobin and the detoxification of released heme via the 
biomineralization of hemozoin are vital metabolic processes of the Plasmodium 
falciparum parasite.  Since nearly all host hemoglobin is consumed during the 
trophozoite stage of P. falciparum’s life cycle, antimalarials that function to 
antagonize the essential life processes at this developmental stage are often regarded 
as having the greatest antiparasitic potentials.  However, it is nearly impossible to 
assess whether antimalarial action is due to diminished hemoglobin catabolism, the 
inhibition of hemozoin formation, or whether parasite growth is simply arrested via 
other pathways. 
Though most antimalarials are hypothesized to function by disrupting some 
aspect of the biomineralization of hemozoin1-3 either by interfering with heme,4-7 a 
heme binding template,8-10 or a heme/template complex,11,12 differing experimental 
conditions have plagued the literature with a wealth of conflicting half-maximal 
inhibitory effects (IC50 values), especially in in vitro assays.  Inhibitory effects of 
antimalarial drugs are often attributed to salt concentrations, anions, metal ions and 
the experimental conditions, which require an acidic reaction medium (pH 4.8-5.5) to 
mimic the environment of the digestive vacuole of P. falciparum, the place where 
active hemoglobin proteolysis occurs.  Despite this, an enormous amount of 
experimental research still occurs at neutrality. 
Additionally, few considered the very nature of the malarial pigment, failing 
to acknowledge that experimental protocol washing procedures could become a such 
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tedious, yet innate part of correctly assembling true inhibition activities.  Only as 
recently as the year 2000 did a few research groups begin focusing on the mode of 
antimalarial inhibition and surmounted the importance of washing protocols.13 
Extraneous peaks were often present in the Fourier transformed infrared spectra of 
hemozoin that was used to characterize the final product, but these could often be 
considerably reduced through additional washing of the pigment.  Never before had 
the differential solubility of the product been so pertinent in its characterization.  
Aggregates of heme were soluble in sodium bicarbonate buffer (pH 9.1) and sodium 
dodecyl sulfate (SDS), while hemozoin retained its insolubility in such solutions.  The 
washing protocol therefore, must be able to dissolve all of the ferriprotoporphyrin 
aggregates that are not genuine hemozoin.  Consequently, inadequate washing could 
lead to an artifactual lack of inhibition since the ferriprotoporphyrin aggregates would 
be quantitated as the malaria pigment. 
Information is also obscured in the fact that certain antimalarials are more 
effective against particular strains of the parasite.  Often a peculiar strain in one 
geographic location is more virulent than another found only a few hundred miles 
away.  Part of this is due to the fact that chromosomal polymorphisms appear to heal 
by the addition of telomeric repeat sequences rather than a typical recombination of 
DNA breakages.14  
By far, the quinoline class of antimalarials, which includes chloroquine, has 
been one of the most successful classes of drugs ever developed at combating 
malaria.  Research has shown these antimalarials have the ability to disrupt hemozoin 
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formation.1-3 Despite such early success as an antimalarial, chloroquine prophylaxis 
has receded due to the ever emerging resistant strains of Plasmodia.  The 
development of new drugs for the treatment of malaria is thus of utmost importance. 
Since the parasite’s proteolysis of hemoglobin releases free heme, a number of 
metal chelating agents have been examined as potential antimalarials.  Sharma and 
Piwnica-Worms used a hexadentate ethylenediamine-N,N’-bis[propyl(2-hydroxy-R-
benzylimino)] ligand (R-ENBPI) and a reduced (R-benzylamino) analogue             
(R-ENBPA) to form metal (III) complexes with aluminum, iron, gallium, and indium, 
developing a novel class of antimalarials that was shown to blockade hemozoin 
formation.  Such multi-dentate metal (III) coordination complexes exhibited a wide 
range of activity among both chloroquine-sensitive and chloroquine-resistant strains 
of P. falciparum.15-17  Detailed structural studies emphasized the importance of the 
spatial arrangement of the ligand periphery in localization and biotransport of these 
molecules.16  Goldberg et al. meanwhile demonstrated that in vivo hemozoin 
formation was greatly diminished in parasites cultured with both the iron and gallium 
complexes.15  None however, examined the specific role of the coordination complex 
in the inhibition of β-hematin aggregation.  With this in mind and the fact such 
topological constraints warrant further investigations into three dimensional growth 
processes such as the biomineralization of hemozoin, we examined the basis for the 
observed inhibitory effects of these N4O2 Schiff bases using our histidine-rich protein 
II  (HRP II) biomimetic model peptide, BNT II . 
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5.2.  Synthesis and Characterization of N4O2 Complexes 
All reagents were purchased from commercial sources and used as received.  
Hemin chloride (Fe(III)PPIX), protoporphyrin IX (PPIX), and deuterated methylene 
chloride-d2 (CD2Cl2), chloroform-d (CDCl3), methanol-d3 (CD3OH), 
dimethylsulfoxide-d6 (DMSO),  sodium acetate-d3 (CD3CO2Na), glacial acetic acid-d4 
(CD3COOD), and water (D2O) were purchased from Sigma-Aldrich (St. Louis, MO).  
The ligand and metal (III) complexes were prepared according to a method 
previously described by Sharma et al.18  Briefly, the prepared N4O2 ligand was 
reacted with the appropriate amount of metal salt in ethanol.  The metal (II) complex 
was synthesized according to methods previously described by Polyakov.19  Isolated 
complexes were characterized by proton nuclear magnetic resonance spectroscopy 
(1H NMR), infrared spectroscopy (IR), and electrospray ionization mass spectrometry 
(ESI).  The corresponding spectra were omitted from this publication since the 
physical characterizations of these compounds were previously reported by the 
aforementioned authors.18,15,16,19  Instead, proof of each characterization is briefly 
summarized. 
IR analyses of dried reaction mixtures in KBr matrixes were performed on a 
Perkin-Elmer 1760 X FT-IR spectrophotometer (Boston, MA).  Typically, 256 scans 
were collected at a resolution of 4 cm-1 from 4000-400 cm-1.  UV-Vis measurements 
were carried out on a Cary 3-E UV-Vis spectrophotometer (Walnut Creek, CA).  
Fluorescence measurements were performed on a Photon Technology International 
QM-1 spectrofluorometer (Lawrenceville, NJ).  NMR studies were recorded on a 
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Bruker ACP-300 MHz spectrometer (Newark, DE) at room temperature.  Chemical 
shifts were reported in δ (ppm). 
      5.2.1.  Ligand Synthesis.  2-(2’-Hydroxy-3’-methoxyphenyl)-1,3-bis[4-aza-5-    
(2’’-hydroxy-3’’-methoxyphenyl)but-4’-en-1’-yl]-1,3’-imidazolidine (H3Mabi) 
N,N’-Bis(aminopropyl)ethylenediamine (858 mg, 4.92 mmole) and o-vanillin 
(2,244 mg, 14.76 mmole) were dissolved in a minimum amount of ethanol.  The 
reaction was heated to reflux for 3 hours.  After cooling to room temperature, the 
mixture was subjected to rotary evaporation to remove all volatiles.  The remaining 
residue was then dried under reduced pressure typically overnight, until a bright 
yellow solid formed.    
 1H NMR (in CD2Cl2) δ 8.15 (s, 2H), 6.60-7.15 (m, 7H), 6.50 (dd, 1H), 4.05    
(s, 6H), 3.65 (m, 3H), 2.15-2.85 (m, 6H), 1.85 (m, 4H); IR (KBr pellet, cm-1) 1630  ν 
(C=N). 
      5.2.2.  Synthesis of Metal (III) Complexes [(3-OMe-ENBPI)M+]I- 
5.2.2a  Fe(III) Complex - FeIIIENBPI 
Equimolar amounts of H3Mabi ligand (459 mg, 0.78 mmole) and iron (III) 
acetylacetonate (Fe(acac)3, 282 mg, 0.79 mmole) were dissolved in a minimum 
amount of ethanol.  The reaction was heated to reflux for 1 hour before potassium 
iodide (KI, 132 mg, 0.78 mmole) was added to the mixture and permitted to reflux for 
another 10 minutes.  The solution was then removed from heat and allowed to 
precipitate overnight.  The microcrystalline precipitate was then filtered from 
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solution, washed with cold ethanol and then ether.  The remaining residue was then 
dried under reduced pressure. 
1H NMR (in CD3OH) δ 25 b, 20 b, 9 s, 5.5 s, 3.5 s, 1 s, –1 s, -8 b; IR (KBR 
pellet, cm-1) 3000–2800 ν (C-H), 1620 ν (C=N), 1540 σ (N-H); ESI Mass Spec 
496.3 m/z; UV-Vis λmax 375 nm (ε = 8765). 
5.2.2b  Ga(III) Complex - GaIIIENBPI 
Equimolar amounts of H3Mabi ligand (420 mg, 0.72 mmole) and gallium (III) 
acetylacetonate (Ga(acac)3, 267 mg, 0.72 mmole) were dissolved in a minimum 
amount of ethanol.  The reaction was heated to reflux for 1 hour before KI (120.9 mg, 
0.72 mmole) was added to the mixture and permitted to reflux for another 10 minutes.  
The solution was then removed from heat and allowed to precipitate overnight.  The 
microcrystalline precipitate was then filtered from solution, washed with cold ethanol 
and then ether.  The remaining residue was then dried under reduced pressure. 
1H NMR (in CD2Cl2) δ 8.14 (s, 2H), 7.05 (d, 2H), 6.8 (d, 2H), 6.65 (t, 2H), 
3.85 (s, 6H), 3.2-3.6 (m, 6H), 1.9 (m, 2H), 1.6 (m, 2H); IR (KBr pellet, cm-1) 1630 ν 
(C=N) ESI Mass Spec 509.2 m/z; UV-Vis λmax 390 nm (ε = 4470). 
    5.2.3.  Synthesis of Metal (II) Complex [(3-OMe-ENBPI)M] 
4.2.3a  Mg(II) Complex - MgIIENBPI 
The magnesium complex was prepared as a batch reaction.  Magnesium 
sulfate (MgSO4, 6.0 g, 0.05 mole) and N,N’-bis(3-aminopropyl)ethylenediamine 
(3.49 g, 0.02 mole) were dissolved in 300 ml of methylene chloride (CH2Cl2).        
O-vanillin (2.28g, 0.015 mole) dissolved in 60 ml of CH2Cl2 was then added 
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dropwise to the above solution.  The reaction mixture was then allowed to stir for 
24 hours at room temperature.  The resulting solid was then filtered from solution 
and permitted to dry under low vacuum.  The dried solid residue was then 
crystallized from nitromethane. 
1H NMR (in CDCl3) δ 7.81 (s, 2H), 6.72 (d, 2H), 6.61 (d, 2H), 6.31 (t, 2H), 
4.15 (m, 2H), 3.89 (m, 2H), 3.79 (s, 6H), 2.92 (m, 8H), 2.00 (d, 2H), 1.56 (m, 2H), 
1.37 (m, 2H); IR (KBr pellet, cm-1) 3329 ν (N-H), 3049 ν (C-Harom), 2911 and 2861 
ν (C-Halip), 1629 ν (C=N); ESI Mass Spec 465.1 m/z; UV-Vis λmax 353 nm                
(ε = 2990). 
5.3.  Experimental Methods 
      5.3.1.  BNT Binding Assay 
Following the UV-Vis difference titration methods of Morgan,20,21 1-10 
nmoles of BNT II dissolved in 100 mM sodium acetate buffer, pH 4.8, were added to 
a 1.0 mL semi-micro quartz cell (10 mm, Starna Cells, Atascadero, CA).  Blanks 
contained 1.0 mL of the aforementioned buffer.  Aliquots of stock solutions of the 
N4O2 complex substrate (~ 1 mM) dissolved in DMSO were then titrated into both the 
blank and reference cuvettes. Samples were equilibrated for fifteen minutes prior to 
measurements on a Cary 3-E UV-Vis spectrophotometer (Walnut Creek, CA). 
      5.3.2.  In Vitro Heme Aggregation Assay 
BNT II was assayed for hemozoin formation by incubating 2-2.5  nmol of 
template and 50-100 µM hemin chloride (dissolved in 0.1 M NaOH) in a total volume 
of 2.0 mL of 25-500 mM sodium acetate buffer, pH 4.8, for 48 hours at 37 0C in the 
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presence of varying concentrations of drug dissolved in DMSO.  Control blanks of 
DMSO showed that the solvent had no effect on the assay.  The volume of hemin 
added was less than 10% of the total volume of the solution in order to maintain 
buffering capacity.  After 48 hours the samples were vortexed, transferred to 50 mL 
polycarbonate Oak Ridge centrifuge tubes, and centrifuged at 19,000 g for 1 hour at  
4 0C on a Sorvall RC-5B refrigerated superspeed centrifuge equipped with a SS-34 
fixed angle rotor.  The supernatant was discarded and the pellet resuspended in 5 mL 
of 0.1 M sodium bicarbonate, pH 9.1, to solubilize any free heme.  The centrifuge 
tubes were then vortexed every ½ hour for two hours before centrifuging again and 
decanting the supernatant.  The pellet was treated with an additional sodium 
bicarbonate wash and centrifuged.  The remaining pellet was washed with water, 
vortexed, and centrifuged until the pH of the decanted supernatant was neutral.  The 
final pellet of aggregated heme was quantitated on the basis of its absorbance at     
400 nm (ε = 100,000).  Briefly, the pellet was dissolved in 1.0 mL of 0.1 M NaOH 
and vortexed every 15 minutes for 1 hour before recording the absorbance 
measurement on a Cary 3-E UV-Vis spectrophotometer (Walnut Creek, CA). 
      5.3.3.  Porphyrin Aggregation Fluorescence Studies 
Stock solutions of the fluorophore (the N4O2 complexes) dissolved in DMSO 
and heme quencher, which was 1.0 mM hemin chloride dissolved in 100 mM NaOH, 
were used.  According to the assay, an appropriate amount of 100 mM sodium acetate 
buffer, pH 4.8, was added to a 4.0 mL quartz fluorometer cell (10 mm, Starna Cells, 
Atascadero, CA), along with varying amounts of the fluorophore (20-40 µM).  
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Aliquots of a stock solution of Fe(III)PPIX dissolved in 0.1 M NaOH were then 
added to the cuvette (final hemin concentration: 4-320 µM).  The sample was scanned 
rapidly from 450-700 nm upon addition of the fluorophore on a Photon Technologies 
QM-1 T format spectrofluorometer (Lawrenceville, NJ).  All samples were excited at 
the respective excitation maxima and monitored at the emission maxima of the 
corresponding fluorophore.  This included excitation values of 310 nm for 
FeIIIENBPI, 380 nm for GaIIIENBPI, and 350 nm for MgIIENBPI. 
      5.3.4.  NMR Stability Studies 
Briefly, 4.0 mL of 50 mM deuterated acetate buffer was prepared by adding 
4.3 mg deuterated sodium acetate (CD3CO2Na-d3) dissolved in 2.0 mL deuterated 
water (D2O) and 2.87 mL deuterated glacial acetic acid diluted in 1.997 mL D2O.  
The pH was adjusted to 4.8 by the dropwise addition of deuterated sodium hydroxide 
(NaOD).  Next 7-10 mg of the ENBPI complex dissolved in 1.0 mL deuterated 
dimethylsulfoxide (DMSO-d6) were added to 1.0 mL of the above prepared acetate 
buffer.  The sample was then filtered into an NMR tube and the initial time zero 
measurement recorded.  The sample was then incubated at 370C for the duration of 
the experimental time intervals.  Samples were permitted to return to room 
temperature before recording additional spectra. 
5.4.  Results and Discussion 
Previous studies by Zielger et al. demonstrated that a dendrimeric peptide, 
BNT II,  based on the putative heme binding domain of the histidine-rich protein II of 
Plasmodium falciparum, served as a functioning analogue for this protein in an in 
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vitro hemozoin aggregation assay.22 In conjunction with his ongoing studies, 
undergraduate summer research projects, and as an introduction for myself into    
BNT II chemistry, this template was utilized as a means to probe the inhibitory 
effects of the synthesized Schiff base compounds.   
      5.4.1.   Inhibitory Effects 
Once the compounds (Figure 5.1) were fully 
characterized, the dose responses of hemozoin 
formation to the FeIIIENBPI, GaIIIENBPI, and 
MgIIENBPI  complexes were evaluated.    In 25 mM 
acetate buffer, pH 4.8, the half-maximal inhibitory 
effects (IC50) for both FeIIIENBPI and  GaIIIENBPI 
(9.5 and 58 µM respectively) were similar those 
reported by reported by Goldberg  (4 and 40 µM, 
respectively).  The neutral MgIIENBPI did not 
inhibit hemozoin aggregation. 
Figure 5.1.  Representation
of the N4O2 Schiff base
complex.  M = Fe(III),
Ga(III), or Mg(II). 
When considering the proposed mechanisms of inhibiting hemozoin 
aggregation, three possible scenarios arise.  First, (1) the drug can intercalate the 
growing face of the hemozoin crystal preventing further crystal development.11,12   
Second, (2) hematin could also be displaced from substrates such as lipids or HRP II, 
in such that drug binding to the substrate would enable free heme concentrations to 
become lethal to P. falciparum.8-10  Finally, (3) the drug could physically interact with 
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hematin via π-π stacking of its aromatic structure with that of heme,23-26 preventing 
further crystalline hemozoin growth.   
First and foremost, the drugs did not appreciably bind to BNT II (data not 
shown), eliminating drug inhibition by scenario (2).  Furthermore, when considering 
the topology of the complexes investigated, planar stacking of the drug onto the 
growing face of a hemozoin crystal in scenario (1) is not likely since the N4O2 Schiff 
base complexes do not offer this orientation.  The fact however, that the neutral Schiff 
base compound, MgIIENBPI, is not inhibitory while the cationic complexes are, 
suggests the charge of the complex may be critical for the inhibition of heme 
aggregation.  Upon consideration of the structure of hemozoin, whereby the critical 
linkage involves the oxygen from a propionate of one heme monomer serving as the 
axial ligand to the ferric ion of another11 with hydrogen bonding between the 
propionic acid side chains of the porphyrin rings,27 one could envision the N4O2 
cationic Schiff base compounds preventing the critical axial linkage for the 
dimerization of heme units by electrostatic interaction with the anionic propionate 
moiety of heme.  If the drug formed a drug:heme salt complex, the requisite 
propionate linkage in hemozoin aggregation would not be available.    
If the mode of action of the antimalarial coordination complexes were charge 
dependent based on specific interactions originating from the propionate of heme, 
then such interactions should also be susceptible to competitive receptors, such as the 
acetate buffer used in the assays.   Experiments performed in 500 mM acetate buffer 
were not inhibitory for both FeIIIENBPI and GaIIIENBPI.  In 100 mM acetate buffer, 
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GaIIIENBPI was an ineffective inhibitor while FeIIIENBPI had an IC50 of 15 µM (See 
Table 5.1 below).  In contrast, assays performed in 25 mM acetate buffer with 
increasing amounts of sodium chloride had no effect on the IC50 values (Figure 5.2) 
Drug concentrations were selected near maximal inhibitory concentrations - 50 µM 
Table 5.1.  Acetate buffer dependence of the IC50 of N4O2 Schiff base
complexes for the BNT II mediated aggregation of hemozoin.  
  IC50 µM  
Schiff Base Complex 25 mM acetate buffer 
100 mM 
acetate buffer 
500 mM 
acetate buffer 
FeIIIENBPI 9.5 15 NI 
GaIIIENBPI 58 NI NI 
MgIIENBPI NI NI NI 
  NI = No Inhibition 
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 Figure 5.2.  Effect of increasing salt concentration on hemozoin aggregation and 
drug inhibition.  Assays were performed in 25 mM acetate buffer with increasing 
concentrations of NaCl.  Vertical bar identification: white (left), no drug, black 
(middle), 50 µM FeIIIENBPI, and right (gray) 200 µM GaIIIENBPI. 
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FeIIIENBPI and 200 µM GaIIIENBPI.  This suggests the interactions between the 
drugs and heme may not be simply charge dependent, but also contingent on the 
specific carboxylate moiety.   
The sensitivity of the cationic ENBPI complexes to acetate buffer 
concentration is distinct from other classes of heme aggregation inhibitors, such as 
the quinolines, hydroxyxanthones, and porphyrins, which are seemingly unaffected 
by such conditions.  In fact, two laboratories independently reported that heme 
inhibition by porphyrins is unaffected by acetate buffer concentration, one being our 
template mediated heme aggregation assay,22 the other being a heme polymerization 
inhibition activity assay28 which does not utilize a template in the reaction medium.29  
The ability of the ENBPI complexes to directly associate with heme is further 
substantiated by means of fluorescence quenching experiments performed in various 
concentrations of acetate buffer, pH 4.8 (Figure 5.3).  The titration of dilute solutions 
of the individual ENBPI complexes with Fe(III)PPIX resulted in the partial 
quenching of the fluorophore.  At ratios of 1:1 Fe(III)PPIX to ENBPI complex, the 
fluorescence values were 70% of the original intensity for FeIIIENBPI, 50% for 
GaIIIENBPI, and 60% for MgIIENBPI.  Complete quenching of FeIIIENBPI was 
achieved with approximately 4 fold excess of Fe(III)PPIX, while GaIIIENBPI 
required nearly 6 fold excess of the iron porphyrin.  MgIIENBPI, the noninhibitory 
complex, was quenched when roughly 7.5-8 fold excess of heme was used.  All 
curves followed a second order exponential decay quenching pattern.   
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 Figure 5.3.  Fluorescence quenching study of ENBPI complexes by Fe(III)PPIX in
50 mM acetate buffer, pH 4.8.  Each data point represents the average of three
individual experiments with a standard deviation of < 5% for each point.
● GaIIIENBPI , □ FeIIIENBPI, and ▲ MgIIENBPI. 
Quenching studies at increasing concentrations of acetate buffer (Figure 5.4)  
demonstrated a systematic decrease in the quenching of fluorescence as the 
concentration of the acetate buffer increased for the cationic ENBPI complexes.  
Fluorescence quenching of the FeIIIENBPI complex was slowed to the same degree at 
higher concentrations of acetate buffer (200 and 500 mM), while the GaIIIENBPI 
complex did not experience this trend at the concentrations investigated.     
MgIIENBPI showed little sensitivity to the acetate buffer concentration, especially at 
acetate buffer concentrations greater than 25 mM.  Moreover, the intensity of the 
fluorescence emissions of the complexes remained relatively stable over time, up to 
48 hours in both 25 mM and 500 mM acetate buffer, pH 4.8, at 370C.  
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Figure 5.4.  Fluorescence aggregation studies of fluorophores: (A) FeIIIENBPI,
(B) GaIIIENBPI, and (C) MgIIENBPI with heme in various concentrations of
acetate buffer.  Briefly, 20 µM of each complex dissolved in DMSO was added to
4-320 µM of heme dissolved in 0.1 M NaOH.  All samples were excited at
respective excitation maxima (FeIIIENBPI – 310 nm, GaIIIENBPI – 380 nm, and
MgIIENBPI – 350 nm) and monitored at the emission maxima of each fluorophore.
● 25 mM acetate, □ 50 mM acetate, ▲ 100 mM acetate,    200 mM acetate, and
♦  500 mM acetate. 
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Representative studies for the cationic and neutral Schiff base compounds are listed in 
Figure 5.5.   
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 Figure 5.5.  Fluorescence emission time study for representative ENBPI 
complexes.  Samples were excited at the respective excitation maxima. 
Experiments were performed in pH 4.8 buffer at 37 0C.  □ 25 mM acetate buffer, 
● 500 mM acetate 
Controls for the effect of possible demetalation reactions were negative.15  
NMR stability studies of these same complexes in 25 mM or 500 mM acetate buffer, 
displayed no signs of hydrolysis.  The FeIIIENBPI complex was stable in 25 mM 
acetate buffer for 48 hours (data not shown), much like the stability reported at 
neutrality (pH 7.4, 72 hours) by Sharma et al.18  The MgIIENBPI complex (Figure 
5.6) was also stable under the acidic assay conditions.   The NMR spectra were 
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Figure 5.6.  Typical NMR spectrum of MgIIENBPI in 25mM acetate buffer. 
superimposable before and after incubation in water at 37 0C throughout the duration 
of the 48 hour experimental time period (Figure 5.7).  Additionally, the stability was 
assessed via the integration ratios in Figure 5.8.  The aldimino resonance signal      
(N-metal) at δ 7.36 did not decrease in intensity throughout the study.  Furthermore, 
little compound decomposition occurred, as signified by the lack of aldimino proton 
at δ 8.15, which represents protons resulting from demetalation.   This result differs 
from that recorded by Polyakov et al., whom not only described the aldimino proton 
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 Figure 5.7.  Representative NMR stability study of MgIIENBPI.  The spectra did
not change over the course of the experiment.  
9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0
δ, ppm
48 Hours
24 Hours
0 Hours
resonance at δ 8.1, but also demonstrated an additional reduced stability under acidic 
conditions.19   
5.5.  Conclusions 
Given the relative importance of iron in the metabolic processing of 
Plasmodium falciparum, metal chelating agents are often examined as potential 
antimalarials.  If the administered drug is lethal to the parasite, the question often then 
becomes which plausible mechanism of interaction halted or disrupted the very 
sustenance of the malaria parasite.  With known antimalarials such as chloroquine, 
being more effective at specific stages of parasite growth,30 understanding 
antimalarial drug action may seem like a daunting task.  With the ENBPI complexes 
possessing an excellent correlation between the inhibition of hemozoin, both in vitro 
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and in vivo, and the ability of these compounds to arrest parasite development in both 
chloroquine sensitive and chloroquine resistant strains, 15-17 a more detailed account 
was deemed necessary.  Here we report the basis for the inhibition is most likely the 
formation of a salt complex between the anionic propionate of heme and the cationic 
drug complex.   
 
B 
 
C 
Figure 5.8.  Representative NMR stability study of MgIIENBPI.  The ratio of the
small peak at 8.15 ppm relative to the triplet at 7.36 ppm did not change over the
course of the experiment.  Sample times include: (A) initial NMR, (B) 24 hour
incubation, (C) 48 hour incubation. 
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Chapter 6 
Concluding Remarks 
6.1.  Hemoglobin Proteolysis as an Antimalarial Strategy 
Hemoglobin proteolysis is essential for parasite survival, and therefore 
provides a wealth of catabolic targets for the development of novel antimalarials.  
While earlier investigations targeted the disruption of proteolytic events, recent 
research focuses on arresting parasite development after the catabolism of 
hemoglobin; either during the ensuing formation of hemozoin from free released iron 
(III) protoporphyrin IX or during events outside the digestive vacuole once the 
biomineral has formed.    
While hemoglobin ingestion and digestion are energetically expensive to the 
parasite, quantitative estimates of the actual proteolysis remain highly controversial.  
Some research demonstrates that only ~ 16% of the amino acids from hemoglobin 
proteolysis is utilized by the Plasmodium falciparum parasites,1 despite hemoglobin 
digestion estimates as high as 80%.  In addition to obtaining requisite amino acids, 
Lew et al. have suggested that parasites proteolyze hemoglobin as a mechanism to 
prevent the host red blood cell from premature lysis.2 Sound evidence of this 
evolutionary strategy however, fails to exist until advances in the validation of host 
cell volume measurements and hemoglobin concentration experiments in vivo 
improve.  Nevertheless, parasite growth remains directly correlated to hemoglobin 
proteolysis and thus halting any stage of hemoglobin consumption will definitively 
arrest parasite development.   
Quests to understand antimalarial drug action through the inhibitory activity 
of hematin aggregation is also contentious, due to the fact that an overwhelming 
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number of possible mechanisms exist, with each hypothesis being a reasonable and 
partially substantiated event.  Heme, hemozoin, and templates such as HRP II and 
lipids have all been shown to act as drug receptor sites, preventing the aggregation of 
heme.  With malarial antagonists being operational amid different receptors, 
uncovering novel antimalarial drug strategies has become a daunting task.  
Stereoelectronic models are now being used to search for new potential antimalarial 
compounds.3  
6.2.  Biochemical Involvement of HRP II 
Consequently,  the in vivo measurement of cellular HRP II levels has also long 
been correlated to parasitemia, as well as to parasite development, increasing in 
concentration during the late ring and trophozoite stages of development, while 
remaining at a relatively constant level during schizont development and the later 
rupture and red blood cell reinvasion stages.  Thus, it appears that HRP II production 
is mediated by Plasmodium falciparum’s metabolic activity, remaining associated 
with the parasites and/or erythrocytes.   
Significant increases in the concentration of this protein are not noted in the 
culture medium in in vitro experiments.  However, the inhibition of parasite 
development with common antimalarials, such as mefloquine and artesumate, is 
reflected in the inhibition of HRP II production,4 following a sigmoidal inhibition 
curve similar to traditional in vitro drug sensitivity assays.  In hindsight, impeding 
HRP II production could disrupt the metabolic activity of Plasmodium falciparum to 
an extent that parasitemia may be controlled or decreased.  Knowing how HRP II 
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secretion and production are growth-related and affected by antimalarials is only one 
avenue of investigation.  Why not know which particular amino acids or repeats 
within the protein sequence are associated with the viability of the parasite?     
In addition to its proposed role in the detoxification of heme, HRP II has also 
been evidenced to bind actin, suggesting it plays a role in the stabilization of actin 
filaments in an acidic environment (pH 6.0-6.5).5 This acidic pH dependence of   
HRP II in both actin binding and heme binding and hemozoin formation is also noted 
with the knob-associated HRP (KAHRP) and its binding to the cytoplasmic domain 
of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1),6 which 
has regions rich in histidine and lysine.   
HRP II from Plasmodium falciparum was found to also decrease the 
lipopolysaccharide (LPS) induced production of interleukin-8,7 demonstrating yet 
another reason to examine the sequence specificity of HRP II activity, not only in 
hemozoin formation, but also since it may play additional role(s) in monocyte 
activation.  
Despite its numerous avenues of biochemical involvement, even if HRP II is 
not definitively implicated in the nucleation and formation of hemozoin or other such 
events, such site-directed mutagenesis studies are warranted for the advancement of 
the current scientific understanding of this protein in immunochromatographic assays.  
Currently, the detection of the HRP II antigen8-10 is the only alternative to the 
microscopic diagnosis of malaria.  HRP II however, has a long half-life in vivo which 
has limited its application in developing tests to monitor therapeutic efficacy.   
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6.3.  Role of BNT II Model Systems 
In retrospect, since hemozoin formation is a biomineralization process, 
understanding the stages of assemblage becomes essential for understanding 
antimalarial drug interactions.  With a model system such as the BNTs, hemozoin 
formation could be evaluated at the single amino acid residue level.  By the 
determination of single anchor points along the template that elicit hemozoin 
production, drug:template interactions can be better assessed.  With multiple sites of 
interactions and the specific affinities therein for different antimalarials, many drugs 
have diverse modes of interaction.  The parasites additionally have many modes of 
resistance including the overexpression of target proteins, mutations of target 
proteins, enzyme modifications, and alterations in efflux pumps.  With such 
overwhelming dynamics in the life cycle of Plasmodium falciparum interplayed with 
possible scenarios for antimalarial drug interactions and insecticide resistance in the 
vector, a fundamental understanding at the single amino acid residue level will lead to 
novel control strategies in both the immunology of the tropical disease of malaria and 
biochemistry of P. falciparum. 
While conflicting reports on mode of hemozoin formation continue to be 
presented in the literature, the exact mechanism of malarial pigment growth will be 
disputed until science overcomes some of the technological problems associated with 
studying life processes within a living organism.  Crystals of synthetic ß-hematin vary 
in microscopic morphologies (Figure 6.1 and 6.2),11,12 but are still biochemically 
similar   to  hemozoin   formed   by   Plasmodium   falciparum   and   other  hemozoin  
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Figure 6.1.  Scanning electron microscopy of β-hematin synthesized by the
dehydrohalogenation of 2,6-lutidine according to methods published by Bohle. 
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Figure 6.2.  Scanning electron microscopy of β-hematin synthesized in aqueous 
solution according to methods published by Blauer. 
producing species.  The spectra of hemozoin and synthetic β-hematin are similar, 
including the Raman imaging13 and Fourier transform infrared (FT-IR) 
spectroscopy.14-16  Though in vitro growth conditions may mimic hemozoin formation 
and yield approximations for inhibition, such biochemical events are directly 
controlled by the parasite.  With this in mind, the BNT dendrimers are no less an 
effective mimic than the other templates, whether lipid or protein based. 
6.4.  Summary 
 While advances have been made, questions still arise and are resultant from 
the different methodologies employed in studying hemozoin formation.  Though a 
recent paper by Tripathi et al.17 highlights the importance of the removal residual 
heme aggregates from hemozoin formation assays before pigment quantification, 
which our laboratory definitively agrees with the authors on, their research still poses 
another question upon further examination.  The authors examine the in vitro process 
of β-hematin formation with heme alone, parasite lysate extracts and lipid extracts.  
Curiously, the lipid mediated formation of hemozoin was found to be concentration 
dependent to 10 µg/mL for most fatty acids except for oleoyl glycerol, which was 
notably more soluble under the experimental conditions.  If a lipid mediated route to 
hemozoin formation was employed by Plasmodium falciparum, then the parasite 
would not only have to regulate hemoglobin degradation, but also fatty acid synthesis, 
which the parasite may very well do, but preliminary results suggest that fatty acid 
synthesis is decreased during parasite proteolysis.18 This would cause the parasite to 
expend an enormous amount of energy to simply sustain its life.   In addition to this, 
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would fatty acid concentration be another unexplored antimalarial strategy?  
Increasing fatty acid concentration would decrease hemozoin formation and the 
excess free heme could still effectively kill the parasite.   
The exploitation of a functional model system like BNT II is seemingly 
boundless.  Studies beyond site-directed mutagenesis work are readily envisioned in 
order to better understand the critical interactions between the substrate and template.  
The relevance of histidine, which is critical for heme binding and hemozoin 
formation, can be evaluated further by modifying the residue with 
diethylpyrocarbonate19-21 and studying the effects thereto. 
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Appendix I 
 
Sample program for Model 90 Peptide Synthesizer for 1 mmole synthesis, generously 
supplied by AnaSpec, Inc..  Modifications were tailored according to the 
experimentally developed peptide synthesis protocol outlined in Section 2.5.2b. -  
Automated Synthesis of Templates. 
 
 
RV-1 = reaction vessel 1   DMF = dimethylformamide  
Mech = mechanical shaker   PIP = piperidine 
AA = amino acid    COUP = coupling mixture 
 
 
 
 
 
1. Fill RV-1 from DMF, 40.00 mL. 
2. Mix RV-1 with Mech for 1.0 min. 
3. Empty RV-1. 
4.  
5. Fill RV-1 from PIP, 50.00 mL. 
6. Mix RV-1 with Mech for 10.0 min. 
7. Empty RV-1. 
8. Fill RV-1 from PIP, 50.00 mL. 
9. Mix RV-1 with Mech for 40.0 min. 
10. Empty RV-1. 
11. Fill RV-1 with DMF, 50.00 mL. 
12. Mix RV-1 with Mech for 1.5 min. 
13. Empty RV-1. 
14. Repeat from step 11, 4 times. 
15. Stop. 
16.  
17. Fill RV-1 from AA-1, 25.0 mL. 
18. Fill RV-1 from COUP, 15.0 mL. 
19. Mix RV-1 with Mech for 60.0 min. 
20. Empty RV-1. 
21. Fill RV-1 from DMF, 50.0 mL. 
22. Mix RV-1 with Mech for 1.5 min. 
Swelling 
Deprotection 
Wash 
Coupling 
Wash 23. Empty RV-1. 
24. Repeat from step 21, 4 times. 
25. Stop. 
26.  
27. Fill RV-1 from PIP, 50.0 mL. 
28. Mix RV-1 with Mech for 10.0 min. 
29. Empty RV-1. 
30. Fill RV-1 from PIP, 50.0 mL. 
 A-1 
31. Mix RV-1 from Mech for 40.0 min. 
32. Empty RV-1. 
33. Fill RV-1 from DMF, 50.0 mL. 
34. Mix RV-1 with Mech for 1.5 min. 
35. Empty RV-1. 
36. Repeat from step 33, 4 times. 
37. Stop. 
38.  
39. Fill RV-1 from AA-2, 25.0 mL. 
40. Fill RV-1 from COUP, 15.0 mL. 
41. Mix RV-1 with Mech for 60.0 min. 
42. Empty RV-1. 
43. Fill RV-1 from DMF, 50.0 mL. 
44. Mix RV-1 with Mech for 1.5 min. 
45. Empty RV-1. 
46. Repeat from step 43, 4 times. 
47. Stop. 
48.  
49. Fill RV-1 from PIP, 50.0 mL. 
50. Mix RV-1 with Mech for 10.0 min. 
51. Empty RV-1. 
52. Fill RV-1 from PIP, 50.0 mL. 
53. Mix RV-1 from Mech for 40.0 min. 
54. Empty RV-1. 
55. Fill RV-1 from DMF, 50.0 mL. 
56. Mix RV-1 with Mech for 1.5 min. 
57. Empty RV-1. 
58. Repeat from step 55, 4 times. 
59. Stop. 
60.  
61. Fill RV-1 from AA-3, 25.0 mL. 
62. Fill RV-1 from COUP, 15.0 mL. 
63. Mix RV-1 with Mech for 60.0 min. 
64. Empty RV-1. 
65. Fill RV-1 from DMF, 50.0 mL. 
66. Mix RV-1 with Mech for 1.5 min. 
67. Empty RV-1. 
68. Repeat from step 65, 4 times. 
69. Stop. 
70.  
71. Fill RV-1 from PIP, 50.0 mL. 
72. Mix RV-1 with Mech for 10.0 min. 
73. Empty RV-1. 
 A-2 
74. Fill RV-1 from PIP, 50.0 mL. 
75. Mix RV-1 from Mech for 40.0 min. 
76. Empty RV-1. 
77. Fill RV-1 from DMF, 50.0 mL. 
78. Mix RV-1 with Mech for 1.5 min. 
79. Empty RV-1. 
80. Repeat from step 77, 4 times. 
81. Stop. 
82.  
83. Fill RV-1 from AA-4, 25.0 mL. 
84. Fill RV-1 from COUP, 15.0 mL. 
85. Mix RV-1 with Mech for 60.0 min. 
86. Empty RV-1. 
87. Fill RV-1 from DMF, 50.0 mL. 
88. Mix RV-1 with Mech for 1.5 min. 
89. Empty RV-1. 
90. Repeat from step 87, 4 times. 
91. Stop. 
92.  
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0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 2.26
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.20
0.40
0.60
0.80
1.00
x = 2.28
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
 A-11 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 2.77
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 2.91
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
0.0 0.5 1.0 1.5
0.00
0.20
0.40
0.60
0.80
1.00
2.0 2.5 3.0 3.5
x = 2.55
10 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
  
 
 A-12 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 3.02
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 2.26
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
  A-13 
0 1 2 3 4 5 6 7 8
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.90
2 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0 1 2 3 4 5 6 7 8
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 3.62
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0 1 2 3 4 5 6 7 8
0.00
0.20
0.40
0.60
0.80
1.00
x = 4.14
2 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[(Zn(II)PPIX]/[BNT IID]
 
0 1 2 3 4 5 6 7 8
0.00
0.20
0.40
0.60
0.80
1.00
x = 4.01
2 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0 1 2 3 4 5 6 7 8
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.96
2 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
0 1 2 3 4 5
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 4.11
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
32
 n
m
[Zn(II)PPIX]/[BNT IID]
 
 0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 2.91
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.45
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
0 1 2
0.00
0.20
0.40
0.60
0.80
1.00
3 4 5 6
x = 3.33
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
  
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
10 nmoles Template
x = 3.80
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 2.83
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
 A-14 
 A-15 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.21
10 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 2.86
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.25
10 nmoles Template
 
Re
la
tic
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.26
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.22
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.99
10 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
 
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.79
10 nmoles Template
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.76
10 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
9.69 nmoles Template
x = 3.89
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
9.69 nmoles Template
x = 2.96
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
17
 n
m
[Hemin]/[BNT IIX]
 
 A-16 
 
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
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1.00
x = 3.46
 
 5 nmoles Template
Re
la
tiv
e 
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so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 3.20
5 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
0 1 2
0.00
0.20
0.40
0.60
0.80
1.00
3 4 5 6
5 nmoles Template
x = 3.15
 
 
Re
la
tiv
e 
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so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
  
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 4.82
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 4.62
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
 
 A-17 
 0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
x = 4.63
2 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 5.26
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
0 1 2
0.00
0.20
0.40
0.60
0.80
1.00
3 4 5 6
x = 5.07
2 nmoles Template 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
  
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 4.73
 
Re
la
tiv
e 
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so
rb
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ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
 
0 1 2 3 4 5 6
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 5.39
 
 
Re
la
tiv
e 
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so
rb
an
ce
 a
t 3
90
 n
m
[Zn(II)PPIX]/[BNT IIX]
 
 A-18 
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.04 nmoles Template
x = 8.63
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
20
 n
m
[Hemin]/[BNT IIY]
 
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.04 nmoles Template
x = 7.81
 
 
Re
la
tiv
e 
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so
rb
an
ce
 a
t 4
20
 n
m
[Hemin]/[BNT IIY]
 
0 2 4 6 8 10 12
0.00
0.20
0.40
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0.80
1.00
x = 8.06
3.04 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
20
 n
m
[Hemin]/[BNT IIY]
 
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
x = 7.65
3.04 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
20
 n
m
[Hemin]/[BNT IIY]
 
 
 A-19 
 0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
 
 
x = 7.52
3.04 nmoles Template
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
12
 n
m
[Hemin]/[BNT IIY]
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
 
 
x = 8.27
3.04 nmoles Template
Re
la
tiv
e 
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so
rb
an
ce
 a
t 4
12
 n
m
[Hemin]/[BNT IIY]
0 2
0.00
0.20
0.40
0.60
0.80
1.00
4 6 8 10
 
 
x = 7.85
3.04 nmoles Template
Re
la
tiv
e 
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rb
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t 4
12
 n
m
[Hemin]/[BNT IIY]
  
 
0 2 4 6 8 10
0.00
0.20
0.40
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1.00
 
 
x = 7.48
3.04 nmloes Template
Re
la
tiv
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t 4
12
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m
[Hemin]/[BNT IIY]
 
0 2 4 6 8 10
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0.20
0.40
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x = 7.15
3.04 nmoles Template
Re
la
tiv
e 
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12
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m
[Hemin]/[BNT IIY]
 
 A-20 
0 2 4 6
0.00
0.20
0.40
0.60
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1.00
8 10 12
x = 7.65
3.05 nmoles Template
 
 
Re
la
tiv
e 
Ab
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rb
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 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
 
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.05 nmoles Template
x = 7.45
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
x = 9.81
3.05 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
 A-21 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
 
 3.05 nmoles Template 
x = 8.92
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
 
 
x = 8.54
3.05 nmoles Template
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
 
 
x = 9.73
3.05 nmoles Template
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
 
 
x = 8.12
3.05 nmoles Template
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
80
 n
m
[Zn(II)PPIX]/[BNT IIY]
 
 
 A-22 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 9.16
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 8.40
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 9.26
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 9.25
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
 
 A-23 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 10.45
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 10.79
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 9.99
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
0 2 4 6 8 10 12 14
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 11.09
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 4
18
 n
m
[Hemin]/[BNT IIZ]
 
 
 A-24 
 0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 7.13
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
0 2 4 6 8
0.00
0.20
0.40
0.60
0.80
1.00
10 12
3.33 nmoles Template
x = 7.27
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
  
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 7.96
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10 12
0.00
0.20
0.40
0.60
0.80
1.00
3.33 nmoles Template
x = 7.44
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
 A-25 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 6.42
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PIIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 5.22
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 6.82
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 6.60
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
 
 A-26 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
x= 5.39
2 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
x = 6.88
2 nmoles Template
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 5.51
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 5.26
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
 
0 2 4 6 8 10
0.00
0.20
0.40
0.60
0.80
1.00
2 nmoles Template
x = 6.28
 
 
Re
la
tiv
e 
Ab
so
rb
an
ce
 a
t 3
85
 n
m
[Zn(II)PPIX]/[BNT IIZ]
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Appendix III 
 
Circular Dichroism Titration Experiments 
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